PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9522163-8	1998	However, ketanserin (10(-7) to 10(-6) M), a 5-HT2 receptor antagonist, induced significant inhibition of the concentration-response curve to 5-HT.	Ketanserin	9-19	5-hydroxytryptamine receptor 2A	Homo sapiens	44-58
9512061-6	1998	An attenuation of the fluoxetine-enhanced cocaine-induced behaviors was also observed after pretreatment with the 5-HT2A antagonist ketanserin (0.1 and 1.0 mg/kg).	Ketanserin	132-142	5-hydroxytryptamine receptor 2A	Rattus norvegicus	114-120
9476868-6	1998	In the in vivo rat model, 5-HT2a antagonist ketanserin, 5-HT7 agonist 5-carboxamidotryptamine, and (to a limited extent) 5-HT3 antagonist ondansetron could all, like epinastine, block bronchospasm, but the "classic" antihistamine chlorpheniramine was ineffective.	Ketanserin	44-54	5-hydroxytryptamine receptor 2A	Rattus norvegicus	26-32
9542727-2	1998	The 5-HT-evoked Ca(2+)-transients, inhibited by the 5-HT2A antagonists ketanserin or 4-(4-fluorobenzoyl)-1-(4-phenylbutyl) piperidine oxalate, consisted of an initial peak caused by inositol 1,4,5-trisphosphate (IP3)-mediated Ca2+ release from internal stores, and a second sustained part which was due to Ca2+ transport over the plasma membrane.	Ketanserin	71-81	5-hydroxytryptamine receptor 2A	Rattus norvegicus	52-58
9484853-12	1998	The effect of sumatriptan was prevented by ketanserin, a drug known to display much higher affinity for recombinant h 5-HT1D than for h 5-HT1B receptors.	Ketanserin	43-53	5-hydroxytryptamine receptor 1D	Homo sapiens	118-124
9484853-12	1998	The effect of sumatriptan was prevented by ketanserin, a drug known to display much higher affinity for recombinant h 5-HT1D than for h 5-HT1B receptors.	Ketanserin	43-53	5-hydroxytryptamine receptor 1B	Homo sapiens	136-142
9484854-17	1998	Ketanserin acted as a weak antagonist (pK(B): 5.87) at gp 5-HT1B receptors.	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	58-64
9485168-9	1998	Addition of the 5-HT2 receptor antagonist, ketanserin (1 microM) into the incubation medium resulted in the loss of cellular responsiveness to 5-HT, preventing not only the stimulatory effect of 5-HT on the basal but also on the TRH-induced PRL release.	Ketanserin	43-53	prolactin	Rattus norvegicus	241-244
9466454-6	1998	This distribution pattern was indistinguishable from specific 5-HT1B receptor labelling in the presence of ketanserin under conditions to occlude 5-HT1D receptor labelling; hence the latter were below detection level.	Ketanserin	107-117	5-HT1B receptor	Cavia porcellus	62-77
9485168-12	1998	In addition, it was shown that ketanserin completely antagonizes PRL response to 5-HT, indicating the involvement of the 5-HT2 receptor type in mediating PRL release.	Ketanserin	31-41	prolactin	Rattus norvegicus	65-68
9485168-12	1998	In addition, it was shown that ketanserin completely antagonizes PRL response to 5-HT, indicating the involvement of the 5-HT2 receptor type in mediating PRL release.	Ketanserin	31-41	prolactin	Rattus norvegicus	154-157
9403612-5	1997	Platelet-derived products (PDPs) released by aggregating human platelets enhanced thrombin receptor mRNA levels in a time- and concentration-dependent manner, an effect that was potentiated by transient acidification of PDPs, which release bioactive transforming growth factor (TGF)-beta1, and that was slightly inhibited by ketanserin.	Ketanserin	325-335	coagulation factor II, thrombin	Homo sapiens	82-90
16793742-0	1998	Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies.	Ketanserin	31-41	erythropoietin	Homo sapiens	45-59
16793742-2	1998	We studied if ketanserin, a blocker of platelet and vascular smooth muscle receptors for 5-HT, could reverse any EPO-induced changes in hemostasis.	Ketanserin	14-24	erythropoietin	Homo sapiens	113-116
16793742-5	1998	Ketanserin co-treatment produced an unexpected 33% fall in serum EPO level ( P < 0.02), a decrease in the platelet count ( P < 0.05), prolongation of the BT ( P < 0.05) and depressed platelet aggregation in response to both agonists.	Ketanserin	0-10	erythropoietin	Homo sapiens	65-68
16793742-9	1998	The ketanserin-induced falls in serum EPO concentration and the platelet count provide new evidence of the dependency of thrombocytopoiesis on EPO in the initial weeks of the therapy.	Ketanserin	4-14	erythropoietin	Homo sapiens	38-41
16793742-9	1998	The ketanserin-induced falls in serum EPO concentration and the platelet count provide new evidence of the dependency of thrombocytopoiesis on EPO in the initial weeks of the therapy.	Ketanserin	4-14	erythropoietin	Homo sapiens	143-146
9403612-5	1997	Platelet-derived products (PDPs) released by aggregating human platelets enhanced thrombin receptor mRNA levels in a time- and concentration-dependent manner, an effect that was potentiated by transient acidification of PDPs, which release bioactive transforming growth factor (TGF)-beta1, and that was slightly inhibited by ketanserin.	Ketanserin	325-335	transforming growth factor beta 1	Homo sapiens	250-288
9404824-4	1997	Confirming our previous results, the Bmax and KD values for the specific [3H]ketanserin binding at cortical 5-HT2A receptors were respectively identical in both strains.	Ketanserin	77-87	5-hydroxytryptamine receptor 2A	Rattus norvegicus	108-114
9384503-13	1997	Contractions to (+/-)-alpha-me-5-HT, which is selective for 5-HT2A over 5-HT1B and 5-HT1D receptors, were competitively antagonized by low concentrations of ketanserin.	Ketanserin	157-167	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	72-78
9384503-13	1997	Contractions to (+/-)-alpha-me-5-HT, which is selective for 5-HT2A over 5-HT1B and 5-HT1D receptors, were competitively antagonized by low concentrations of ketanserin.	Ketanserin	157-167	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	83-89
9326273-7	1997	In contrast to that in caudate, PLC activity in frontal cortex was stimulated by 5-HT in a manner that was inhibited by the 5-HT2A-selective antagonists, spiperone and ketanserin.	Ketanserin	168-178	5-hydroxytryptamine receptor 2A	Rattus norvegicus	124-130
9272479-8	1997	Fluoxetine, a selective serotonin uptake inhibitor (SSRI) and ketanserin a 5-HT2A antagonist, attenuated PKC translocation by MDMA with differing efficacies; however, both compounds completely prevented the loss of 5-HT uptake sties after multiple doses of MDMA.	Ketanserin	62-74	5-hydroxytryptamine receptor 2A	Rattus norvegicus	75-81
9301661-5	1997	Also, 1, 8, and 9 were assayed for their ability to displace [3H]ketanserin from rat cortical homogenate 5-HT2A receptors and [3H]8-OH-DPAT from rat hippocampal homogenate 5-HT1A receptors.	Ketanserin	61-75	5-hydroxytryptamine receptor 2A	Rattus norvegicus	105-111
9346323-3	1997	The Bmax value of [3H]ketanserin binding at cortical 5-HT2A receptors was decreased by repeated DOI pretreatment.	Ketanserin	22-32	5-hydroxytryptamine receptor 2A	Rattus norvegicus	53-59
9282925-2	1997	Incubation of cells expressing the 5-HT2A receptor with mianserin (100 nM) for 24 h caused a significant decrease (48%) in the binding capacity of [3H] ketanserin.	Ketanserin	152-162	5-hydroxytryptamine receptor 2A	Homo sapiens	35-50
9292627-2	1997	The 5-HT2 receptor antagonist, ketanserin, at a moderate dose (5 mg/kg) prevented the ability of a muscarinic acetylcholine receptor agonist, (oxotremorine 0.1 mg/kg), and a nicotinic acetylcholine receptor agonist (nicotine 0.1 mg/kg), to decrease HVSs.	Ketanserin	31-41	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	174-206
9500663-7	1997	Characterisation of the receptor subtypes involved in this response implicated the 5HT2c receptor on the basis of the response to (+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane HCl (DOI, 0.1-0.5 mg/kg) and the potent antagonism by ritanserin and ketanserin.	Ketanserin	251-261	5-hydroxytryptamine receptor 2C	Rattus norvegicus	83-88
9262333-3	1997	DOI-induced HTR had an ED50 of 12.8 nmoles/0.5 microl/side and was inhibited by the 5-HT2A antagonists ketanserin and MDL 100,907 but was not blocked by pretreatment with the selective 5-HT(2C/2B) antagonist SDZ SER 082.	Ketanserin	103-113	5-hydroxytryptamine receptor 2A	Rattus norvegicus	84-90
9262338-4	1997	All of these compounds produced dose-related decreases in DOI-induced head twitches; however pretreatment with the 5-HT1A antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohe xanecarboxamide (WAY-100635) failed to alter the ability of ritanserin, ketanserin or CGS 18102A to attenuate DOI-induced head twitches.	Ketanserin	275-285	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
9214741-1	1997	Parthenolide displaces [3H]ketanserin from 5HT2A receptors from rat and rabbit brain and cloned 5HT2A receptors.	Ketanserin	23-37	5-hydroxytryptamine receptor 2A	Rattus norvegicus	43-48
9178960-1	1997	This study aimed at comparing the binding characteristics of [3H]ketanserin, a high-affinity serotonin 2A (5-HT2A) receptor antagonist, in the prefrontal cortex, hippocampus and striatum of human brain post-mortem.	Ketanserin	61-75	5-hydroxytryptamine receptor 2A	Homo sapiens	93-123
9178960-3	1997	The pharmacological profile of [3H]ketanserin binding was consistent with the labeling of the 5-HT2A receptor, since it revealed a competing drug potency ranking of ketanserin = spiperone > clozapine = haloperidol > methysergide > mesulergine > 5-HT.	Ketanserin	35-45	5-hydroxytryptamine receptor 2A	Homo sapiens	94-109
9245653-7	1997	Changes in the distribution patterns of [3H]oxotremorine-M- and [3H]ketanserine-binding sites precisely matched the borders between areas 4/3a, 3b/1, and 1/2, as defined cytoarchitectonically.	Ketanserin	68-79	WD repeat and HMG-box DNA binding protein 1	Homo sapiens	144-157
9500663-8	1997	DOI (0.5 mg/kg) also induced c-Fos in the SCN and the induction was prevented by ritanserin and ketanserin.	Ketanserin	96-106	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	29-34
9200567-6	1997	Ketanserin and ritanserin showed low affinity for [3H]GR 125,743 binding to guinea-pig striatal sites (K(i) = 12600 and 369 nM), suggesting that 5-HT1B (rather than 5-HT1D) receptors are predominantly labelled in this tissue.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Cavia porcellus	165-171
9200494-6	1997	Among the 5-HT agents studied, only the 5-HT2A receptor antagonists ketanserin and ritanserin were able to reduce the ACh release induced by dopamine D1 receptor stimulation.	Ketanserin	68-78	5-hydroxytryptamine receptor 2A	Rattus norvegicus	40-46
9169297-2	1997	Methysergide and methiothepin bind at the 5-HT1 and 5-HT2 as well as the 5-HT5-7 receptors, with varying degrees of selectivity, and ketanserin binds at the 5-HT2A receptors rather selectively.	Ketanserin	133-143	5-hydroxytryptamine receptor 2A	Rattus norvegicus	157-163
9092600-7	1997	Pretreatment with ketanserin, a 5-HT2A /2C receptor antagonist, significantly blocked the stress-induced downregulation of BDNF mRNA in hippocampus, in support of this hypothesis.	Ketanserin	18-28	5-hydroxytryptamine receptor 2A	Homo sapiens	32-38
13677667-5	1997	A decrease in the [3H]ketanserin specific binding in the striatum of cataleptic rats and CBA mice was found indicating a decrease in 5-HT2A receptor density.	Ketanserin	22-32	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	133-148
9225276-9	1997	Ketanserin displayed modest (five-fold) 5-HT1D receptor selectivity, while methiothepin exhibited a similar selectivity for the 5-HT1B subtype.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Cavia porcellus	40-55
9092600-7	1997	Pretreatment with ketanserin, a 5-HT2A /2C receptor antagonist, significantly blocked the stress-induced downregulation of BDNF mRNA in hippocampus, in support of this hypothesis.	Ketanserin	18-28	brain derived neurotrophic factor	Homo sapiens	123-127
9225276-10	1997	In particular, ketanserin exhibits profound differences in 5-HT1D receptor affinity (and selectivity) across species.	Ketanserin	15-25	5-hydroxytryptamine receptor 1D	Cavia porcellus	59-74
9058826-5	1997	Furthermore, in vitro depletion of 5-HT from platelets or in vivo pretreatment of recipients with a 5-HT2A receptor antagonist (ketanserin) abolished the IgE-dependent CS initiation mediated by platelets.	Ketanserin	128-138	5-hydroxytryptamine receptor 2A	Homo sapiens	100-115
9058826-5	1997	Furthermore, in vitro depletion of 5-HT from platelets or in vivo pretreatment of recipients with a 5-HT2A receptor antagonist (ketanserin) abolished the IgE-dependent CS initiation mediated by platelets.	Ketanserin	128-138	immunoglobulin heavy constant epsilon	Homo sapiens	154-157
9088878-6	1997	In agreement with previous contraction studies, the generation of InsPs stimulated by 5-hydroxytryptamine was blocked by 10 nM ketanserin, a specific 5-HT2A receptor antagonist.	Ketanserin	127-137	5-hydroxytryptamine receptor 2A	Ovis aries	150-156
9085039-4	1997	Injection of pharmacological doses of the 5-HT2A receptor antagonist ketanserin resulted in reduction of cortical and striatal radioactivities to the level observed in the cerebellum.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Homo sapiens	42-57
9122367-9	1997	The selective 5-HT2A antagonists ketanserin (MED = 3.0 mg/kg) and MDL 100,907 (MED = 0.3 mg/kg) produced dose-related decreases in locomotor activity and ketanserin (MED = 0.1 mg/kg) and MDL 100,907 (MED = 0.003 mg/kg) reversed the effects of PCP.	Ketanserin	33-43	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	14-20
9225278-7	1997	The decrease in [3H]sumatriptan binding in the presence of 200 nM ketanserin, indicative of the presence of 5-HT1D receptors, was very limited throughout the human brain, only reaching 20% of total specific binding over the periaqueductal grey.	Ketanserin	66-76	5-hydroxytryptamine receptor 1D	Homo sapiens	108-114
9016798-3	1997	Superfusing 5-HT (10 microM) in the bath solution increased both K+ and Cl- currents, which were antagonized by the presence of ketanserin (1 microM), a selective 5-HT2A antagonist, in the bath solution.	Ketanserin	128-138	5-hydroxytryptamine receptor 2A	Rattus norvegicus	163-169
9042572-9	1997	The 5-HT-induced activation in Egr-1 binding was inhibited by ketanserin and mesulergine, indicating that 5-HT exerted its action via a 5-HT2 receptor subtype.	Ketanserin	62-72	early growth response 1	Rattus norvegicus	31-36
9305412-21	1997	The 5-HT2A receptor antagonist, ketanserin (32 mg/kg, s.c.), which reduced immobility when given alone, did not interfere with fluoxetine given at a subactive dose.	Ketanserin	32-42	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	4-19
9178960-3	1997	The pharmacological profile of [3H]ketanserin binding was consistent with the labeling of the 5-HT2A receptor, since it revealed a competing drug potency ranking of ketanserin = spiperone > clozapine = haloperidol > methysergide > mesulergine > 5-HT.	Ketanserin	165-175	5-hydroxytryptamine receptor 2A	Homo sapiens	94-109
9178960-4	1997	In conclusion, the 5-HT2A receptor, as labeled by [3H]ketanserin, would seem to consist of a homogenous population of binding sites and to be equally distributed in human prefronto-cortical, limbic and extrapyramidal structures.	Ketanserin	54-64	5-hydroxytryptamine receptor 2A	Homo sapiens	19-34
9176059-6	1997	The antagonists ketanserin, methysergide and spiperone attenuated the action of serotonin, while yohimbine and spiroxatrine were ineffectual, thus indicating that the potentiating effect was through the 5-HT1A receptor.	Ketanserin	16-26	5-hydroxytryptamine receptor 1A	Homo sapiens	203-209
9070726-3	1997	The contractile effects of 5-HT and alpha-methyl-5-HT were antagonized by the 5-HT2 receptor antagonist ketanserin and the non-selective antagonist methiothepin.	Ketanserin	104-114	5-hydroxytryptamine receptor 2A	Homo sapiens	78-92
9117091-17	1997	However, ketanserin is a more potent antagonist of rb 5-HT1B receptors.	Ketanserin	9-19	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	54-60
9288829-4	1997	For quantitating 5-HT2A binding sites, [3H]ketanserin (2 nM) was used.	Ketanserin	39-53	5-hydroxytryptamine receptor 2A	Rattus norvegicus	17-23
9606727-7	1997	Selective 5-HT1B receptor labeling was achieved using [3H]alniditan in the presence of 300 nM of ketanserin (sufficient to block 5-HT1D receptor labeling).	Ketanserin	97-107	5-hydroxytryptamine receptor 1B	Homo sapiens	10-16
9606727-7	1997	Selective 5-HT1B receptor labeling was achieved using [3H]alniditan in the presence of 300 nM of ketanserin (sufficient to block 5-HT1D receptor labeling).	Ketanserin	97-107	5-hydroxytryptamine receptor 1D	Homo sapiens	129-135
9122367-9	1997	The selective 5-HT2A antagonists ketanserin (MED = 3.0 mg/kg) and MDL 100,907 (MED = 0.3 mg/kg) produced dose-related decreases in locomotor activity and ketanserin (MED = 0.1 mg/kg) and MDL 100,907 (MED = 0.003 mg/kg) reversed the effects of PCP.	Ketanserin	154-164	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	14-20
8968381-5	1996	5-HT-induced contraction in all arteries was mediated by 5-HT2A receptors as ketanserin (3-30 nM) was a competitive antagonist in all arteries (pKB = 8.58-8.96).	Ketanserin	77-87	5-hydroxytryptamine receptor 2A	Rattus norvegicus	57-63
9017620-8	1996	Ketanserin produced a fall in ristocetin-induced platelet aggregation (P < 0.02), prolongation of the BT (P < 0.02) and, unexpectedly, a decrease in serum Epo concentration (P < 0.0002) and the Hb level (P < 0.001).	Ketanserin	0-10	erythropoietin	Homo sapiens	161-164
8923801-7	1996	Lysergol-induced contractile responses were surmountably antagonized by ketanserin (10 nM) with a pKB of 9.1 which is consistent with an interaction of lysergol with 5-HT2A receptors.	Ketanserin	72-82	5-hydroxytryptamine receptor 2A	Rattus norvegicus	166-172
8700138-5	1996	In GF-62 cells, agonist-induced internalization was blocked by preincubation with the 5-HT2A receptor antagonist ketanserin.	Ketanserin	113-123	5-hydroxytryptamine receptor 2A	Homo sapiens	86-101
8878052-0	1996	Differences in ligand binding profiles between cloned rabbit and human 5-HT1D alpha and 5-HT1D beta receptors: ketanserin and methiothepin distinguish rabbit 5-HT1D receptor subtypes.	Ketanserin	111-121	5-hydroxytryptamine receptor 1D	Homo sapiens	71-83
8878052-0	1996	Differences in ligand binding profiles between cloned rabbit and human 5-HT1D alpha and 5-HT1D beta receptors: ketanserin and methiothepin distinguish rabbit 5-HT1D receptor subtypes.	Ketanserin	111-121	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	88-99
8878052-0	1996	Differences in ligand binding profiles between cloned rabbit and human 5-HT1D alpha and 5-HT1D beta receptors: ketanserin and methiothepin distinguish rabbit 5-HT1D receptor subtypes.	Ketanserin	111-121	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	71-77
8878052-6	1996	Ketanserin exhibited high affinity (pKi = 7.66) and selectivity (> 20-fold) for the 5-HT1D alpha receptor while methiothepin displayed high affinity (pKi = 7.86) and selectivity (16-fold) for the 5-HT1D beta receptor subtype.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	87-108
8878052-6	1996	Ketanserin exhibited high affinity (pKi = 7.66) and selectivity (> 20-fold) for the 5-HT1D alpha receptor while methiothepin displayed high affinity (pKi = 7.86) and selectivity (16-fold) for the 5-HT1D beta receptor subtype.	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	199-219
8876023-6	1996	[3H]Ketanserin (5-HT2A) binding assays revealed that the SSRIs fluoxetine, norfluoxetine and citalopram show 10- to 23-fold selectivity for the 5-HT2C receptor in vitro, whereas the TCA imipramine does not.	Ketanserin	4-14	5-hydroxytryptamine receptor 2A	Rattus norvegicus	16-22
9015328-0	1997	Ketanserin selectively blocks acute stress-induced changes in NGFI-A and mineralocorticoid receptor gene expression in hippocampal neurons.	Ketanserin	0-10	early growth response 1	Rattus norvegicus	62-68
9015328-0	1997	Ketanserin selectively blocks acute stress-induced changes in NGFI-A and mineralocorticoid receptor gene expression in hippocampal neurons.	Ketanserin	0-10	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	73-99
9015328-7	1997	These changes are sustained for 4 h, but not 12 h. Ketanserin attenuates the stress-induced rise in NGFI-A and fall in mineralocorticoid receptor gene expression, and partly also the fall in AP-2 messenger RNA expression.	Ketanserin	51-61	early growth response 1	Rattus norvegicus	100-106
9015328-7	1997	These changes are sustained for 4 h, but not 12 h. Ketanserin attenuates the stress-induced rise in NGFI-A and fall in mineralocorticoid receptor gene expression, and partly also the fall in AP-2 messenger RNA expression.	Ketanserin	51-61	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	119-145
9015328-7	1997	These changes are sustained for 4 h, but not 12 h. Ketanserin attenuates the stress-induced rise in NGFI-A and fall in mineralocorticoid receptor gene expression, and partly also the fall in AP-2 messenger RNA expression.	Ketanserin	51-61	fatty acid binding protein 4	Rattus norvegicus	191-195
8914117-6	1996	5-HT2A binding sites, determined by [3H]ketanserin, were decreased in the dorsolateral prefrontal cortex (-27%) and parahippocampal gyrus (-38%) of schizophrenics, with a similar trend in cingulate gyrus, but not in superior temporal gyrus or striate cortex.	Ketanserin	40-50	5-hydroxytryptamine receptor 2A	Rattus norvegicus	0-6
8798428-7	1996	The 5HT2c receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT2c receptor activity.	Ketanserin	60-70	5-hydroxytryptamine receptor 2C	Bos taurus	4-9
8798428-7	1996	The 5HT2c receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT2c receptor activity.	Ketanserin	60-70	5-hydroxytryptamine receptor 2C	Bos taurus	218-223
8798428-7	1996	The 5HT2c receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT2c receptor activity.	Ketanserin	182-192	5-hydroxytryptamine receptor 2C	Bos taurus	4-9
8798428-7	1996	The 5HT2c receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT2c receptor activity.	Ketanserin	182-192	5-hydroxytryptamine receptor 2C	Bos taurus	218-223
8853371-5	1996	The stimulatory effect of dopamine on the expression of pOGH (angiotensinogen N-1498/+18) was inhibited by the presence of SCH-23390 (D1-dopaminergic receptor antagonist) and spiperone (D2-dopaminergic receptor antagonist), but not by ketanserin (5 HT2/5HT1c-serotonergic receptor antagonist).	Ketanserin	235-245	angiotensinogen	Homo sapiens	62-77
8886409-12	1996	The 5-HT2A receptor antagonist ketanserin (10 nM, 100 nM and 1 microM) also reduced the maximum contractile response to both 5-HT and sumatriptan without affecting tissue sensitivity to these agonists.	Ketanserin	31-41	5-hydroxytryptamine receptor 2A	Homo sapiens	4-19
8880946-9	1996	Either antidepressant given repeatedly decreased the density of 5-HT2A receptors ([3H]-ketanserin as a ligand) in the brain cortex, but did not change their affinity.	Ketanserin	87-97	5-hydroxytryptamine receptor 2A	Rattus norvegicus	64-70
8797129-8	1996	5-HT2A-receptor antagonist, ketanserin (1 microM) inhibited responses to 5-HT, whereas it affected only the responses to the smaller concentrations of SUM.	Ketanserin	28-38	5-hydroxytryptamine receptor 2A	Homo sapiens	0-15
8841890-5	1996	5-HT2A sites labeled by [3H]ketanserin were found in the dorsal horn of the cervical segments but no specific binding of this radioligand could be detected at any other level of the spinal cord of such aged subjects.	Ketanserin	24-38	5-hydroxytryptamine receptor 2A	Homo sapiens	0-6
8700116-6	1996	However, interchange mutations in either receptor led to decreased or unchanged affinity for (+/-)-1-)(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin, which have higher affinity for the 5-HT2A receptor, consistent with little contribution of this locus to the selectivity of these ligands.	Ketanserin	150-160	5-hydroxytryptamine receptor 2A	Homo sapiens	197-212
8857590-11	1996	The 8-OH-DPAT effect also is likely mediated by 5-HT1D receptors; stereoselectivity was found with its enantiomers at this receptor site and the effect was blocked by ketanserin (1 microM) but not by spiperone (1 microM).	Ketanserin	167-177	5-hydroxytryptamine receptor 1D	Homo sapiens	48-54
8800567-10	1996	The 5-HT2-receptor antagonists, cinanserin and ketanserin, both increased Td.	Ketanserin	47-57	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
8643547-10	1996	Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2.	Ketanserin	14-24	solute carrier family 18 member A2	Homo sapiens	64-69
8643547-10	1996	Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2.	Ketanserin	14-24	solute carrier family 18 member A1	Homo sapiens	97-102
8738578-7	1996	Ketanserin (5-HT2A antagonist) and methysergide (5-HT2C antagonist) blocked 5-HTP-induced prolactin release, but did not block the LH or FSH responses.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	12-18
8741180-0	1996	Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935.	Ketanserin	116-126	5-hydroxytryptamine receptor 1D	Homo sapiens	30-36
8737973-3	1996	The 5-HT2A antagonist, ketanserin, at 2.5 mg/kg, increased the self-stimulation at high currents but not at threshold current.	Ketanserin	23-33	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-10
8741180-2	1996	Ketanserin demonstrated potent (pA2: 7.76), competitive antagonism of naratriptan-induced inhibition of forskolin (100 microM)-stimulated cAMP formation in C6-glial/5-HT1D cells.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Homo sapiens	165-171
8741180-5	1996	The differential antagonist effects of ketanserin and GR 127,935 on naratriptan responses elicited in C6-glial/5-HT1D and C6-glial/5-HT1B cells demonstrate these compounds do selectively block human 5-HT1D and 5-HT1B receptors, respectively.	Ketanserin	39-49	5-hydroxytryptamine receptor 1D	Homo sapiens	111-117
8741180-5	1996	The differential antagonist effects of ketanserin and GR 127,935 on naratriptan responses elicited in C6-glial/5-HT1D and C6-glial/5-HT1B cells demonstrate these compounds do selectively block human 5-HT1D and 5-HT1B receptors, respectively.	Ketanserin	39-49	5-hydroxytryptamine receptor 1D	Homo sapiens	199-205
15321364-4	1996	Ketanserin, a 5-HT(2) receptor blocker, has been used successfully to treat preeclampsia.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-30
8727685-5	1996	In a cohort of multiple sclerosis (MS) patients ketanserin, a selective 5-HT2A receptor antagonist, induces recurrent yawning particularly when administered in daytime.	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Homo sapiens	72-87
8740141-7	1996	ketanserin, a 5-HT2A antagonist, at the middle and distal sites only.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	14-20
8726569-3	1996	The specific binding of [3H]-ketanserin in C57BL was higher in the frontal cortex and lower in the neostriatum than in the same structures of CBA mice being indicative of the differences in 5-HT2A receptor density.	Ketanserin	29-39	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	190-205
8692281-12	1996	The ability of ketanserin to antagonize the inhibitory effect induced by activation of these receptors suggests that they can be subclassified as 5-HT1D alpha.	Ketanserin	15-25	5-hydroxytryptamine receptor 1D	Homo sapiens	146-158
8652901-1	1996	We have recently shown that ketanserin, an antagonist of peripheral serotonin 5-HT2 receptors lowers blood erythropoietin (Epo) levels in some chronic hemodialysis patients.	Ketanserin	28-38	erythropoietin	Homo sapiens	107-121
8652901-1	1996	We have recently shown that ketanserin, an antagonist of peripheral serotonin 5-HT2 receptors lowers blood erythropoietin (Epo) levels in some chronic hemodialysis patients.	Ketanserin	28-38	erythropoietin	Homo sapiens	123-126
8652901-2	1996	Based on this finding, a preliminary study was undertaken to investigate the effect of a 3-week oral ketanserin administration on serum Epo concentration and relevant hematological parameters in 4 renal allograft recipients with posttransplant erythrocytosis (PTE).	Ketanserin	101-111	erythropoietin	Homo sapiens	136-139
8652901-3	1996	We found a marked decrease in Epo concentrations following ketanserin administration, from 48% to 76% of the abnormally elevated pretreatment values with subsequent increases at 3 weeks after discontinuation of the drug in all patients studied.	Ketanserin	59-69	erythropoietin	Homo sapiens	30-33
8652901-6	1996	It is hypothesized that ketanserin diminishes erythropoietin synthesis and may become a new drug in the treatment of posttransplant erythrocytosis.	Ketanserin	24-34	erythropoietin	Homo sapiens	46-60
8632342-7	1996	Similarly, certain benzoylpiperidines, e.g., ketanserin, pirenperone and pipamperone, and the antipsychotics clozapine and olanzapine have higher affinity for the human 5-HT2B receptor.	Ketanserin	45-55	5-hydroxytryptamine receptor 2B	Homo sapiens	169-184
8692282-16	1996	According to the results of the interaction experiment of ketanserin and methiothepin with 5-CT on 5-HT release, the presynaptic 5-HT autoreceptors can be subclassified as 5-HT1D beta-like.	Ketanserin	58-68	5-hydroxytryptamine receptor 1B	Homo sapiens	172-183
8788476-4	1996	In addition, evidence is presented for the existence of two classes of 5-HT2A/2C antagonists consisting of negative antagonists that retard learning when given alone (ritanserin, MDL-11,939, pizotifen and cyproheptadine) and those that are neutral antagonists in that they have no effect on learning (ketanserin, mianserin, BOL and LY-53,857).	Ketanserin	301-311	5-hydroxytryptamine receptor 2A	Rattus norvegicus	71-77
8788483-6	1996	Subclassification (5-HT1D alpha or 5-HT1D beta) has been tried with ketanserin which has an at least 60 times higher affinity for 5-HT1D alpha (pki = 7.1) than 5-HT1D beta receptors.	Ketanserin	68-78	5-hydroxytryptamine receptor 1D	Homo sapiens	19-31
8788483-6	1996	Subclassification (5-HT1D alpha or 5-HT1D beta) has been tried with ketanserin which has an at least 60 times higher affinity for 5-HT1D alpha (pki = 7.1) than 5-HT1D beta receptors.	Ketanserin	68-78	5-hydroxytryptamine receptor 1B	Homo sapiens	35-46
8788483-6	1996	Subclassification (5-HT1D alpha or 5-HT1D beta) has been tried with ketanserin which has an at least 60 times higher affinity for 5-HT1D alpha (pki = 7.1) than 5-HT1D beta receptors.	Ketanserin	68-78	5-hydroxytryptamine receptor 1D	Homo sapiens	130-142
8788483-11	1996	Since this inhibitory effect was antagonized by ketanserin (0.3 but not 0.03 microM) and methiothepin, the presynaptic 5-HT receptor in this tissue may belong to the 5-HT1D alpha subtype.	Ketanserin	48-58	5-hydroxytryptamine receptor 1D	Homo sapiens	166-178
8789380-17	1996	In rings with intact endothelium the 5-HT2A receptor partial agonist SK&F 103829 (2,3,4,5-tetrahydro-8[methyl sulphonyl]-1H3-benzazepin-7-ol methensulphonate) contracted rings with a -log EC50, M of 5.0 and an intrinsic activity of 0.49 with respect to 5-HT; the effects were antagonized by ketanserin 1000 nM.	Ketanserin	295-305	5-hydroxytryptamine receptor 2A	Homo sapiens	37-52
8684602-7	1996	The pain response produced by alpha-methyl-5-HT plus PGE2 was blocked by pretreatment with the 5-HT2A/2C antagonists ketanserin and ritanserin, and the 5-HT2A antagonist spiperone (MPE50 values 1.4, 7.7 and 0.06 nmol, respectively).	Ketanserin	117-127	5-hydroxytryptamine receptor 2A	Rattus norvegicus	95-101
8534270-3	1996	Consequently, the human 5-HT2A receptor stably expressed in NIH 3T3 cells was radiolabelled with the endogenous agonist [3H]-5-HT, the partial agonist [3H]-DOB, and the antagonist [3H]-ketanserin.	Ketanserin	185-195	5-hydroxytryptamine receptor 2A	Homo sapiens	24-39
8602111-5	1996	Radioactivity in the neocortex, but not in the cerebellum, was reduced after injection of ketanserin, indicating that neocortical radioactivity following injection of [11C]MDL 100907 represents specific binding to 5-HT2A receptors.	Ketanserin	90-100	5-hydroxytryptamine receptor 2A	Homo sapiens	214-220
8717154-9	1996	Together with the 5-HT1D receptor binding selectivity and antagonist activity of ketanserin and ritanserin, the findings define important pharmacological differences between cloned human 5-HT1D and 5-HT1B receptor sites.	Ketanserin	81-91	5-hydroxytryptamine receptor 1B	Homo sapiens	198-204
8543023-3	1995	The receptors were transiently expressed in COS-7 cells and exhibit a pharmacological profile closely resembling their human homologues, including a higher affinity of ketanserin for the 5-HT1D alpha subtype.	Ketanserin	168-178	5-hydroxytryptamine receptor 1D	Homo sapiens	187-199
8848700-6	1995	In a subsequent placebo-controlled study based on pathophysiological considerations, we attempted to beneficially influence the sleep disturbance and the pain syndrome with the 5-HT2-receptor antagonist ketanserine, as this system has been proved to play a major role in the regulation of both sleep and pain.	Ketanserin	203-214	5-hydroxytryptamine receptor 2A	Homo sapiens	177-191
7498643-4	1995	RESULTS: 5-HT binding was completely inhibited by 5-HT and partially by 5-HT2A (ketanserin), 5-HT4 (SDZ-205,557), and 5-HT1p (N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide; 5-HTP-DP) receptor antagonists.	Ketanserin	80-90	5-hydroxytryptamine receptor 2A	Homo sapiens	72-78
7498967-7	1995	Ketanserin (5-HT2A antagonist) competitively inhibited contraction to 5-HT in arteries from normotensive rats (-log dissociation constant [mol/L]; pKB = 8.54) but not from hypertensive rats (pKB > 6.5).	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	12-18
8569225-0	1995	Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone.	Ketanserin	0-10	erythropoietin	Homo sapiens	18-32
8749037-0	1995	Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin.	Ketanserin	131-141	5-hydroxytryptamine receptor 2A	Homo sapiens	105-119
8749037-3	1995	The present study was therefore designed to examine the effect of the 5-HT2 receptor antagonist, ketanserin, against a dizocilpine-induced disruption of prepulse inhibition, as well as the behavioural stereotypy produced by this drug.	Ketanserin	97-107	5-hydroxytryptamine receptor 2A	Homo sapiens	70-84
8749037-4	1995	Ketanserin (2 mg/kg) reversed the prepulse inhibition disruption produced by dizocilpine (0.15 mg/kg), as did the non-selective 5-HT1/5-HT2 receptor antagonist metergoline (1 mg/kg).	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	134-148
8685087-6	1996	The 5-HT2 receptor antagonist ketanserin antagonised the contraction induced by 5-HT, alpha-methyl-5-HT and 2-methyl-5-HT.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
7473132-6	1995	Results of ex vivo binding studies designed to estimate occupancy of 5-HT2A and 5-HT2C receptors suggested that the training dose of ketanserin blocked only 5-HT2A receptors and not 5-HT2C receptors.	Ketanserin	133-143	5-hydroxytryptamine receptor 2A	Rattus norvegicus	69-81
7473132-6	1995	Results of ex vivo binding studies designed to estimate occupancy of 5-HT2A and 5-HT2C receptors suggested that the training dose of ketanserin blocked only 5-HT2A receptors and not 5-HT2C receptors.	Ketanserin	133-143	5-hydroxytryptamine receptor 2A	Rattus norvegicus	69-75
7473132-6	1995	Results of ex vivo binding studies designed to estimate occupancy of 5-HT2A and 5-HT2C receptors suggested that the training dose of ketanserin blocked only 5-HT2A receptors and not 5-HT2C receptors.	Ketanserin	133-143	5-hydroxytryptamine receptor 2C	Rattus norvegicus	80-86
7473132-7	1995	The combined results from the substitution, antagonism and ex vivo receptor autoradiographic studies suggest that the discriminative stimuli of quipazine and ketanserin are mediated at least in part by the 5-HT2A receptor.	Ketanserin	158-168	5-hydroxytryptamine receptor 2A	Rattus norvegicus	206-212
8569225-1	1995	Ketanserin, an antagonist of peripheral serotonin receptors when given to hemodialyzed patients treated with recombinant human erythropoietin (rHuEpo) corrects some changes in hemostasis but also apparently delays an increase in hematocrit.	Ketanserin	0-10	erythropoietin	Homo sapiens	127-141
8569225-2	1995	We wished to elucidate the effects of oral administration of ketanserin on serum Epo, some hematological and biochemical blood parameters, arterial blood pressure (BP), and bleeding time in hemodialyzed patients receiving rHuEpo therapy.	Ketanserin	61-71	erythropoietin	Homo sapiens	81-84
8569225-3	1995	We noted a 33% decrease in Epo concentration (p < 0.05) after a 4-week ketanserin trial in patients in the initial stage of rHuEpo therapy.	Ketanserin	74-84	erythropoietin	Homo sapiens	27-30
8569225-5	1995	Ketanserin administered for 14 days to patients between 32 and 34 weeks of rHuEpo therapy also produced a decrease of 26% in Epo concentration (p < 0.005).	Ketanserin	0-10	erythropoietin	Homo sapiens	78-81
7644088-6	1995	In fact, at the end of the treatment with ketanserin, supine SBP was decreased 10 +/- 20 and DBP 5 +/- 10 mmHg, standing SBP was reduced 15 +/- 19 and DBP 7 +/- 15 mmHg.	Ketanserin	42-52	selenium binding protein 1	Homo sapiens	61-64
8532076-4	1995	Ketanserin at a concentration which should block the 5-HT 1D alpha but not the 5-HT 1D beta receptor failed to antagonize the inhibitory effect of 5-carboxamidotryptamine.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Homo sapiens	53-66
8532076-4	1995	Ketanserin at a concentration which should block the 5-HT 1D alpha but not the 5-HT 1D beta receptor failed to antagonize the inhibitory effect of 5-carboxamidotryptamine.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Homo sapiens	53-60
8549648-0	1995	Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Homo sapiens	65-77
8549648-0	1995	Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes.	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	82-93
8549648-2	1995	In [3H]5-HT competition assays, the classical 5-HT2A receptor antagonists, ritanserin and ketanserin, displayed moderate affinity (pKi = 7.30 and 7.17, respectively) and marked selectivity (22- and 71-fold, respectively) for the recombinant human 5-HT1D alpha subtype relative to the 5-HT1D beta receptor.	Ketanserin	90-100	5-hydroxytryptamine receptor 2A	Homo sapiens	46-61
8549648-2	1995	In [3H]5-HT competition assays, the classical 5-HT2A receptor antagonists, ritanserin and ketanserin, displayed moderate affinity (pKi = 7.30 and 7.17, respectively) and marked selectivity (22- and 71-fold, respectively) for the recombinant human 5-HT1D alpha subtype relative to the 5-HT1D beta receptor.	Ketanserin	90-100	5-hydroxytryptamine receptor 1D	Homo sapiens	247-259
8584041-11	1995	Ketanserin had a low affinity for [3H]sumatriptan binding sites in all guinea-pig brain regions, compatible with the presence of the 5-HT1D beta subtype.	Ketanserin	0-10	5-hydroxytryptamine receptor 1D	Cavia porcellus	133-139
7632610-3	1995	The distribution and density of 5-HT2A receptors were determined by in vitro binding of [3H]ketanserin in the presence of prazosin to exclude binding to alpha 1-adrenoreceptors.	Ketanserin	88-102	5-hydroxytryptamine receptor 2A	Rattus norvegicus	32-38
8597525-8	1995	In the doses used, CLOZ, CPZ, and ORG decreased the frontal cortical 5-HT2A receptor binding of [3H]ketanserin and [125I]DOI by 40% to 60%.	Ketanserin	100-110	5-hydroxytryptamine receptor 2A	Rattus norvegicus	69-75
8584618-7	1995	Ketanserin (2.5 mg/kg), an antagonist with greater than 1 order of magnitude higher affinity for 5-HT2A receptors than either 5-HT2C or D2 receptors, also fully blocked the substitution of these compounds for the (-)DOM stimulus, while the selective D2 antagonist thiothixene (0.1-1.0 mg/kg) failed to block the substitution of lisuride for the (-)DOM stimulus.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	97-103
8584622-7	1995	Alternatively, a trend toward a lower hypothalamic [3H]citalopram binding in (group-housed) RLA rats than in RHA rats could be noted, whereas cortical [3H]ketanserin binding at 5-HT2A receptors was lower in RLA rats than in RHA rats, a difference prevented by prior isolation.	Ketanserin	155-165	5-hydroxytryptamine receptor 2A	Rattus norvegicus	177-183
8570772-4	1995	It has previously been demonstrated that ketanserin, a 5-HT2A antagonist, and ritanserin, a 5-HT2A/5-HT2C antagonist, block the prolactin and attenuate the hypothalamic-pituitary-adrenal axis responses to mCPP in man or rodents.	Ketanserin	41-51	5-hydroxytryptamine receptor 2A	Homo sapiens	55-61
8549648-2	1995	In [3H]5-HT competition assays, the classical 5-HT2A receptor antagonists, ritanserin and ketanserin, displayed moderate affinity (pKi = 7.30 and 7.17, respectively) and marked selectivity (22- and 71-fold, respectively) for the recombinant human 5-HT1D alpha subtype relative to the 5-HT1D beta receptor.	Ketanserin	90-100	5-hydroxytryptamine receptor 1B	Homo sapiens	284-295
8549648-7	1995	Since ketanserin exhibits significant selectivity for the human 5-HT1D alpha receptor, this antagonist can be used as a pharmacological tool to discriminate between 5-HT1D alpha and 5-HT1D beta receptor-mediated responses in human tissues.	Ketanserin	6-16	5-hydroxytryptamine receptor 1D	Homo sapiens	64-76
8549648-7	1995	Since ketanserin exhibits significant selectivity for the human 5-HT1D alpha receptor, this antagonist can be used as a pharmacological tool to discriminate between 5-HT1D alpha and 5-HT1D beta receptor-mediated responses in human tissues.	Ketanserin	6-16	5-hydroxytryptamine receptor 1D	Homo sapiens	165-177
8549648-7	1995	Since ketanserin exhibits significant selectivity for the human 5-HT1D alpha receptor, this antagonist can be used as a pharmacological tool to discriminate between 5-HT1D alpha and 5-HT1D beta receptor-mediated responses in human tissues.	Ketanserin	6-16	5-hydroxytryptamine receptor 1B	Homo sapiens	182-193
7498311-6	1995	Thus, antagonism by ketanserin and GR127935 confirms the presence of 5-HT1D receptors in rabbit saphenous vein and guinea-pig jugular vein.	Ketanserin	20-30	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	69-75
8527286-8	1995	After maximal response to each agonist had been obtained, ketanserin (a 5-HT2 receptor antagonist) 0.6 microM was added to the tissue bath, followed by methiotepin (0.6 microM) and the reduction in tension produced by the addition of each antagonist was determined.	Ketanserin	58-68	5-hydroxytryptamine receptor 2A	Homo sapiens	72-86
8532190-7	1995	The 5-HT receptor antagonists ketanserin and ritanserin (10(-7)-10(-6)M, when applied to the substantia nigra, inhibited raphe-stimulated AChE release.	Ketanserin	30-40	acetylcholinesterase	Cavia porcellus	138-142
8556225-0	1995	Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic-hyperinsulinemic clamp technique.	Ketanserin	0-10	insulin	Homo sapiens	22-29
8556225-1	1995	The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients.	Ketanserin	51-61	insulin	Homo sapiens	65-72
7562606-9	1995	The effect of 5-HT was blocked by the 5-HT1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide (NAN-190) but not by ketanserin, a 5-HT2A/2C antagonist.	Ketanserin	147-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-44
8546536-9	1995	The 5-HT1/5-HT2 antagonist, methysergide (0.5 mg/kg), and the selective 5-HT2 antagonist, ketanserin (50 micrograms/kg), completely abolished all responses to alpha-Me-5-HT.	Ketanserin	90-100	5-hydroxytryptamine receptor 2A	Rattus norvegicus	72-77
7596129-1	1995	To elucidate the complex pharmacological actions of the 5-hydroxytryptamine2A (5-HT2A)-receptor antagonist ketanserin, we investigated certain similarities between these properties and those of the Ca antagonist verapamil.	Ketanserin	107-117	5-hydroxytryptamine receptor 2A	Rattus norvegicus	56-77
7596129-1	1995	To elucidate the complex pharmacological actions of the 5-hydroxytryptamine2A (5-HT2A)-receptor antagonist ketanserin, we investigated certain similarities between these properties and those of the Ca antagonist verapamil.	Ketanserin	107-117	5-hydroxytryptamine receptor 2A	Rattus norvegicus	79-85
7644088-6	1995	In fact, at the end of the treatment with ketanserin, supine SBP was decreased 10 +/- 20 and DBP 5 +/- 10 mmHg, standing SBP was reduced 15 +/- 19 and DBP 7 +/- 15 mmHg.	Ketanserin	42-52	selenium binding protein 1	Homo sapiens	121-124
7707322-1	1995	Ketanserin (1) is a fairly selective 5-HT2 antagonist that binds both at 5-HT2A and 5-HT2C receptors.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	73-79
8695057-5	1995	Serotonin 5-HT2 and dopamine D4 receptor binding sites could also be detected by displacement experiments using ketanserin and nemonapride, respectively, in frontal cortex and limbic area, but not in hippocampus or striatum.	Ketanserin	112-122	dopamine receptor D4	Rattus norvegicus	20-40
7708749-2	1995	Both agonists and antagonists specific for various serotonin (5-hydroxytryptamine, 5HT) receptor subtypes interacted directly with alpha 2 beta 4 nAcChoRs: 5HT, (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin, methysergide, spiperone, and ketanserin reversibly reduced the amplitude of AcCho currents and accelerated their decay.	Ketanserin	236-246	MGC75582, possible similarity to act2 S homeolog	Xenopus laevis	131-138
7617676-1	1995	Specific binding of [3H]ketanserin to 5-HT2A serotonin receptor sites in the corpus striatum and frontal cortex and the effect of 5-HT2A antagonists in rats and mice hereditarily predisposed to catalepsy has been studied.	Ketanserin	20-34	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	38-44
8801774-26	1995	The 5-HT2-receptor antagonist ketanserin reduced cardiovascular tolerance without significant effects on the hormonal responses.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
8808177-3	1995	The aim of this study was to evaluate the effects of two relatively selective 5-HT2A receptor antagonists, ketanserin and ritanserin, on delayed hyperactivity and the ensuing neuronal degeneration induced by 3 minutes of bilateral carotid artery ligation in Mongolian gerbils.	Ketanserin	107-117	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	78-93
8903941-7	1995	In addition, methiothepin and ketanserin inhibited basal [35S]-GTPgammaS binding to membranes containing 5-HT1Dalpha or 5-HT1Dbeta receptors, suggesting that these compounds show negative efficacy at 5-HT1D receptor subtypes.	Ketanserin	30-40	5-hydroxytryptamine receptor 1D	Homo sapiens	105-116
7869838-4	1995	Ketanserin (10(-5) M) also caused a decrease in the CCK-8s response.	Ketanserin	0-10	cholecystokinin	Gallus gallus	52-55
7777653-6	1995	The 5-HT2 antagonist, ketanserin was able to reduce the adrenocortical response in the conditioned fear paradigm and the response to IL-1 alpha injection.	Ketanserin	22-32	interleukin 1 alpha	Homo sapiens	133-143
8588266-4	1995	The 5HT2 receptor antagonist ketanserin (KT; 10(-5)-10(-4) M) and mixed 5HT1/5HT2 receptor antagonist methysergide (MS; 5 x 10(-5) M) inhibited the effect of 5-HT.	Ketanserin	29-39	5-hydroxytryptamine receptor 2A	Homo sapiens	4-17
8087924-4	1994	Although these subtypes have similar pharmacology, 5-HT1D beta receptors appear to have lower affinity for ketanserin than 5-HT1D alpha receptors.	Ketanserin	107-117	5-hydroxytryptamine receptor 1B	Homo sapiens	51-62
8087924-10	1994	Using [3H]-serotonin to label transfected and expressed receptors, we verified that ketanserin has lower affinity for 5-HT1D beta (pKi [-log Ki, mol/L] less than 5.0) than for 5-HT1D alpha (pKi = 7.1 +/- 0.1) receptors.	Ketanserin	84-94	5-hydroxytryptamine receptor 1B	Homo sapiens	118-129
8087924-11	1994	A concentration of ketanserin (1 mumol/L) that would occupy more than 90% of 5-HT1D alpha receptors failed to block 5-HT-induced contractions (4 patients).	Ketanserin	19-29	5-hydroxytryptamine receptor 1D	Homo sapiens	77-89
7813581-3	1994	Ketanserin, a 5-HT2 receptor antagonist, blocked the performance-impairing effect of DOI on passive avoidance consolidation.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-28
7959408-10	1994	Ketanserin, a serotonin 5-HT2/1C-receptor antagonist, showed a distinctive inhibition of acid secretion induced by CCK-8 (i.c.v.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-41
7959408-10	1994	Ketanserin, a serotonin 5-HT2/1C-receptor antagonist, showed a distinctive inhibition of acid secretion induced by CCK-8 (i.c.v.	Ketanserin	0-10	cholecystokinin	Rattus norvegicus	115-118
7894528-3	1994	There was an associated decrease in the number of 5-HT2A receptors labelled with ketanserin in the cortex on the side of infusion.	Ketanserin	81-91	5-hydroxytryptamine receptor 2A	Rattus norvegicus	50-56
7994200-6	1994	Moreover, ketanserin, an antagonist of 5-HT2 receptor, also induces activation of AA incorporation into membrane lipids.	Ketanserin	10-20	5-hydroxytryptamine receptor 2A	Homo sapiens	39-53
7925513-3	1994	We compared the effects of the intracoronary infusion of 1 mg ketanserin (5-HT2 receptor antagonist) on proximal and distal coronary arterial segments immediately after PTCA in both vessels subjected to PTCA and control vessels.	Ketanserin	62-72	5-hydroxytryptamine receptor 2A	Homo sapiens	74-88
7714755-2	1995	HTW were dose-dependently inhibited by the 5-HT2A/2C antagonists, ritanserin, metergoline, mesulergine, mianserin, ICI 169,369 and LY 58,537, by the preferential 5-HT2A antagonist, ketanserin and by the novel, selective 5-HT2A antagonist, SR 46349B.	Ketanserin	181-191	5-hydroxytryptamine receptor 2A	Rattus norvegicus	43-49
7725978-0	1994	Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist.	Ketanserin	87-97	5-hydroxytryptamine receptor 2A	Homo sapiens	122-136
7851485-3	1994	In addition the results indicate that, under the assay conditions described, [3H]L-694,247 specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.	Ketanserin	150-160	5-hydroxytryptamine receptor 1B	Sus scrofa	115-126
7882182-8	1994	(v) The 5-HT2 receptor antagonist ketanserin at low concentration (10 nM) inhibited contractile responses to 5-HT in an apparently competitive manner.	Ketanserin	34-44	5-hydroxytryptamine receptor 2A	Homo sapiens	8-22
7531292-3	1994	The vascular permeability induced by 5-HT was inhibited by pretreatment with intraperitoneal injection of ketanserin (5-HT2A antagonist) and methysergide (5-HT1/2A antagonist), less efficiently by 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine (NAN-190) (5-HT1A antagonist), but not by granisetron (5-HT3 antagonist).	Ketanserin	106-116	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	118-124
7531292-3	1994	The vascular permeability induced by 5-HT was inhibited by pretreatment with intraperitoneal injection of ketanserin (5-HT2A antagonist) and methysergide (5-HT1/2A antagonist), less efficiently by 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine (NAN-190) (5-HT1A antagonist), but not by granisetron (5-HT3 antagonist).	Ketanserin	106-116	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	266-272
7828173-5	1994	In contrast, 5-HT2A receptor antagonists, ketanserin and mianserin, had high affinity in antagonizing the changes in [Ca2+]i response to 5-HT with pKB values of 8.3 and 8.3, respectively.	Ketanserin	42-52	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	13-28
8903941-7	1995	In addition, methiothepin and ketanserin inhibited basal [35S]-GTPgammaS binding to membranes containing 5-HT1Dalpha or 5-HT1Dbeta receptors, suggesting that these compounds show negative efficacy at 5-HT1D receptor subtypes.	Ketanserin	30-40	5-hydroxytryptamine receptor 1B	Homo sapiens	120-130
8903941-7	1995	In addition, methiothepin and ketanserin inhibited basal [35S]-GTPgammaS binding to membranes containing 5-HT1Dalpha or 5-HT1Dbeta receptors, suggesting that these compounds show negative efficacy at 5-HT1D receptor subtypes.	Ketanserin	30-40	5-hydroxytryptamine receptor 1D	Homo sapiens	105-111
8190100-3	1994	This effect of 5-HT was blocked by 10 nM ketanserin as well as by 10 nM spiperone, indicating a response mediated by the 5-HT2A receptor subtype.	Ketanserin	41-51	5-hydroxytryptamine receptor 2A	Homo sapiens	121-136
8174779-6	1994	In vivo, the IgE-independent MC secretagogues, compound 48/80 and ACTH, induced anagen in mouse telogen follicles after intracutaneous administration, while inhibitors of mast cell degranulation (cromoglycate, tiacrilast) and antagonists of selected MC products (clemastin, ranitidine, ketanserin) significantly retarded the induced development of anagen follicles in these mice.	Ketanserin	286-296	pro-opiomelanocortin-alpha	Mus musculus	66-70
7984284-4	1994	The effect of mCPP was more potently inhibited by 1-(1-naphthyl)piperazine than by ketanserin, indicative of its mediation via activation of 5-HT2C rather than 5-HT2A receptors.	Ketanserin	83-93	5-hydroxytryptamine receptor 2C	Rattus norvegicus	141-147
8078486-7	1994	Both compounds exhibited higher affinity at the human 5-HT2B receptor (ketanserin, Ki = 376 +/- 58 nM; spiperone, Ki = 697 +/- 54 nM) than at the rat 5-HT2B receptor (ketanserin, Ki = 3559 +/- 175 nM; spiperone, Ki = 3278 +/- 92 nM).	Ketanserin	71-81	5-hydroxytryptamine receptor 2B	Homo sapiens	54-69
7908849-3	1994	Pretreatment with naftidrofuryl or ketanserin prevented hippocampal CA1 neuronal loss after 5 min of transient ischemia.	Ketanserin	35-45	carbonic anhydrase 1	Homo sapiens	68-71
17972821-1	1994	Ketanserin is a selective 5-HT2-receptor antagonist.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	26-40
8012704-13	1994	Ketanserin prevented both the constrictor effect of SK&F 103829 and the SK&F 103829-evoked potentiation of the responses to noradrenaline and angiotensin II in the mesenteric arterial bed.	Ketanserin	0-10	angiotensinogen	Rattus norvegicus	150-164
8313550-8	1994	Contraction was significantly attenuated after pretreatment of the vessel segments with ketanserin (5-HT2 receptor antagonist, 1 mumol/L) or SQ30741 (TXA2 receptor antagonist, 0.01 mumol/L), reaching 8.8 +/- 2.3% and 3.2 +/- 2.2% of contraction to 100 mmol/L K+, respectively.	Ketanserin	88-98	5-hydroxytryptamine receptor 2A	Homo sapiens	100-114
9234277-3	1994	Regional mouse brain retention of [11C]TBZ is highest in brain regions with greatest monoaminergic innervation (striatum, hypothalamus) and can be reduced with ligands for the monoamine vesicular transporter (TBZ, ketanserin) but not haloperidol, a dopamine D2 receptor antagonist.	Ketanserin	214-224	dopamine receptor D2	Mus musculus	249-269
8139757-4	1994	Tryptamine induced hyperglucagonemia in tolbutamide-treated mice, and this effect elicited by tryptamine was strongly inhibited by the 5-HT2 receptor antagonist ketanserin.	Ketanserin	161-171	hypothermia due to alcohol sensitivity 2	Mus musculus	137-140
7731894-0	1994	[Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].	Ketanserin	1-11	erythropoietin	Homo sapiens	22-36
7731894-12	1994	The study shows that ketanserin administered to haemodialyzed patients on long-term rHuEPO therapy induces a decrease in erythropoietin concentration and inhibits erythropoiesis.	Ketanserin	21-31	erythropoietin	Homo sapiens	121-135
8165366-2	1994	injection of ketanserin (K) (20mg/kg) on the levels of monoamines and neuropeptide Y (NPY) in some central and peripheral tissues was examined in normotensive (WKY) and spontaneously hypertensive (SHR) rats.	Ketanserin	13-23	neuropeptide Y	Rattus norvegicus	70-84
8165366-2	1994	injection of ketanserin (K) (20mg/kg) on the levels of monoamines and neuropeptide Y (NPY) in some central and peripheral tissues was examined in normotensive (WKY) and spontaneously hypertensive (SHR) rats.	Ketanserin	13-23	neuropeptide Y	Rattus norvegicus	86-89
8266806-7	1993	The 5-HT2-receptor antagonist ketanserin reduced the tolerated tilt time (10 +/- 4 vs. 32 +/- 2 min; P < 0.0003, n = 7) but had no significant effects on hormonal variables.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
8276064-3	1993	The reduction induced by 8-OH-DPAT and DOI was antagonized by the 5-HT1A antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin ((S)-UH-301) and the 5-HT2 antagonist ketanserin, respectively.	Ketanserin	174-184	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
7907025-5	1993	Spiperone, spiperone plus propranolol, LY 53857, ketanserin and propranolol antagonised the pressor effects of DOI suggesting the stimulation of both 5-HT2 and 5-HT1C receptors.	Ketanserin	49-59	5-hydroxytryptamine receptor 2C	Rattus norvegicus	160-166
8253115-2	1993	In addition the results indicate that, under the assay conditions described, [125I]GTI specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.	Ketanserin	146-156	5-hydroxytryptamine receptor 1B	Homo sapiens	111-122
8229069-6	1993	In C3H mice, methysergide, mianserin, ketanserin, and spiperone significantly decreased the TRH content in all regions of the spinal cord, while 3 alpha-tropanyl-1H-indole-3-carboxylic acid ester (ICS205-930) did not affect it.	Ketanserin	38-48	thyrotropin releasing hormone	Mus musculus	92-95
8347897-3	1993	It is very likely that the 5-HT2 receptor is involved in the inhibition of cytotoxicity because ketanserin, an inhibitor of the 5-HT2 receptor, partially prevented the effect of 5-HT.	Ketanserin	96-106	5-hydroxytryptamine receptor 2A	Homo sapiens	27-41
8223940-8	1993	Ketanserin, which binds more weakly than 1-(1-naphthyl)piperazine to 5-HT1C receptors and more strongly to 5-HT2 receptors, attenuated weaker but not stronger hypophagic effects of d-fenfluramine (1.25, 2.0 mg/kg) when given at high dosage (8, 16 mumol/kg s.c.).	Ketanserin	0-10	5-hydroxytryptamine receptor 2C	Rattus norvegicus	69-75
8347897-3	1993	It is very likely that the 5-HT2 receptor is involved in the inhibition of cytotoxicity because ketanserin, an inhibitor of the 5-HT2 receptor, partially prevented the effect of 5-HT.	Ketanserin	96-106	5-hydroxytryptamine receptor 2A	Homo sapiens	128-142
8335063-1	1993	Ketanserin, a 5HT2 receptor antagonist completely blocked the response of 5-HT plus epinephrine and this in the nanomolar concentration range in which the drug selectively antagonizes 5-HT2 receptor-mediated responses.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-27
8335063-1	1993	Ketanserin, a 5HT2 receptor antagonist completely blocked the response of 5-HT plus epinephrine and this in the nanomolar concentration range in which the drug selectively antagonizes 5-HT2 receptor-mediated responses.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	184-198
8489249-3	1993	Tetrabenazine (TBZ)-displaceable [3H]ketanserin binding was used to label the granular 5-HT transporter.	Ketanserin	33-47	solute carrier family 6 member 4	Homo sapiens	87-103
8391650-10	1993	The 5-HT2 receptor antagonist ketanserin (1 mumol/l) inhibited the contractile response but did not alter vasodilatation.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
8103393-5	1993	(3) Administration of atenolol and ketanserin to the SHR decreased the Bmax value of the beta 1-adrenoceptor.	Ketanserin	35-45	adrenoceptor beta 1	Rattus norvegicus	89-108
8512759-9	1993	A similar result was obtained with the 5-HT2-receptor antagonist ketanserin.	Ketanserin	65-75	5-hydroxytryptamine receptor 2A	Homo sapiens	39-53
8423526-6	1993	Five structurally distinct 5-HT2-receptor antagonists (ketanserin, cisapride, spiperone, MDL11939, ICI169369) blocked 5-HT-induced contraction with antagonist dissociation constants similar to reported 5-HT2-receptor affinities.	Ketanserin	55-65	5-hydroxytryptamine receptor 2A	Homo sapiens	27-41
11224176-1	1993	A place-conditioning procedure was used to investigate the affective properties in rats of non-selective serotonin receptor antagonists (mianserin, eltoprazine and ketanserin) differing from each other by their affinity for 5-HT(1C) and 5-HT(2) receptors among others.	Ketanserin	164-174	5-hydroxytryptamine receptor 2C	Rattus norvegicus	224-231
8386235-5	1993	The 5-HT1C/2 receptor agonist 2,5-dimethoxy-4-bromoamphetamine also completely reversed HAL-induced catalepsy, an effect blocked by ketanserin, but not pindolol.	Ketanserin	132-142	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-10
8386213-6	1993	The suppressive effects of 8-OH-DPAT and DOI on CRH-stimulated ACTH release were antagonized by (-)propranolol, a beta-adrenergic receptor antagonist which binds the 5-HT1A receptor with elevated affinity, and ketanserin, a 5-HT2 receptor antagonist respectively.	Ketanserin	210-220	corticotropin releasing hormone	Rattus norvegicus	48-51
8453957-1	1993	The 5-HT2-receptor antagonist ketanserin (20-40 mg b.i.d.)	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
1479590-0	1992	Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.	Ketanserin	0-10	5-hydroxytryptamine receptor 2C	Homo sapiens	69-75
8502121-2	1993	The hyperglucagonemic effects of 5-HT were completely antagonized by methysergide, ketanserin and ritanserin which have a high affinity for 5-HT2 receptors.	Ketanserin	83-93	hypothermia due to alcohol sensitivity 2	Mus musculus	142-145
1479590-2	1992	Furthermore, ketanserin also binds at 5-HT1C receptors and even less is known about the influence of its structural features on 5-HT1C receptor affinity.	Ketanserin	13-23	5-hydroxytryptamine receptor 2C	Homo sapiens	38-44
1479590-7	1992	All of the compounds examined bind at 5-HT1C sites with lower affinity than ketanserin, and some of the simplified analogues bind with nearly 10 times the 5-HT2 versus 5-HT1C selectivity of ketanserin; however, none displays > 120-fold selectivity.	Ketanserin	190-200	5-hydroxytryptamine receptor 2C	Homo sapiens	168-174
1301238-4	1992	Intravenous administration of the mixed 5-HT1C/5-HT2 antagonists (cinanserin, cyproheptadine, ketanserin, and ritanserin) prevented both desynchronization and the change in unit activity induced by noxious stimulation within 2.5-15 min of the injection.	Ketanserin	94-104	5-hydroxytryptamine receptor 2C	Rattus norvegicus	40-46
1336746-6	1992	The 5-HT2/5-HT1c agonist DOI (3 x 10(-7) mol/l) decreased the evoked release of tritium, an effect which was prevented by ketanserin (10(-7) mol/l).	Ketanserin	122-132	5-hydroxytryptamine receptor 2C	Rattus norvegicus	10-16
1491739-2	1992	In the present study, we determined whether a subeffective dose of the serotonergic type-2 receptor antagonist, ketanserin, would augment the facilitative effects produced by the acetylcholinesterase inhibitor, physostigmine, on memory in aged rats using the same task.	Ketanserin	112-122	acetylcholinesterase	Rattus norvegicus	179-199
8321084-6	1993	In fact, although it is known that 5-HT added to PRP was only able to induce a moderate platelet aggregation, the 5-HT2 antagonist ketanserin counteracted the aggregation induced by ADP, epinephrine and thrombin.	Ketanserin	131-141	coagulation factor II, thrombin	Homo sapiens	203-211
1451743-2	1992	Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 microM), exacerbated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist, Y-25130 (0.1-100 microM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 microM), produced dose-dependent neuroprotection against the ischemia-induced decrease.	Ketanserin	253-263	5-hydroxytryptamine receptor 3A	Rattus norvegicus	19-33
1434709-7	1992	In contrast, in the porcine and human mammary arteries, endothelium-dependent relaxations to platelets mediated by nitric oxide were noted, particularly in rings preincubated with the thromboxane A2 receptor antagonist SQ-30741 and the 5-hydroxytryptamine (5HT2)-serotonergic receptor antagonist ketanserin.	Ketanserin	296-306	thromboxane A2 receptor	Homo sapiens	184-207
1330647-6	1992	Cells expressing the 5-HT2 receptor exhibited high affinity binding for the antagonist [3H]ketanserin with a 5-HT2 receptor specific pharmacological profile.	Ketanserin	87-101	5-hydroxytryptamine receptor 2A	Homo sapiens	21-35
1448780-3	1992	The potency ranking of antithrombotic effect was vapiprost > ketanserin (serotonin 5-HT2 receptor antagonist) >> ticlopidine (inhibitor of ADP-induced platelet aggregation) = dipyridamole (adenosine uptake inhibitor) > aspirin (cyclooxygenase inhibitor).	Ketanserin	64-74	5-hydroxytryptamine receptor 2A	Rattus norvegicus	76-100
1443511-2	1992	Ketanserin, a 5HT2- and alpha 1-receptor antagonist, decreases blood pressure by decreasing systemic vascular resistance without causing reflex cardiac stimulation, while cardiac output remains unchanged.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-40
1330647-6	1992	Cells expressing the 5-HT2 receptor exhibited high affinity binding for the antagonist [3H]ketanserin with a 5-HT2 receptor specific pharmacological profile.	Ketanserin	87-101	5-hydroxytryptamine receptor 2A	Homo sapiens	109-123
1386277-3	1992	Following a control period of Krebs-Ringer Phosphate (KRP) superfusion, ketanserin (5-HT2 receptor antagonist, 1 x 10(-6) M) significantly increased LHRH release (p less than 0.05).	Ketanserin	72-82	5-hydroxytryptamine receptor 2A	Rattus norvegicus	84-89
1513320-7	1992	The rank order of potency of ligands to compete for the [3H]5-HT-labeled site best matched the binding profile of the pharmacologically defined 5-HT1E binding site, 5-HT greater than methysergide greater than ergotamine greater than 8-hydroxy-2-(di-n-propylamino)tetralin greater than 5-carboxyamidotryptamine greater than ketanserin.	Ketanserin	323-333	5-hydroxytryptamine receptor 1E	Homo sapiens	144-150
1511336-26	1992	Each of the 5-HT3 receptor selective antagonists (ICS 205-930 or MDL 72222) produced a dose-dependent attenuation of the Bezold-Jarisch reflex-mediated hypotension and bradycardia, and each of the 5-HT2 receptor selective antagonists (xylamidine, ketanserin or LY 53857) produced a dose-dependent attenuation of the pressor response.	Ketanserin	247-257	5-hydroxytryptamine receptor 3A	Rattus norvegicus	12-26
1354865-4	1992	However, there are also several arguments which do not support a causal role of 5HT in hypertensive disease: 5HT is not a generally accepted pressor agent, whereas its concentration in the circulating blood is subthreshold; the 5HT2-receptor antagonist ketanserin is the only agent of this type which lowers blood pressure, other 5HT2-receptor blockers (ritanserin; LY 53587) being inactive.	Ketanserin	253-263	5-hydroxytryptamine receptor 2A	Homo sapiens	228-241
1532676-6	1992	Presumably this binding, which was blocked by ketanserin, corresponds to 5HT1C sites.	Ketanserin	46-56	5-hydroxytryptamine receptor 2C	Rattus norvegicus	73-78
1320445-9	1992	The 5-HT1C/2 antagonist ketanserin and the 5-HT1A/2 antagonist spiperone significantly attenuated the 5-HT-induced depression of NMDA-depolarizations.	Ketanserin	24-34	5-hydroxytryptamine receptor 2C	Homo sapiens	4-10
1608150-1	1992	Plasma levels of catecholamines, aldosterone and cortisol as well as plasma renin activity during hypotension by ketanserin were studied in 9 mongrel dogs under 0.87% halothane in oxygen (1MAC).	Ketanserin	113-123	renin	Canis lupus familiaris	76-81
1315815-6	1992	RESULTS OF DATA ANALYSIS: A number of agents have a favourable benefit-risk profile for use in women with PIH/preeclampsia; these include alpha-methyldopa, beta-blockers, hydralazine, prazosin, calcium channel antagonists and ketanserin.	Ketanserin	226-236	pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included)	Homo sapiens	106-109
1506656-7	1992	The addition of ketanserin to vasopressin corrected most of the systemic hemodynamic disturbances produced by vasopressin.	Ketanserin	16-26	arginine vasopressin	Homo sapiens	110-121
1506656-10	1992	The addition of ketanserin to vasopressin improves the detrimental systemic hemodynamic effects of vasopressin without further reducing the portal pressure.	Ketanserin	16-26	arginine vasopressin	Homo sapiens	99-110
1528269-5	1992	The same concentration of ketanserin caused a parallel rightward shift of the concentration-response curves of alpha-methyl-5-HT and DOI with pKB values of 7.1 and 7.1, respectively.	Ketanserin	26-36	AKT serine/threonine kinase 1	Homo sapiens	142-145
1312425-9	1992	The selective 5HT2 receptor antagonist ketanserin prevented CRF stimulation and blocked the inhibitory actions of 5HT and DOI, while the alpha 1-adrenergic antagonist prazosin had no effect.	Ketanserin	39-49	5-hydroxytryptamine receptor 2A	Homo sapiens	14-27
1312425-10	1992	Also, treatment of cells with ketanserin increased sensitivity to hCG and raised maximal cAMP and testosterone production.	Ketanserin	30-40	hypertrichosis 2 (generalised, congenital)	Homo sapiens	66-69
1535317-9	1992	Vasopressin responses to m-CPP were entirely antagonised by the 5-HT1/5-HT2 antagonist metergoline, partially by the 5-HT2/5-HT1C antagonists ritanserin and LY 53857, but not by the 5-HT2 antagonist ketanserin.	Ketanserin	199-209	arginine vasopressin	Rattus norvegicus	0-11
1371395-3	1992	The flare evoked by bradykinin was abolished by pretreatment with lignocaine (local anesthetic), compound 48/80 (mast-cell histamine liberator), mepyramine (H1-receptor antagonist) and indomethacin (cyclo-oxygenase inhibitor) but was unaffected by atropine and ketanserin (serotonin antagonist).	Ketanserin	261-271	kininogen 1	Homo sapiens	20-30
1534067-12	1992	The responses after 5HT and NA stimulation were blocked to baseline levels after exposure to ketanserin (5HT2 receptor antagonist) and a combination of prazosin, yohimbine, and propranolol (alpha 1, alpha 2, and beta adrenoceptor antagonists, respectively).	Ketanserin	93-103	5-hydroxytryptamine receptor 2A	Homo sapiens	105-118
1493845-8	1992	The 5-HT2 receptor antagonist ketanserin (1 mumol.l-1 in vitro) reduced the extent of aggregation induced by 5 mumol.l-1 ADP after the volunteers had taken a high sodium diet, whereas the angiotensin II receptor antagonist saralasin (1 nmol.l-1) increased the rate of aggregation after the low sodium diet.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
1493845-8	1992	The 5-HT2 receptor antagonist ketanserin (1 mumol.l-1 in vitro) reduced the extent of aggregation induced by 5 mumol.l-1 ADP after the volunteers had taken a high sodium diet, whereas the angiotensin II receptor antagonist saralasin (1 nmol.l-1) increased the rate of aggregation after the low sodium diet.	Ketanserin	30-40	angiotensinogen	Homo sapiens	188-202
1435968-2	1992	Both the discriminative stimulus and human hallucinogenic potencies of the agonists are significantly correlated with 5-HT2 receptor affinity when [3H]-ketanserin is used as radioligand (Glennon et al., 1984).	Ketanserin	152-162	5-hydroxytryptamine receptor 2A	Homo sapiens	118-132
1568865-1	1992	In eight asthmatic subjects a randomized, double-blind, placebo controlled study was performed to investigate the effect of inhaled ketanserin, a 5-HT2 receptor blocking agent, in a dose of 10 mg given 30 min before test, on adenosine-induced bronchospasm.	Ketanserin	132-142	5-hydroxytryptamine receptor 2A	Homo sapiens	146-160
1861158-11	1991	Immunostaining of cells by the anti-idiotypic antibodies was inhibited by appropriate pharmacological agents: immunostaining of cells expressing 5-HT1C receptors was blocked by mesulergine (but not ketanserin, 8-OH-DPAT, or spiperone), whereas that of cells expressing 5-HT2 receptors was blocked by ketanserin or spiperone (but not mesulergine or 8-OH-DPAT).	Ketanserin	300-310	5-hydroxytryptamine receptor 2C	Homo sapiens	145-151
1819150-1	1991	Both intravenous and central administration of ketanserin, a 5-HT2 receptor antagonist, decrease blood pressure and sympathetic nerve activity, suggesting a central origin of its effects.	Ketanserin	47-57	5-hydroxytryptamine receptor 2A	Homo sapiens	61-75
1838579-4	1991	In competition studies, the rank order of drug affinities was suggestive of a 5-HT1A binding site: 5-HT greater than 8-OH-DPAT, RU24969 greater than methysergide, methiothepin, 1-2,5-dimethoxy-4-iodophenyl aminopropane (DOI), ketanserin greater than mianserin.	Ketanserin	226-236	5-hydroxytryptamine receptor 1A	Homo sapiens	78-84
1892486-3	1991	Serotonin-induced DNA synthesis was significantly inhibited by ketanserin (5-hydroxytryptamine-2 (5HT-2) receptor antagonist).	Ketanserin	63-73	5-hydroxytryptamine receptor 2A	Homo sapiens	98-113
2065721-4	1991	In all patients, ketanserin significantly lowered IOP and SBP, while no variations in pupil diameter, DBP and HR were found.	Ketanserin	17-27	selenium binding protein 1	Homo sapiens	58-61
1920817-5	1991	The combination of KET + HCTZ in the acute study reduced significantly systolic (SBP) and diastolic (DBP) blood pressures for up to 10 hrs.	Ketanserin	19-22	selenium binding protein 1	Homo sapiens	81-84
2068047-2	1991	The early availability of specific antagonists for the serotonin-2 (5-HT2) receptor subtype (spiperone, ketanserin and ritanserin represented an important step towards the biochemical, physiological and, more recently, molecular characterization of 5-HT2 receptors in brain.	Ketanserin	104-114	5-hydroxytryptamine receptor 2A	Homo sapiens	68-83
1855122-6	1991	In ring preparations contracted with the stable thromboxane-A2-mimetic, U-46619 (10 nM), and in the presence of the 5-HT2 receptor antagonist ketanserin (1 microM), low concentrations of 5-HT (1-100 nM) evoked an endothelium-dependent, rapid, "spike-like" relaxation.	Ketanserin	142-152	5-hydroxytryptamine receptor 2A	Homo sapiens	116-130
1710012-2	1991	Serotonin caused a 15% increase in POMC mRNA levels, an effect which was blocked by the 5-HT2 receptor antagonist ketanserin.	Ketanserin	114-124	proopiomelanocortin	Rattus norvegicus	35-39
1905236-4	1991	The renin release induced by 5-HT was suppressed during intrarenal arterial infusion of a 5-HT1 and 5-HT2 antagonist, methysergide (30 micrograms/kg per min), or a selective 5-HT2 antagonist, ketanserin (3 micrograms/kg per min).	Ketanserin	192-202	renin	Canis lupus familiaris	4-9
1702633-4	1991	Pretreatment with the 5-HT2/5-HT1C antagonist, ketanserin, inhibited the MDMA-induced decrease in 5-HT and 5-HIAA concentrations and the number of [3H]paroxetine binding sites in the frontal cortex 7 days following a single administration.	Ketanserin	47-57	5-hydroxytryptamine receptor 2C	Rattus norvegicus	28-34
1702633-6	1991	The ability of ketanserin pretreatment to block MDMA-induced decreases in [3H]paroxetine binding sites in the frontal cortex is suggestive that 5-HT2/5-HT1C receptors may be involved in the neurotoxic effects of MDMA.	Ketanserin	15-25	5-hydroxytryptamine receptor 2C	Rattus norvegicus	150-156
1717767-1	1991	We advance the hypothesis that ketanserin, a 5-HT2 receptor antagonist, may provide vascular protection.	Ketanserin	31-41	5-hydroxytryptamine receptor 2A	Homo sapiens	45-59
1717769-2	1991	The development of ketanserin, the selective 5-HT2-receptor blocker, has made it possible to explore the role of serotonin in animal models and patients with endothelial injury and atherosclerotic disease.	Ketanserin	19-29	5-hydroxytryptamine receptor 2A	Homo sapiens	45-59
1717771-9	1991	5-HT2-Receptor blockade with ketanserin interferes with this chain of events at several sites.	Ketanserin	29-39	5-hydroxytryptamine receptor 2A	Homo sapiens	0-14
1992284-4	1991	The hypothermic effects of 5-HT were strongly antagonized by the 5-HT1 and 5-HT2 receptor antagonist methysergide and the 5-HT2 receptor antagonist ketanserin.	Ketanserin	148-158	hypothermia due to alcohol sensitivity 2	Mus musculus	124-127
20504708-2	1991	[(3)H]8-OH-DPAT, [(125)I]ICYP, [(3)H]mesulergine and [(3)H]ketanserin are radiolabeled ligands for 5-HT(1A), 5-HT(1B), 5-HT(1C) and 5-HT(2) sites, respectively.	Ketanserin	59-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-106
1848947-7	1991	Ketanserin, a selective 5-HT-2 antagonist, was a potent inhibitor of 5-HT-stimulated IP-1 accumulation with a Ki value of 12 nM, but (-)propranolol (10 microM), a 5-HT-1 antagonist, failed to block the 5-HT response.	Ketanserin	0-10	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	85-89
1811246-4	1991	Ketanserin increased levels of GR mRNA in hippocampus of male, but not female, rats.	Ketanserin	0-10	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	31-33
1811246-6	1991	We conclude that desipramine, imipramine, ketanserin and lithium can modulate GR mRNA in regions of rat brain involved in the control of the HPA axis and may have a common mechanism of action at the level of the GR gene.	Ketanserin	42-52	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	78-80
1811246-6	1991	We conclude that desipramine, imipramine, ketanserin and lithium can modulate GR mRNA in regions of rat brain involved in the control of the HPA axis and may have a common mechanism of action at the level of the GR gene.	Ketanserin	42-52	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	212-214
2079001-2	1990	Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	16-30
2233696-0	1990	4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes.	Ketanserin	57-67	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	102-106
2046478-2	1991	The inhibitory effect was specifically blocked by the 5-HT1 and 5-HT2 serotonin antagonist methysergide and the 5-HT2 receptor antagonist ketanserin.	Ketanserin	138-148	5-hydroxytryptamine receptor 2A	Homo sapiens	112-126
2243353-1	1990	The 5-HT2 (serotonin) receptor has traditionally been labeled with antagonist radioligands such as [3H]ketanserin and [3H]spiperone, which label both agonist high-affinity (guanyl nucleotide-sensitive) and agonist low-affinity (guanyl nucleotide-insensitive) states of this receptor.	Ketanserin	99-113	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-30
2233697-8	1990	These data on a single human 5-HT2 receptor cDNA expressed in two different transfection host cells indicate that [3H]DOB and [3H]ketanserin binding reside on the same gene product, apparently interacting with agonist and antagonist conformations of a single human 5-HT2 receptor protein.	Ketanserin	130-140	5-hydroxytryptamine receptor 2A	Homo sapiens	29-43
2233697-8	1990	These data on a single human 5-HT2 receptor cDNA expressed in two different transfection host cells indicate that [3H]DOB and [3H]ketanserin binding reside on the same gene product, apparently interacting with agonist and antagonist conformations of a single human 5-HT2 receptor protein.	Ketanserin	130-140	5-hydroxytryptamine receptor 2A	Homo sapiens	265-279
2127400-3	1990	Pretreatment with the 5-HT1C/5-HT2 receptor antagonists LY 53857, ritanserin, or the mixed 5-HT2/alpha 1-adrenoceptor antagonist ketanserin either diminished or prevented the hyperglycemic effect of DOI (0.5 mg/kg).	Ketanserin	129-139	5-hydroxytryptamine receptor 2C	Rattus norvegicus	22-28
2127400-3	1990	Pretreatment with the 5-HT1C/5-HT2 receptor antagonists LY 53857, ritanserin, or the mixed 5-HT2/alpha 1-adrenoceptor antagonist ketanserin either diminished or prevented the hyperglycemic effect of DOI (0.5 mg/kg).	Ketanserin	129-139	5-hydroxytryptamine receptor 2A	Rattus norvegicus	91-117
2078270-6	1990	Second, the single protein encoded by the human 5-HT2 receptor gene is capable of binding both [3H]DOB and [3H]ketanserin.	Ketanserin	111-121	5-hydroxytryptamine receptor 2A	Homo sapiens	48-62
2149874-6	1990	The excitatory effect of iontophoretically applied 5-HT was antagonized by the nonselective 5-HT antagonist, methysergide and by ketanserin and ritanserin, which have relatively selective affinity for 5-HT1C and 5-HT2 receptors.	Ketanserin	129-139	5-hydroxytryptamine receptor 2C	Rattus norvegicus	201-207
2258891-8	1990	5HT2-receptor blockade with ketanserin interferes with these events by inhibition of platelet 5HT release and by a greater antiaggregatory and antihypertensive action in older age.	Ketanserin	28-38	5-hydroxytryptamine receptor 2A	Homo sapiens	0-13
2145051-8	1990	The 5-HT2/alpha 1-adrenoceptor antagonist ketanserin in a low dose (0.25 mg kg-1) significantly increased the 5-HT behavioural syndrome induced by 8-OH-DPAT or 5-MeODMT, while in a higher dose (2.5 mg kg-1) this drug decreased the response.	Ketanserin	42-52	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-30
2145051-15	1990	We suggest that ritanserin, ICI 170,809 and ketanserin enhance 5-HT1A agonist-induced behaviour through blockade of an inhibitory 5-HT2 receptor regulating or coupled to 5-HT1A receptor-mediated function.	Ketanserin	44-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
2145051-15	1990	We suggest that ritanserin, ICI 170,809 and ketanserin enhance 5-HT1A agonist-induced behaviour through blockade of an inhibitory 5-HT2 receptor regulating or coupled to 5-HT1A receptor-mediated function.	Ketanserin	44-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	170-176
2379381-9	1990	A decreased mean ketanserin elimination half-life (t1/2 = 12 +/- 4 and 10 +/- 3h vs 16 +/- 3 and 18 +/- 4h in healthy controls after oral ketanserin 40mg and intravenous ketanserin 5mg, respectively) contrasted with a substantial increase in t1/2 for ketanserinol (33 +/- 13 vs 19 +/- 4h).	Ketanserin	17-27	CD2 molecule	Homo sapiens	51-99
2379381-9	1990	A decreased mean ketanserin elimination half-life (t1/2 = 12 +/- 4 and 10 +/- 3h vs 16 +/- 3 and 18 +/- 4h in healthy controls after oral ketanserin 40mg and intravenous ketanserin 5mg, respectively) contrasted with a substantial increase in t1/2 for ketanserinol (33 +/- 13 vs 19 +/- 4h).	Ketanserin	138-148	CD2 molecule	Homo sapiens	51-99
2379381-9	1990	A decreased mean ketanserin elimination half-life (t1/2 = 12 +/- 4 and 10 +/- 3h vs 16 +/- 3 and 18 +/- 4h in healthy controls after oral ketanserin 40mg and intravenous ketanserin 5mg, respectively) contrasted with a substantial increase in t1/2 for ketanserinol (33 +/- 13 vs 19 +/- 4h).	Ketanserin	138-148	CD2 molecule	Homo sapiens	51-99
2080086-1	1990	Experiments were conducted on 182 rats with acute cholestasis to study the effect of intra-abdominal dalargin injection (10 mcg/kg) with the serotonin antagonist ketanserine (150 mg/kg) on xanthine oxidase (XO) activity and level of lipid peroxidation in the hepatic tissue and on the activity of the hepatospecific enzymes histidase and urokaninase in hepatic tissue and blood serum 1, 3, and 5 hours after the injection.	Ketanserin	162-173	histidine ammonia lyase	Rattus norvegicus	324-333
1696753-9	1990	Pretreatment with cyproheptadine (2.5 mg/kg, iv), a dual serotonin/histamine antagonist, or ketanserin (3 mg/kg, iv), a selective serotonin antagonist, prevented the GH-RP-6-induced hypotension and lethality.	Ketanserin	92-102	gonadotropin releasing hormone receptor	Rattus norvegicus	166-168
2166922-6	1990	The potentiation was blocked by the 5-HT2 receptor antagonist ketanserin.	Ketanserin	62-72	5-hydroxytryptamine receptor 2A	Homo sapiens	36-50
1694908-1	1990	This study evaluates the vasoactive effects and mode of action of ketanserin, a selective 5HT2 receptor antagonist, on digital circulation in 11 patients with primary Raynaud"s phenomenon.	Ketanserin	66-76	5-hydroxytryptamine receptor 2A	Homo sapiens	90-103
2359025-2	1990	Similar pA2 values (8.56 and 8.33, respectively) of ketanserin, tested against 5-HT and DOM, indicate that responses produced by both agonists are mediated by the 5-HT2 receptor.	Ketanserin	52-62	5-hydroxytryptamine receptor 2A	Homo sapiens	163-177
2365539-7	1990	Ketanserin significantly reduced both SBP and DBP (p less than 0.005) with no changes in HR.	Ketanserin	0-10	selenium binding protein 1	Homo sapiens	38-41
2365539-7	1990	Ketanserin significantly reduced both SBP and DBP (p less than 0.005) with no changes in HR.	Ketanserin	0-10	D-box binding PAR bZIP transcription factor	Homo sapiens	46-49
2140838-0	1990	Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension.	Ketanserin	11-21	natriuretic peptide A	Homo sapiens	58-83
2345079-2	1990	The development of ketanserin, the selective 5HT2 receptor blocker, has made it possible to explore the role of serotonin in patients with advanced atherosclerotic disease.	Ketanserin	19-29	5-hydroxytryptamine receptor 2A	Homo sapiens	45-58
2303819-8	1990	Various antagonists completed for the soluble receptors with a rank order of potency typical for binding at a 5-HT3 receptor site: zacopride (Ki = 0.26 nM) greater than quipazine (0.37 nM) = Q ICS 205-930 (0.33 nM) greater than ICS 205-930 (0.93 nM) greater than GR 38032F (2.2 nM) greater than BRL 24924 (4.1 nM) greater than MDL 72222 (23.4 nM) greater than ketanserin (6,000 nM).	Ketanserin	360-370	5-hydroxytryptamine receptor 3A	Rattus norvegicus	110-124
2272071-8	1990	Responses to alpha-me-5-HT were surmountably antagonised by the non-selective antagonist methiothepin (0.1 mumol.litre-1) as well as the 5-HT2 receptor antagonist ketanserin (0.1 mumol.litre-1).	Ketanserin	163-173	5-hydroxytryptamine receptor 2A	Homo sapiens	137-151
2285638-7	1990	Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94.5 sec-1) and at low shear rate (0.376 sec-1), with no change in plasma viscosities; significant shortening of plasma passage times; and marked decreases in blood concentrations of total protein, albumin, and globulin.	Ketanserin	0-10	secretory blood group 1, pseudogene	Homo sapiens	306-311
2285638-7	1990	Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94.5 sec-1) and at low shear rate (0.376 sec-1), with no change in plasma viscosities; significant shortening of plasma passage times; and marked decreases in blood concentrations of total protein, albumin, and globulin.	Ketanserin	0-10	secretory blood group 1, pseudogene	Homo sapiens	342-347
2285643-2	1990	These effects are mediated via the 5HT2 receptor and are specifically antagonized by ketanserin.	Ketanserin	85-95	5-hydroxytryptamine receptor 2A	Homo sapiens	35-48
2285652-1	1990	5-hydroxytryptamine (5HT) treatment produced dose-related contractions in the human internal mammary artery with an EC50 value of 3.4 X 10(-7) M. The 5HT2 receptor antagonist ketanserin reversed the contractions evoked by 5HT in a competitive manner at a low concentration (10(-8) M), whereas a noncompetitive antagonism was apparent at higher concentrations (5 X 10(-8) M to 5 X 10(-7) M).	Ketanserin	175-185	5-hydroxytryptamine receptor 2A	Homo sapiens	150-163
2285652-4	1990	These findings indicate that the mammary artery is a vascular tissue sensitive to contractions induced by 5HT and that the drug ketanserin antagonizes this contractile response through the 5HT2 receptor subtype.	Ketanserin	128-138	5-hydroxytryptamine receptor 2A	Homo sapiens	189-202
2125095-2	1990	Several 5HT2 receptor antagonists, including ketanserin and ritanserin, are known to antagonize serotonin-mediated aggregation of human platelets.	Ketanserin	45-55	5-hydroxytryptamine receptor 2A	Homo sapiens	8-21
2343074-5	1990	These compounds have in common a strong affinity for the 5-HT1C receptor, mCPP (0.46 mg/kg)-induced PE could be antagonized by the 5-HT antagonists metergoline, cyproheptadine, mesulergine, mianserin, ritanserin and ketanserin.	Ketanserin	216-226	5-hydroxytryptamine receptor 2C	Rattus norvegicus	57-63
1974625-6	1990	Contractions elicited by 5-HT were antagonized by ketanserin, a 5-HT2-receptor antagonist, which also antagonized the responses to NA and histamine, but at greater concentrations than those needed for 5-HT responses.	Ketanserin	50-60	5-hydroxytryptamine receptor 2A	Homo sapiens	64-78
1969761-6	1990	Evidence from binding studies indicates that MDMA has a micromolar affinity for the 5-HT2 receptor, and our studies in culture showed that ketanserin, a specific 5-HT2 antagonist, was effective at attenuating the effects of S(+)-MDMA on the development of the [3H]5-HT uptake capacity by the cultured raphe neurons.	Ketanserin	139-149	5-hydroxytryptamine receptor 2A	Homo sapiens	84-98
2180341-0	1990	Effect of ketanserin, a new blocking agent of the 5-HT2 receptor, on airway responsiveness in asthma.	Ketanserin	10-20	5-hydroxytryptamine receptor 2A	Homo sapiens	50-64
2137698-8	1990	The putative 5-HT1A autoreceptor antagonist spiperone reversed the cocaine-induced depression of firing rate in 64% of 5-HT neurons tested whereas receptor antagonists for dopamine D2 (haloperidol), 5-HT2 (ketanserin), gamma-aminobutyric acid (picrotoxin) and 5-HT1/beta-adrenergic (propranolol) were ineffective.	Ketanserin	206-216	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
2268504-2	1990	Based on the interaction with the 5-HT2 receptor antagonist ketanserin, both 5-HT1 and 5-HT2 receptors are involved in contractions of human saphenous vein, but the predominant subtype involved in contractions of human coronary artery is the 5-HT1 receptor.	Ketanserin	60-70	5-hydroxytryptamine receptor 2A	Homo sapiens	34-48
2268504-2	1990	Based on the interaction with the 5-HT2 receptor antagonist ketanserin, both 5-HT1 and 5-HT2 receptors are involved in contractions of human saphenous vein, but the predominant subtype involved in contractions of human coronary artery is the 5-HT1 receptor.	Ketanserin	60-70	5-hydroxytryptamine receptor 5A	Homo sapiens	77-88
2132170-9	1990	This development is the basis of various drugs which interact with the serotonergic system and its receptors, like the various 5HT2 receptor antagonists (of which ketanserin is the prototype), methysergide, pizotifen, urapidil, flesinoxan and a variety of psychoactive drugs.	Ketanserin	163-173	5-hydroxytryptamine receptor 2A	Homo sapiens	127-140
2257855-2	1990	To clarify the mechanism of this effect the effect of ketanserin on 3-hydroxy-3-methylglutaryl (HMG) CoA reductase and LDL receptor activity in cultured human skin fibroblasts has been examined.	Ketanserin	54-64	low density lipoprotein receptor	Homo sapiens	119-131
2257855-3	1990	After incubation with ketanserin for 14 h HMG CoA reductase activity was decreased in a dose-dependent manner up to 300 ng/ml (550 nM) without changing the free cholesterol content in the cells.	Ketanserin	22-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-59
2257855-6	1990	It appears that ketanserin induces up-regulation of LDL receptor activity by direct suppression of HMG CoA reductase, and this may be one mechanism by which plasma LDL-cholesterol is reduced by ketanserin.	Ketanserin	16-26	low density lipoprotein receptor	Homo sapiens	52-64
2257855-6	1990	It appears that ketanserin induces up-regulation of LDL receptor activity by direct suppression of HMG CoA reductase, and this may be one mechanism by which plasma LDL-cholesterol is reduced by ketanserin.	Ketanserin	16-26	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	99-116
2257855-6	1990	It appears that ketanserin induces up-regulation of LDL receptor activity by direct suppression of HMG CoA reductase, and this may be one mechanism by which plasma LDL-cholesterol is reduced by ketanserin.	Ketanserin	194-204	low density lipoprotein receptor	Homo sapiens	52-64
2166523-6	1990	CT-induced release of PGE2 and fluid secretion can be decreased by indomethacin or by the 5-HT2-receptor antagonist, ketanserin, whereas the release of 5-HT and cAMP is not affected by either substance.	Ketanserin	117-127	5-hydroxytryptamine receptor 2A	Homo sapiens	90-104
2144886-5	1990	The effectiveness of different doses of ketanserin (KET), a 5-HT2 receptor antagonist, to reduce plasma PRL levels during the surge was established.	Ketanserin	40-50	prolactin	Rattus norvegicus	104-107
2144886-5	1990	The effectiveness of different doses of ketanserin (KET), a 5-HT2 receptor antagonist, to reduce plasma PRL levels during the surge was established.	Ketanserin	52-55	prolactin	Rattus norvegicus	104-107
2141111-8	1990	These depolarizations, and those produced by high concentrations of serotonin, were blocked by the 5-HT1C/5-HT2 antagonists ketanserin, methysergide and mianserin.	Ketanserin	124-134	5-hydroxytryptamine receptor 2C	Homo sapiens	99-105
2107558-4	1990	Proaversive effects were found with the mixed 5-HT1C/5-HT2 antagonists cyproheptadine and ritanserin; this effect was already reported for the mixed 5-HT1C/5-HT2 antagonists metergoline and mianserin and is opposite to the effects of the selective 5-HT2 antagonists ketanserin, pirenperone, trazodone and spiperone.	Ketanserin	266-276	5-hydroxytryptamine receptor 2C	Rattus norvegicus	46-52
11401004-11	2001	Microinjections of methysergide, a non-specific antagonist of 5-HT receptors, or ketanserin, an antagonist of 5-HT2A receptors, into the dPAG before testing significantly inhibited the antinociception without affecting any of the behavioral or autonomic conditioned responses.	Ketanserin	81-91	5-hydroxytryptamine receptor 2A	Rattus norvegicus	110-116
2575564-6	1989	Since the 5-HT2 receptor antagonist ketanserin, which has an antihypertensive effect, decreased SNA and the 5-HT2 agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) increased SNA, central 5-HT2 receptors may be connected with the 5-HT-induced increases in both BP and SNA.	Ketanserin	36-46	5-hydroxytryptamine receptor 2A	Homo sapiens	10-24
35437266-8	2022	Specifically, although the application of 5HT led to a depolarisation of both auditory and CA3 NPY-positive neurons, the 5HT2a receptor antagonist ketanserin only reversed membrane potential changes in auditory NPY-positive neurons.	Ketanserin	147-157	carbonic anhydrase 3	Mus musculus	91-94
35437266-8	2022	Specifically, although the application of 5HT led to a depolarisation of both auditory and CA3 NPY-positive neurons, the 5HT2a receptor antagonist ketanserin only reversed membrane potential changes in auditory NPY-positive neurons.	Ketanserin	147-157	neuropeptide Y	Mus musculus	95-98
35437266-8	2022	Specifically, although the application of 5HT led to a depolarisation of both auditory and CA3 NPY-positive neurons, the 5HT2a receptor antagonist ketanserin only reversed membrane potential changes in auditory NPY-positive neurons.	Ketanserin	147-157	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	121-135
35437266-8	2022	Specifically, although the application of 5HT led to a depolarisation of both auditory and CA3 NPY-positive neurons, the 5HT2a receptor antagonist ketanserin only reversed membrane potential changes in auditory NPY-positive neurons.	Ketanserin	147-157	neuropeptide Y	Mus musculus	211-214
35215325-4	2022	Indeed, blocking either receptor reduces the aggression of MAOA knockout (KO) mice; however, 5-HT2 receptor antagonists, such as ketanserin (KET), reduce locomotor activity, while NMDA receptor blockers are typically associated with psychotomimetic properties.	Ketanserin	141-144	monoamine oxidase A	Mus musculus	59-63
35215325-8	2022	Our results show that the combination of KET and DIZ potently reduces aggression in MAOA KO mice without any PPI deficits and sedative effects.	Ketanserin	41-44	monoamine oxidase A	Mus musculus	84-88
34785417-2	2022	Although clinical data provided compelling evidence for the efficacy of this approach in the prevention of various cardiovascular conditions, the chemical space of 5-HT2A receptor antagonists is limited to ketanserin and sarpogrelate.	Ketanserin	206-216	5-hydroxytryptamine receptor 2A	Homo sapiens	164-179
35600957-8	2022	The 5-HT receptor specific inhibitors alverine citrate, ketanserin, ondansetron and SB-399885 blocked the regulatory effects of 5-HT on NG2 cells.	Ketanserin	56-66	chondroitin sulfate proteoglycan 4	Rattus norvegicus	136-139
2575564-7	1989	On the other hand, ketanserin"s antihypertensive effects via its 5-HT2 receptor blocking action in the vascular system indicates that peripheral 5-HT may contribute to the initiation or the maintenance of elevated vascular resistance in several forms of hypertension including essential hypertension.	Ketanserin	19-29	5-hydroxytryptamine receptor 2A	Homo sapiens	65-79
2698721-6	1989	Antihypertensive treatment with the 5HT2-receptor antagonist ketanserin attenuated platelet 5HT turnover and inhibited 5HT induced platelet aggregation; the latter was more pronounced in older patients.	Ketanserin	61-71	5-hydroxytryptamine receptor 2A	Homo sapiens	36-49
2774700-4	1989	In patients with CREST treatment with ketanserin, a specific serotonin antagonist, normalised platelet serotonin concentrations.	Ketanserin	38-48	SS18L1 subunit of BAF chromatin remodeling complex	Homo sapiens	17-22
2723656-4	1989	Displacement of specific [125I]iodoLSD binding indicated a typical 5-HT2 receptor inhibition profile, which demonstrated a significant linear correlation (r = 0.97, p less than 0.001, n = 17) with that observed using [3H]ketanserin.	Ketanserin	221-231	5-hydroxytryptamine receptor 2A	Homo sapiens	67-81
2723656-8	1989	We conclude that the site labelled by [125I]iodoLSD in human platelet membranes is biochemically similar to that in frontal cortex and most closely resembles the 5-HT2 receptor subtype, although the discrepancy in binding capacities of [125I]iodoLSD and [3H]ketanserin raises a question about the absolute nature of this receptor.	Ketanserin	257-268	5-hydroxytryptamine receptor 2A	Homo sapiens	162-176
3390820-3	1988	Ketanserin, cyproheptadine, and spiperone [serotonin (5-HT) receptor blockers] inhibited or attenuated the antitumor effects of rTNF-alpha, but the other types of receptor blockers tested (histamine H1 and H2, adrenaline alpha and beta, dopamine, and acetylcholine receptor blockers) did not.	Ketanserin	0-10	tumor necrosis factor	Rattus norvegicus	128-138
2622531-9	1989	Moreover, ketanserin has recently been shown to possess a nanomolar affinity for the vesicular monoamine transporter, and autoradiographic localization of brain monoaminergic synaptic vesicles was also obtained by means of the derivative 7-amino-8-[125I]iodoketanserin in the presence of 5-hydroxytryptamine2 and alpha 1 antagonists, although the non-specific labelling was higher than with [3H]dihydrotetrabenazine.	Ketanserin	10-20	solute carrier family 18 member A2	Rattus norvegicus	95-116
2678323-10	1989	The alpha-1 adrenergic antagonists, frusemide and ketanserin have an overall beneficial effect.	Ketanserin	50-60	adrenoceptor alpha 1D	Homo sapiens	4-11
3060193-1	1988	The efficacy of the 5-HT-2-receptor antagonist, ketanserin, in the treatment of Raynaud"s phenomenon was assessed in a double-blind, placebo-controlled, crossover trial in nine patients with generalized scleroderma (GS).	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Homo sapiens	20-35
2906698-4	1988	Urapidil, labetalol and ketanserin are well-known examples of hybrid drugs, which possess additional pharmacological activities besides their alpha 1-adrenoceptor antagonistic potency.	Ketanserin	24-34	adrenoceptor alpha 1D	Homo sapiens	142-149
2906698-7	1988	Ketanserin is a selective 5-hydroxytryptamine (5HT2)-receptor antagonist, with modest alpha 1-adrenoceptor activity.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	47-61
2906698-7	1988	Ketanserin is a selective 5-hydroxytryptamine (5HT2)-receptor antagonist, with modest alpha 1-adrenoceptor activity.	Ketanserin	0-10	adrenoceptor alpha 1D	Homo sapiens	86-93
2977425-14	1988	The antiserotoninergic activity of methysergide and ketanserin was demonstrated by their ability to prevent the PRL-releasing effect to serotonin.	Ketanserin	52-62	prolactin	Rattus norvegicus	112-115
2465437-5	1988	Prolactin levels decreased slightly (4.1 +/- 3.0 vs. 3.7 +/- 2.9 ng/ml, p less than 0.05) during ketanserin therapy when measured 12 h after dosing.	Ketanserin	97-107	prolactin	Homo sapiens	0-9
2975354-6	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	Ketanserin	204-214	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
2975354-6	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	Ketanserin	204-214	5-hydroxytryptamine receptor 2C	Homo sapiens	155-161
2723427-0	1989	Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.	Ketanserin	91-101	5-hydroxytryptamine receptor 2A	Homo sapiens	25-38
2723427-1	1989	Serotonin (5HT) has been implicated in thromboembolic complications and blood pressure elevation and both may be reduced with the 5HT2-receptor blocker ketanserin.	Ketanserin	152-162	5-hydroxytryptamine receptor 2A	Homo sapiens	130-143
2723427-6	1989	Ketanserin corrects 5HT2-receptor-mediated platelet function along with the reduction of blood pressure.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	20-33
2711155-1	1989	The antihypertensive efficacy and tolerability of the 5HT2-receptor antagonist ketanserin was investigated in 188 patients aged 41 to 82 years with mild to moderate essential hypertension.	Ketanserin	79-89	5-hydroxytryptamine receptor 2A	Homo sapiens	54-67
2725702-6	1989	3) The increase in inositol phosphate production induced by 5-HT and other agonists was surmountably antagonised by mesulergine, ketanserin and spiperone with pKB values of 8.7, 6.7 and 5.3, respectively.	Ketanserin	129-139	AKT serine/threonine kinase 1	Sus scrofa	159-162
2569215-5	1989	The 5-HT2 receptor antagonist ketanserin (0.1-3.0 mg/kg) also restored FI and FR responding that was decreased by 3.0 mg/kg MDA, but had no effect on responding suppressed by MDMA.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
2903929-9	1988	There was a close structural correspondence between ketanserin and irindalone in a conformation that we recently identified as a D-2 receptor-relevant configuration of its neuroleptic "parent" tefludazine.	Ketanserin	52-62	solute carrier family 3 member 1	Rattus norvegicus	129-132
3380081-0	1988	Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles.	Ketanserin	0-10	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	24-45
3380081-7	1988	Conversely, ketanserin inhibited the binding of [3H] dihydrotetrabenazine, a ligand that specifically binds to the monoamine transporter.	Ketanserin	12-22	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	115-136
3380081-14	1988	It is concluded that nonspecific displaceable binding sites of [3H]ketanserin previously described in the striatum are tetrabenazine binding sites associated with the synaptic vesicle monoamine transporter.	Ketanserin	63-77	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	184-205
2899303-2	1988	In vitro, chlorpromazine and oxypertine potently displaced the specific binding of [3H]WB 4101 to alpha 1 adrenoreceptors in the cortex and of [3H]ketanserin to 5-HT2 receptors in the frontal cortex.	Ketanserin	147-157	5-hydroxytryptamine receptor 2A	Rattus norvegicus	161-166
3261263-0	1988	[Effects of ketanserin on hemodynamic changes after intracerebroventricular corticotropin releasing factor administration in rats].	Ketanserin	12-22	corticotropin releasing hormone	Rattus norvegicus	76-106
2966310-5	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	Ketanserin	204-214	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103
2966310-5	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	Ketanserin	204-214	5-hydroxytryptamine receptor 2C	Homo sapiens	155-161
2828545-5	1988	It was also inhibited by the selective 5-HT2 antagonists ketanserin and ritanserin but not by the 5-HT1 antagonists isapirone, (-)-propranolol, or pindolol.	Ketanserin	57-67	hypothermia due to alcohol sensitivity 2	Mus musculus	41-44
3359270-1	1988	5-HT2 receptor binding sites were measured (by saturation binding of [3H]ketanserin) in brain tissue obtained at postmortem from 19 suicide victims with definite evidence of depression and 19 sex and age-matched control subjects.	Ketanserin	73-83	5-hydroxytryptamine receptor 2A	Homo sapiens	0-14
2965394-2	1988	Ketanserin, a 5-HT-2 receptor antagonist and pretreatment with the 5-HT neurotoxin parachlorophenylalanine (PCPA) attenuated the manifestation of these behavioral abnormalities.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-29
2906874-4	1988	The ketanserin/beta-blocker combination decreased mean sitting systolic/diastolic blood pressure (SBP/DBP) from 169/107 mmHg to 156/91 mmHg at the end of the 12-week active treatment period.	Ketanserin	4-14	selenium binding protein 1	Homo sapiens	98-101
2906874-4	1988	The ketanserin/beta-blocker combination decreased mean sitting systolic/diastolic blood pressure (SBP/DBP) from 169/107 mmHg to 156/91 mmHg at the end of the 12-week active treatment period.	Ketanserin	4-14	D-box binding PAR bZIP transcription factor	Homo sapiens	102-105
2906874-6	1988	A significant reduction in heart rate by 10 beats.min-1 was observed with the ketanserin + beta-blocker combination.	Ketanserin	78-88	CD59 molecule (CD59 blood group)	Homo sapiens	50-55
2906874-7	1988	The ketanserin/diuretic combination led to a significant reduction in mean SBP/DBP from 164/106 mmHg to 146/92 mmHg after 12 weeks, with no significant change in heart rate.	Ketanserin	4-14	selenium binding protein 1	Homo sapiens	75-78
2906874-7	1988	The ketanserin/diuretic combination led to a significant reduction in mean SBP/DBP from 164/106 mmHg to 146/92 mmHg after 12 weeks, with no significant change in heart rate.	Ketanserin	4-14	D-box binding PAR bZIP transcription factor	Homo sapiens	79-82
2459512-5	1988	Since alpha 1-adrenoceptor-mediated vasoconstriction is independent of age, the age-related antihypertensive efficacy of the 5-HT2-receptor antagonist ketanserin (with alpha 1-blocking property) helps to define pharmacologically 5-HT2-receptor-mediated platelet aggregatory and vasoconstrictor mechanisms.	Ketanserin	151-161	5-hydroxytryptamine receptor 2A	Homo sapiens	125-139
2459512-5	1988	Since alpha 1-adrenoceptor-mediated vasoconstriction is independent of age, the age-related antihypertensive efficacy of the 5-HT2-receptor antagonist ketanserin (with alpha 1-blocking property) helps to define pharmacologically 5-HT2-receptor-mediated platelet aggregatory and vasoconstrictor mechanisms.	Ketanserin	151-161	5-hydroxytryptamine receptor 2A	Homo sapiens	229-243
3443601-6	1987	4 The 5-HT2 receptor antagonist, ketanserin, inhibited the response to 5-HT in a competitive manner in both vessels, with pA2 values obtained from Schild plots of 9.15 in BA and 9.40 in MCA.	Ketanserin	33-43	5-hydroxytryptamine receptor 2A	Homo sapiens	6-20
2893636-11	1987	Ketanserin treatment was associated with significant changes in supine pulse rate (-8 beats min-1, P less than 0.05) and corrected QT interval (+27 ms, P less than 0.05).	Ketanserin	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	92-97
2826756-5	1987	5,7-DHT-treatment increased the number of 5-HT1 ([3H]-5-HT), 5-HT2 ([3H]ketanserin) and PCP ([3H]PCP) binding sites in the synaptic membrane of rat brain, but decreased the brain level of 5-HT (41% of control).	Ketanserin	72-82	5-hydroxytryptamine receptor 2A	Rattus norvegicus	61-66
3663239-4	1987	The 5-HT2 receptor was labeled with the antagonist radioligand [3H]ketanserin or the agonist radioligand [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB).	Ketanserin	63-77	5-hydroxytryptamine receptor 2A	Homo sapiens	4-18
3663239-10	1987	Using the 5-HT2 antagonist radioligand [3H]ketanserin, a similar pattern of underestimating 5-HT2 receptor selectivity and/or overestimating 5-HT1A or 5-HT1B receptor selectivity was observed for a series of serotonin receptor agonists.	Ketanserin	39-53	5-hydroxytryptamine receptor 2A	Homo sapiens	92-106
2957551-6	1987	In 17 additional patients treated with the hypotensive agent ketanserin, ANP levels were not significantly reduced after treatment.	Ketanserin	61-71	natriuretic peptide A	Homo sapiens	73-76
2823165-2	1987	Ketanserin and ritanserin, selective antagonists for the central 5-HT2 receptor, inhibited the 5-HT-stimulated formation of inositol monophosphate.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	65-79
2959699-2	1987	The assay revealed that platelets possess a single population of specific binding sites for 125I-iodoLSD which have a high affinity for the 5-HT2 receptor antagonists, ketanserin and spiperone.	Ketanserin	168-178	5-hydroxytryptamine receptor 2A	Homo sapiens	140-154
2959702-2	1987	5-Hydroxytryptamine-1 (5-HT1) and 5-HT2 receptor binding to homogenates of frontal cortex (Brodmann area 10) was measured using tritiated 5-HT and tritiated ketanserin respectively.	Ketanserin	157-167	5-hydroxytryptamine receptor 2A	Homo sapiens	34-48
3610034-13	1987	Ketanserin, a selective 5HT-2 receptor antagonist was a potent inhibitor of 5HT-stimulated IP1 accumulation, with a Ki value of 12 nM, but a selective 5HT-1 antagonist, (-)-propranolol (1 microM) failed to block the 5HT response.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	24-38
2892349-1	1987	The selective 5-HT2-receptor-blocking agent ritanserin is an analogue of the antihypertensive agent ketanserin.	Ketanserin	100-110	5-hydroxytryptamine receptor 2A	Homo sapiens	14-28
2443265-6	1987	Except for a slight attenuating effect on the antithrombin III (ketanserin and dipyridamole) and alpha 2-macroglobulin (ketanserin) decreases, there were no significant effects of the drugs.	Ketanserin	120-130	LOW QUALITY PROTEIN: pregnancy zone protein	Sus scrofa	97-118
2446214-4	1987	Senktide-induced head twitches were prevented by pretreatment with the 5-HT2 antagonists ketanserin and ritanserin, while forepaw treading was attenuated by the 5-HT1 antagonists (-)-pindolol and methysergide.	Ketanserin	89-99	hypothermia due to alcohol sensitivity 2	Mus musculus	73-76
3567710-0	1987	Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.	Ketanserin	40-50	5-hydroxytryptamine receptor 2A	Homo sapiens	54-68
3567710-1	1987	Ketanserin, a recently developed 5-HT2 receptor antagonist, competitively and selectively blocks the vasoconstrictor activity of 5-hydroxytryptamine (serotonin).	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	33-47
2446066-4	1987	The pharmacotherapeutic relevance of this pathophysiological chain of events can be tested with the 5-HT2-receptor blocker ketanserin, but the drug"s alpha 1-blocking activity has to be taken into account.	Ketanserin	123-133	5-hydroxytryptamine receptor 2A	Homo sapiens	100-114
2446067-3	1987	The development of ketanserin, the 5-HT2-receptor blocker, has both identified the receptor responsible for the arterial spasm and provided new approaches to treatment.	Ketanserin	19-29	5-hydroxytryptamine receptor 2A	Homo sapiens	35-49
2446077-1	1987	Ketanserin is an arteriolar vasodilator, acting on serotoninergic (5-HT2) and adrenergic (alpha 1) receptors.	Ketanserin	0-10	adrenoceptor alpha 1D	Homo sapiens	90-97
2446078-7	1987	Ketanserin therapy induced a slight reduction in plasma renin activity and a marginal increase in the sodium excretion.	Ketanserin	0-10	renin	Homo sapiens	56-61
2942052-1	1986	This report describes the successful use of ketanserin, a 5-HT2 receptor antagonist, for the acute control of systemic blood pressure in a patient with the carcinoid syndrome, undergoing hepatic artery embolisation.	Ketanserin	44-54	5-hydroxytryptamine receptor 2A	Homo sapiens	58-72
2935410-2	1985	[3H]8-OH-DPAT bound in rat and pig cortex to the 5-HT1A recognition site characterized by high affinity for 5-CT (5-carboxamido-tryptamine), 8-OH-DPAT, 5-HT (5-hydroxytryptamine, serotonin) and low affinity for pirenperone, ketanserin and mesulergine.	Ketanserin	224-234	5-hydroxytryptamine receptor 1A	Rattus norvegicus	49-55
3002805-9	1985	The low affinity of 5-HT1B recognition sites for some 5-HT1A, 5-HT1C and 5-HT2 selective compounds (e.g. 8-OH-DPAT, mesulergine, ketanserin) suggests that 5-HT1B recognition sites are pharmacologically different from 5-HT1A, 5-HT1C and 5-HT2 recognition sites.	Ketanserin	129-139	5-hydroxytryptamine receptor 1B	Rattus norvegicus	20-26
2932546-6	1985	The prototype 5-HT2-receptor ligand ketanserin (0.3-10 mg/kg) differed from the other 5-HT antagonists in that it decreased behavior maintained by either event.	Ketanserin	36-46	5-hydroxytryptamine receptor 2A	Homo sapiens	14-28
2905532-3	1987	Intravenous injection of [11C]-MBL in a baboon led to selective labeling of cortical regions that was markedly blocked by prior administration of ketanserin, a selective 5-HT2 receptor antagonist.	Ketanserin	146-156	mannose-binding lectin family member 3, pseudogene	Homo sapiens	31-34
2905532-3	1987	Intravenous injection of [11C]-MBL in a baboon led to selective labeling of cortical regions that was markedly blocked by prior administration of ketanserin, a selective 5-HT2 receptor antagonist.	Ketanserin	146-156	5-hydroxytryptamine receptor 2A	Homo sapiens	170-184
2944433-3	1986	The effect of 10 mg of ketanserin on the pressor responses to noradrenaline, phenylephrine and angiotensin II in 19 patients during cardiopulmonary bypass was observed.	Ketanserin	23-33	angiotensinogen	Homo sapiens	95-109
2423604-6	1986	The concentration of 5-HTP producing the half-maximal effect = 4 X 10(-7) M. 5-HT suppression of IFN-gamma-induced Ia expression was antagonized by the 5-HT2 type receptor antagonists spiperone, ketanserin, and LY53857.	Ketanserin	195-205	interferon gamma	Mus musculus	97-106
3009755-2	1986	Since ketanserin, a specific 5-HT2-receptor antagonist, decreases aldosterone levels in some hypertensive patients, we have performed in vitro experiments to elucidate the mechanism by which ketanserin interferes with aldosterone regulation.	Ketanserin	6-16	5-hydroxytryptamine receptor 2A	Homo sapiens	29-43
3009755-6	1986	Furthermore, we demonstrated that ketanserin is able to have a significant effect on the adrenal response to angiotensin II.	Ketanserin	34-44	angiotensinogen	Homo sapiens	109-123
2942782-5	1986	Metitepin also abolished the inhibitory effect of 8-OH-DPAT on evoked 3H overflow, whereas the 5-HT2 receptor antagonist ketanserin was inactive in this respect.	Ketanserin	121-131	5-hydroxytryptamine receptor 2A	Homo sapiens	95-109
2939698-4	1986	Such an inhibition of secondary platelet recruitment by ketanserin in vitro may be due to an inhibition of the 5-HT2 receptor-mediated amplifying effects of platelet-released 5-HT or to a non-specific interference with the platelet membrane, reducing the release of mediators from the platelets.	Ketanserin	56-66	5-hydroxytryptamine receptor 2A	Homo sapiens	111-125
2419672-1	1986	The cardiovascular effects of ketanserin (5-HT2-receptor antagonist with alpha 1-receptor blocking property) were studied during coronary artery surgery.	Ketanserin	30-40	5-hydroxytryptamine receptor 2A	Homo sapiens	42-56
2933490-6	1986	Furthermore, the ability of N-(m-trifluoromethylphenyl)piperazine and ketanserin to inhibit [3H]PAPP binding reflected their low affinities for the 5-HT1A receptor.	Ketanserin	70-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	148-154
2932476-0	1985	Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.	Ketanserin	11-21	5-hydroxytryptamine receptor 2A	Homo sapiens	25-39
2931964-0	1985	The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.	Ketanserin	14-24	5-hydroxytryptamine receptor 2A	Homo sapiens	28-42
2931964-3	1985	A double-blind placebo-controlled study further showed that a subacute treatment with ketanserin, a selective 5-HT2-receptor antagonist both on platelets and on vascular tissue, efficiently abolished the irreversible platelet aggregation in patients hyperreactive to 5-hydroxytryptamine.	Ketanserin	86-96	5-hydroxytryptamine receptor 2A	Homo sapiens	110-124
3161531-1	1985	We have completed a double-blind parallel group comparison of the 5-HT2 receptor antagonist ketanserin with placebo in 22 hypertensive patients.	Ketanserin	92-102	5-hydroxytryptamine receptor 2A	Homo sapiens	66-80
3891416-9	1985	The agonistic action of 5-HT appears to be receptor mediated in that it can be blocked by pretreating the ECs with ketanserin, a 5-HT2 receptor blocker.	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Homo sapiens	129-143
4000408-4	1985	After 14 days of administration of baclofen the number of 5-HT2 receptor binding sites in frontal cortex (labelled by [3H]-ketanserin) was also elevated.	Ketanserin	123-133	hypothermia due to alcohol sensitivity 2	Mus musculus	60-63
2934860-7	1985	Centrifugation on sucrose gradients revealed only one peak of [3H]ketanserin binding corresponding to the molecular weight of catalase (232,000 Da), thus probably reflecting a close association of the two binding sites.	Ketanserin	62-76	catalase	Sus scrofa	126-134
3158674-1	1985	Ketanserin, an investigational, antiserotonergic agent, at a dose of 40 mg bid was given to 18 patients with mild to moderate primary hypertension in a randomized, double-blind, crossover study, with 100-mg metoprolol bid for four weeks each.	Ketanserin	0-10	BH3 interacting domain death agonist	Homo sapiens	75-78
3157795-6	1985	Pre-treatment with the 5-HT2 receptor antagonist Ketanserin blocked the serotonin response completely.	Ketanserin	49-59	5-hydroxytryptamine receptor 2A	Homo sapiens	23-37
2578277-6	1985	Pretreatment with a 5-HT2-receptor blocking agent, ketanserin, abolished the gastrointestinal effects but had virtually no influence on either 5-HT levels or flushing induced by intravenous pentagastrin.	Ketanserin	51-61	5-hydroxytryptamine receptor 2A	Homo sapiens	20-34
3159583-0	1985	Effect of intravenous ketanserin on plasma catecholamines and renin activity in normal volunteers.	Ketanserin	22-32	renin	Homo sapiens	62-67
2412051-4	1985	In an additional open study, including 10 patients with peripheral arterial obstructive disease, chronic treatment with ketanserin for a period of 3 months significantly suppressed the primary platelet aggregation to 5-HT at 2 X 10(-5) M and at 2 X 10(-6) M and significantly lowered the plasma beta-thromboglobulin levels.	Ketanserin	120-130	pro-platelet basic protein	Homo sapiens	295-315
2412067-5	1985	Pretreatment with a 5-HT2 receptor blocking agent (ketanserin) alleviated gastrointestinal symptoms but had no influence on either 5-HT release or PG-induced flushing.	Ketanserin	51-61	5-hydroxytryptamine receptor 2A	Homo sapiens	20-34
2412069-0	1985	Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.	Ketanserin	103-113	5-hydroxytryptamine receptor 2A	Homo sapiens	117-131
6491656-9	1984	In general, the binding properties of [3H]ketanserin-labelled S2 serotonin receptors strongly resemble those of adenylate-cyclase coupled receptors such as the beta-adrenergic, the alpha 2-receptor, and the D-2 dopamine receptor.	Ketanserin	42-52	dopamine receptor D2	Rattus norvegicus	207-228
2942753-7	1985	On Ketanserin treatment DBP measurements show a significant increase in the digit to brachial systolic blood pressure index (DBI) after cold provocation.	Ketanserin	3-13	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	125-128
6150724-1	1984	The antihypertensive properties of ketanserin, a 5-HT2 receptor antagonist, was investigated in combination with beta-adrenoceptor blockade.	Ketanserin	35-45	5-hydroxytryptamine receptor 2A	Homo sapiens	49-63
6488044-3	1984	We found that the S-2 binding sites (labeled by [3H]spiperone and displaced by ketanserin) consisted of two subtypes (S-2A and S-2B) which are discriminated by competition with methysergide.	Ketanserin	79-89	ribosomal protein S2	Homo sapiens	18-21
6089950-0	1984	Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson"s syndrome.	Ketanserin	40-50	proopiomelanocortin	Homo sapiens	62-66
6089950-1	1984	A study was performed to see whether ketanserin, a serotonin antagonist, would reduce the raised concentrations of adrenocorticotrophic hormone (ACTH) in patients with Nelson"s syndrome.	Ketanserin	37-47	proopiomelanocortin	Homo sapiens	145-149
6089950-4	1984	In healthy people serotonin seems to have a stimulatory role in the regulation of ACTH secretion, and the effect of ketanserin in reducing the ACTH response to hypoglycaemia suggested that it might prove useful in Nelson"s syndrome.	Ketanserin	116-126	proopiomelanocortin	Homo sapiens	143-147
6397984-4	1984	Pharmacodissection in experimental animals with selective serotonergic 5-HT2 receptor antagonists, e.g. ketanserin, shows that 5-HT largely contributes to the platelet-mediated increase in vascular permeability, to platelet-vessel wall interaction during hemostasis, to cardiopulmonary dysfunction provoked by thromboembolism and to the platelet-mediated inhibition of peripheral collateral circulation.	Ketanserin	104-114	5-hydroxytryptamine receptor 2A	Homo sapiens	71-85
6483122-2	1984	In the present paper we report an investigation of 5HT stimulated phosphatidylinositol (PI) hydrolysis in rat cerebral cortex and have found that selective 5HT-2 antagonists (pizotifen and ketanserin) block 5HT"s effect upon PI metabolism.	Ketanserin	189-199	5-hydroxytryptamine receptor 2A	Rattus norvegicus	156-161
6486973-0	1984	Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist.	Ketanserin	79-89	5-hydroxytryptamine receptor 2A	Homo sapiens	103-117
6146746-4	1984	Evidence that there are structural similarities between alpha-adrenoceptors and serotonin receptors is supported by the finding that ketanserin, developed for its 5HT2-receptor blocking property, exerts at least part of its antihypertensive action through alpha 1-adrenoceptor blockade.	Ketanserin	133-143	5-hydroxytryptamine receptor 2A	Homo sapiens	163-176
6365102-0	1984	Treatment of Raynaud"s phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.	Ketanserin	39-49	5-hydroxytryptamine receptor 2A	Homo sapiens	93-108
6427633-6	1984	In addition, 5HT caused a concentration-dependent rise of intracellular free Ca2+ in platelets which was counteracted by ketanserin.	Ketanserin	121-131	carbonic anhydrase 2	Homo sapiens	77-80
6712712-5	1984	The D-2 dopamine receptor Bmax and [3H]SPIRO KD determined in this fashion are indistinguishable from that obtained for the higher affinity binding site by computer analysis of data obtained in the absence of ketanserin.	Ketanserin	209-219	dopamine receptor D2	Rattus norvegicus	4-25
6365102-1	1984	Ketanserin, a selective antagonist of the 5-HT2 receptor, was evaluated in a 4-week open pilot trial of 30 patients with Raynaud"s phenomenon.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	42-56
6325044-4	1984	Ketanserin induced a 50% decrease in the serum prolactin response to hypoglycaemia, 45 and 60 min after administration of insulin (increase in serum prolactin at 60 min: 1145 +/- 295 mU/l without ketanserin; 558 +/- 176 mU/l with ketanserin, P less than 0.05).	Ketanserin	0-10	insulin	Homo sapiens	122-129
6362688-8	1984	The data indicate that ketanserin induces arteriolar dilatation, possibly related to an alpha-1-antagonistic action and to a reduced circulating angiotensin II concentration.	Ketanserin	23-33	angiotensinogen	Homo sapiens	145-159
6196551-0	1983	Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.	Ketanserin	71-81	5-hydroxytryptamine receptor 2A	Homo sapiens	45-59
6717852-1	1984	Using [3H]ketanserin, a specific ligand for the 5-HT2 receptor, the amount of specific binding was measured in preparations of post-mortem frontal cortex from subjects diagnosed as suffering from dementia.	Ketanserin	10-20	5-hydroxytryptamine receptor 2A	Homo sapiens	48-62
6690191-0	1984	Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.	Ketanserin	89-99	renin	Homo sapiens	49-54
6140126-0	1984	Influence of ketanserin, an antihypertensive agent with specific 5-HT2-receptor blocking activity, on intracranial pressure.	Ketanserin	13-23	5-hydroxytryptamine receptor 2A	Homo sapiens	65-79
6139140-0	1983	Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin.	Ketanserin	76-86	adrenoceptor alpha 1D	Homo sapiens	0-7
6626423-4	1983	Plasma active renin concentration and angiotensin II increased after administration of ketanserin, but plasma aldosterone, cortisol and noradrenaline were unchanged.	Ketanserin	87-97	renin	Homo sapiens	14-19
6626423-4	1983	Plasma active renin concentration and angiotensin II increased after administration of ketanserin, but plasma aldosterone, cortisol and noradrenaline were unchanged.	Ketanserin	87-97	angiotensinogen	Homo sapiens	38-52
6628538-0	1983	Effects of pirenperone and ketanserin on rat prolactin secretion in vivo and in vitro.	Ketanserin	27-37	prolactin	Rattus norvegicus	45-54
6628538-3	1983	Ketanserin, also a purported selective 5-HT2 receptor blocker, has no effect on rat PRL secretion in vivo or in vitro, but at high doses, it inhibits the increase in serum PRL levels produced by the two 5-HT agonists, quipazine and 5-methoxy-N,N-dimethyl-tryptamine (5-MeODMT).	Ketanserin	0-10	prolactin	Rattus norvegicus	172-175
31500679-10	2020	Pretreatment with the 5-HT2A antagonist ketanserin normalized all LSD-induced cognitive deficits.	Ketanserin	40-50	5-hydroxytryptamine receptor 2A	Homo sapiens	22-28
6627748-1	1983	Ketanserin, a 5HT2-receptor blocking drug was given to 17 patients with essential hypertension.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	14-27
6188804-0	1983	The 5-hydroxytryptamine antagonist ketanserin inhibits the vasoconstrictor activity of per-operative CSF, from subarachnoid haemorrhage patients, on isolated tissues.	Ketanserin	35-45	colony stimulating factor 2	Homo sapiens	101-104
6188804-2	1983	The 5-hydroxytryptamine antagonist ketanserin inhibited contractions of isolated human intracranial arteries, elicited by this CSF.	Ketanserin	35-45	colony stimulating factor 2	Homo sapiens	127-130
6600382-1	1983	In patients developing hypertension following coronary artery bypass surgery (CABG) the possible role of 5-hydroxytryptamine (5-HT; serotonin) was investigated by injecting ketanserin, a specific 5-HT2-receptor antagonist.	Ketanserin	173-183	5-hydroxytryptamine receptor 2A	Homo sapiens	196-210
6600382-2	1983	Ketanserin was administered intravenously when intraarterial systolic blood pressure (SAP) exceeded 150 mm Hg either as a 10-mg bolus (group 1, N = 15), or as a 10-mg bolus followed by infusion of 4 mg/h for either 2.5 h (group 2, N = 15) or for 1 h (group 3, N = 10).	Ketanserin	0-10	SH2 domain containing 1A	Homo sapiens	86-89
6800533-0	1982	Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.	Ketanserin	31-41	5-hydroxytryptamine receptor 2A	Homo sapiens	59-73
6800533-1	1982	The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension.	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Homo sapiens	18-32
6800533-5	1982	Heart rate and plasma concentrations of renin and noradrenaline rose after ketanserin.	Ketanserin	75-85	renin	Homo sapiens	40-45
7271395-0	1981	Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist.	Ketanserin	21-31	5-hydroxytryptamine receptor 2A	Homo sapiens	56-70
6812750-0	1982	Treatment of Raynaud"s phenomenon with the 5-HT2-receptor antagonist ketanserin.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Homo sapiens	43-57
6812750-1	1982	The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud"s phenomenon.	Ketanserin	67-77	5-hydroxytryptamine receptor 2A	Homo sapiens	36-51
6215842-0	1982	Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.	Ketanserin	87-97	5-hydroxytryptamine receptor 2A	Homo sapiens	122-136
6215842-1	1982	Ketanserin, a selective 5-HT2-receptor antagonist, inhibits the reversible aggregation induced by 5-hydroxytryptamine (5-HT) in human platelet-rich plasma (PRP).	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	24-38
6215842-1	1982	Ketanserin, a selective 5-HT2-receptor antagonist, inhibits the reversible aggregation induced by 5-hydroxytryptamine (5-HT) in human platelet-rich plasma (PRP).	Ketanserin	0-10	complement component 4 binding protein alpha	Homo sapiens	156-159
6751979-0	1982	Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subject.	Ketanserin	10-20	renin	Homo sapiens	68-73
6751979-2	1982	Ketanserin induced a small increase in plasma levels of both renin activity and aldosterone, which was not significantly different from that observed during control test.	Ketanserin	0-10	renin	Homo sapiens	61-66
6751979-5	1982	However, further investigations are needed to elucidate the effects of ketanserin on the renin secretion and blood pressure.	Ketanserin	71-81	renin	Homo sapiens	89-94
6981913-4	1982	At the end of operation the ketanserin treated patients had significantly lower heart rate (84 +/- 16 vs. 96 +/- 14 min-1; Mean +/- S.D.	Ketanserin	28-38	CD59 molecule (CD59 blood group)	Homo sapiens	116-121
33913004-8	2021	The intravenous administration of serotonin increased significantly mesenteric lymph flow and the concentrations of albumin and IL-22; both were significantly reduced by the intravenous pretreatment with ketanserin.	Ketanserin	204-214	albumin	Rattus norvegicus	116-123
33913004-8	2021	The intravenous administration of serotonin increased significantly mesenteric lymph flow and the concentrations of albumin and IL-22; both were significantly reduced by the intravenous pretreatment with ketanserin.	Ketanserin	204-214	interleukin 22	Rattus norvegicus	128-133
32132658-5	2020	Conversely, the ritanserin analog ketanserin (100 microM) inhibited ICa1.2 by ~50%.	Ketanserin	34-44	islet cell autoantigen 1	Rattus norvegicus	68-72
32699231-5	2020	Twenty-four healthy human volunteers received either (1) placebo + placebo, (2) placebo + LSD (100 microg), or (3) the 5-HT2A receptor antagonist ketanserin (40 mg) + LSD (100 microg) at three different occasions in a double-blind, randomized, counterbalanced, cross-over design.	Ketanserin	146-156	5-hydroxytryptamine receptor 2A	Homo sapiens	119-134
32699231-8	2020	Furthermore, pretreatment with the 5-HT2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT2A system in social feedback processing.	Ketanserin	53-63	5-hydroxytryptamine receptor 2A	Homo sapiens	35-41
32699231-8	2020	Furthermore, pretreatment with the 5-HT2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT2A system in social feedback processing.	Ketanserin	53-63	5-hydroxytryptamine receptor 2A	Homo sapiens	155-161
32342136-6	2020	Additionally, results showed that mRNA expression of TGF-beta and collagen IV, which are known to promote fibrosis via various signaling pathways involved in the progression of renal disease, was suppressed by ketanserin treatment.	Ketanserin	210-220	transforming growth factor alpha	Rattus norvegicus	53-61
32342136-7	2020	Furthermore, expression levels of 5-HT2A and pro-inflammatory marker IL-6 have also been reduced significantly after ketanserin administration in adriamycin-treated animals.	Ketanserin	117-127	5-hydroxytryptamine receptor 2A	Rattus norvegicus	34-40
32342136-7	2020	Furthermore, expression levels of 5-HT2A and pro-inflammatory marker IL-6 have also been reduced significantly after ketanserin administration in adriamycin-treated animals.	Ketanserin	117-127	interleukin 6	Rattus norvegicus	69-73
32342136-9	2020	In conclusion, ketanserin reduces renal fibrosis and inflammation in adriamycin-induced chronic kidney disease by suppressing 5-HT2A, IL-6, TGF-beta and collagen IV expression in renal tissue.	Ketanserin	15-25	5-hydroxytryptamine receptor 2A	Rattus norvegicus	126-132
32342136-9	2020	In conclusion, ketanserin reduces renal fibrosis and inflammation in adriamycin-induced chronic kidney disease by suppressing 5-HT2A, IL-6, TGF-beta and collagen IV expression in renal tissue.	Ketanserin	15-25	interleukin 6	Rattus norvegicus	134-138
32342136-9	2020	In conclusion, ketanserin reduces renal fibrosis and inflammation in adriamycin-induced chronic kidney disease by suppressing 5-HT2A, IL-6, TGF-beta and collagen IV expression in renal tissue.	Ketanserin	15-25	transforming growth factor alpha	Rattus norvegicus	140-148
32333296-6	2020	The 5-HT1B antagonists SB224289 and GR55562 reduced responses induced by 5-HT and 5-CT and the 5-HT2A antagonist ketanserin inhibited the effects of 5-HT and alpha-methyl-5-HT.	Ketanserin	113-123	5-hydroxytryptamine receptor 2A	Homo sapiens	95-101
31629087-7	2020	We examined the survival of HaCaT cells treated with 5-HT and the 5-HTR antagonists ketanserin (5-HT2A) and ondansetron (5-HT3) following exposure to direct IR and irradiated cell condition medium (ICCM).	Ketanserin	84-94	5-hydroxytryptamine receptor 2A	Homo sapiens	96-102
31787571-8	2020	Cigarette smoke induced accumulation of macrophages and neutrophils and increased levels of inflammatory cytokines, including IL-1beta and TNF-alpha, in BALF and lung tissue; these effects were inhibited by ketanserin, RS-127445 and quercetin.	Ketanserin	207-217	interleukin 1 alpha	Mus musculus	126-134
31787571-8	2020	Cigarette smoke induced accumulation of macrophages and neutrophils and increased levels of inflammatory cytokines, including IL-1beta and TNF-alpha, in BALF and lung tissue; these effects were inhibited by ketanserin, RS-127445 and quercetin.	Ketanserin	207-217	tumor necrosis factor	Mus musculus	139-148
31896670-10	2020	Subsequent pharmacological blockade of 5-HT2A receptors with ketanserin in RN-NSC grafted rats reduced resting MAP and increased heart rate in all but two controls.	Ketanserin	61-71	5-hydroxytryptamine receptor 2A	Rattus norvegicus	39-45
31618004-15	2019	The antagonist ketanserin was included as inactive drug with demonstrated affinity for 5-HT2A/C receptors.	Ketanserin	15-25	5-hydroxytryptamine receptor 2A	Homo sapiens	89-93
30456914-9	2019	However, recent studies suggest that 5-HT can robustly stimulate adjacent glial-like type II cells via ketanserin-sensitive 5-HT2 receptors, leading to intracellular Ca2+ elevation (Delta[Ca2+ ]i ) and activation of ATP-permeable pannexin-1 (Panx-1) channels.	Ketanserin	103-113	Pannexin 1	Rattus norvegicus	230-240
31219768-5	2019	Intravenous administration of the Gq protein-coupled 5-HT2A/2C receptor antagonist ketanserin blocks mAIH-induced pLTF when administered before, but not after, mAIH; thus, 5-HT2 receptor activation is necessary for the induction but not maintenance of mAIH-induced pLTF.	Ketanserin	83-93	5-hydroxytryptamine receptor 2A	Rattus norvegicus	53-59
30878386-4	2019	In PCA rings, aggregating platelets caused concentration-dependent contractions that were significantly inhibited by the 5-HT2A receptor antagonist ketanserin, and by EPA:DHA 6:1 but not EPA:DHA 1:1 at 0.4% v/v.	Ketanserin	148-158	5-hydroxytryptamine receptor 2A	Homo sapiens	121-136
30456914-9	2019	However, recent studies suggest that 5-HT can robustly stimulate adjacent glial-like type II cells via ketanserin-sensitive 5-HT2 receptors, leading to intracellular Ca2+ elevation (Delta[Ca2+ ]i ) and activation of ATP-permeable pannexin-1 (Panx-1) channels.	Ketanserin	103-113	Pannexin 1	Rattus norvegicus	242-248
29028939-2	2018	In the current report, blood oxygen level-dependent (BOLD) signal was collected during music listening in 25 healthy adults after administration of placebo, lysergic acid diethylamide (LSD), and LSD pretreated with the 5HT2A antagonist ketanserin, to investigate the role of 5HT2A receptor signaling in the neural response to the time-varying tonal structure of music.	Ketanserin	236-246	5-hydroxytryptamine receptor 2A	Homo sapiens	219-224
30393120-4	2018	The inverse agonist pimavanserin (3, 6, and 12 mg/kg) and neural antagonist ketanserin (2.5 and 5 mg/kg) were used to induce the low or constitutive activity of 5-HT2A receptors, respectively.	Ketanserin	76-86	5-hydroxytryptamine receptor 2A	Rattus norvegicus	161-167
30278246-0	2018	Effect of 5-HT2A receptor antagonist ketanserin on micturition in male rats.	Ketanserin	37-47	5-hydroxytryptamine receptor 2A	Rattus norvegicus	10-16
30278246-1	2018	OBJECTIVES: This study aimed to investigate the effects of ketanserin on micturition mediated via the 5-HT2A receptor in the motoneuron nucleus of the Lumbosacral cord, as reflected in high frequency oscillations (HFOs) of intravesical pressure and the external urethral sphincter electromyogram (EUS-EMG) in anesthetized male rats.	Ketanserin	59-69	5-hydroxytryptamine receptor 2A	Rattus norvegicus	102-108
30278246-7	2018	The effects of ketanserin on the HFO and EUS-EMG activity were partially or completely reversed by the 5-HT2A/2C receptor agonist, DOI.	Ketanserin	15-25	5-hydroxytryptamine receptor 2A	Rattus norvegicus	103-109
30278246-9	2018	CONCLUSIONS: The intrathecally administrated 5-HT2A receptor antagonist ketanserin can weaken the EUS bursting activity, decrease HFOs, and reduce voiding efficiency as dose dependently.	Ketanserin	72-82	5-hydroxytryptamine receptor 2A	Rattus norvegicus	45-51
30278246-10	2018	The effects of ketanserin on micturition may be mainly mediated via the 5-HT2A receptors in the motoneuron nucleus of the lumbosacral cord.	Ketanserin	15-25	5-hydroxytryptamine receptor 2A	Rattus norvegicus	72-78
29159869-14	2018	Angiotensin II and 5-HT receptor antagonists, losartan and ketanserin, severely reduced CB responses to individual hypoxic-hypercapnic challenges and prevented the induction of sensory LTF but, if applied after AIH-Hc, failed to reduce plasticity-associated activity.	Ketanserin	59-69	angiotensinogen	Homo sapiens	0-14
30527375-10	2018	However, ketanserin selectively weakened the action of fluoxetine promoted migration and up-regulated Rab27a protein expression in B16F10 cells.	Ketanserin	9-19	RAB27A, member RAS oncogene family	Mus musculus	102-108
29950360-0	2018	Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.	Ketanserin	82-92	5-hydroxytryptamine receptor 2A	Homo sapiens	63-70
29950360-4	2018	Based on the possible role of the 5-HT2A receptor in hallucinations, we treated her with the antihypertensive drug ketanserin, a 5-HT2A receptor antagonist.This significantly reduced her visual but not her auditory hallucinations, suggesting a possible role of the 5HT2A receptor in the pathophysiology of specifically visual hallucinations.	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Homo sapiens	34-49
29950360-4	2018	Based on the possible role of the 5-HT2A receptor in hallucinations, we treated her with the antihypertensive drug ketanserin, a 5-HT2A receptor antagonist.This significantly reduced her visual but not her auditory hallucinations, suggesting a possible role of the 5HT2A receptor in the pathophysiology of specifically visual hallucinations.	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Homo sapiens	129-144
29950360-4	2018	Based on the possible role of the 5-HT2A receptor in hallucinations, we treated her with the antihypertensive drug ketanserin, a 5-HT2A receptor antagonist.This significantly reduced her visual but not her auditory hallucinations, suggesting a possible role of the 5HT2A receptor in the pathophysiology of specifically visual hallucinations.	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Homo sapiens	265-279
29660654-3	2018	Molecular hepatic oxidative stress-fibrotic roles of 5-HT2A and 7 receptors antagonists (ketanserin and SB-269970 respectively) are still a challenging issue.	Ketanserin	89-99	5-hydroxytryptamine receptor 2A	Rattus norvegicus	53-59
29345193-9	2018	In addition, we found that treatment with ketanserin activated pulmonary MAPK and Akt signaling in mice exposed to bleomycin.	Ketanserin	42-52	thymoma viral proto-oncogene 1	Mus musculus	82-85
29499271-3	2018	Actually, the 15 mM KCl-evoked [3H]D-Asp exocytosis from spinal cord synaptosomes was reduced by the 5-HT2A agonist (+-)DOI, an effect reversed by the 5-HT2A antagonists MDL11,939, MDL100907, ketanserin and trazodone (TZD).	Ketanserin	192-202	5-hydroxytryptamine receptor 2A	Rattus norvegicus	101-107
29499271-3	2018	Actually, the 15 mM KCl-evoked [3H]D-Asp exocytosis from spinal cord synaptosomes was reduced by the 5-HT2A agonist (+-)DOI, an effect reversed by the 5-HT2A antagonists MDL11,939, MDL100907, ketanserin and trazodone (TZD).	Ketanserin	192-202	5-hydroxytryptamine receptor 2A	Rattus norvegicus	151-157
29499271-8	2018	Conversely, 5-HT2A antagonists (MDL11,939, MDL100907, ketanserin and TZD) reinforced the release-regulating activity of mGlu2/3 autoreceptors.	Ketanserin	54-64	5-hydroxytryptamine receptor 2A	Rattus norvegicus	12-18
29499271-8	2018	Conversely, 5-HT2A antagonists (MDL11,939, MDL100907, ketanserin and TZD) reinforced the release-regulating activity of mGlu2/3 autoreceptors.	Ketanserin	54-64	glutamate receptor, metabotropic 3	Mus musculus	120-127
29382554-13	2018	Furthermore, microinjection of the 5-HT2A receptor antagonist ketanserin (5 nmol/mouse) into the prefrontal cortex significantly suppressed freezing behavior.	Ketanserin	62-72	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	35-50
29143869-4	2018	It was hypothesized that MDMA would cause an increase in eCB concentrations together with a decrease in memory performance, and that combining MDMA with a 5-HT2 receptor blocker ketanserin would lead to a counteraction of the MDMA effects on eCB concentrations and memory.	Ketanserin	178-188	5-hydroxytryptamine receptor 2A	Homo sapiens	155-169
29555857-10	2018	Furthermore, LSD-induced effects were blocked by the serotonin 2A receptor (5-HT2AR) antagonist ketanserin, indicating that effects of LSD are attributable to 5-HT2AR stimulation.	Ketanserin	96-106	5-hydroxytryptamine receptor 2A	Homo sapiens	53-83
29467649-8	2018	induced HTRs were blocked by the 5-HT2A antagonist ketanserin (0.75 mg/kg, 30 min pre), but not by the 5-HT2C antagonist SB-242084 (0.5 mg/kg, i.p., 30 min pre).	Ketanserin	51-61	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	33-39
28735368-10	2018	This effect was counteracted by ketanserin pre-treatment, indicating involvement of the 5-HT2 receptor in this process.	Ketanserin	32-42	5-hydroxytryptamine receptor 2A	Homo sapiens	88-102
28428755-7	2017	We show that antagonists of 5-HT1D and 5-HT2C receptor subtypes were able to do so (LY 310762 and SB 242084, respectively), but notably, a 5-HT2A-antagonist (ketanserin) was not.	Ketanserin	158-168	5-hydroxytryptamine receptor 1D	Homo sapiens	28-34
28993250-6	2018	iTR hypoalgesia was antagonized by blockade of beta2 and 5HT2A receptors with administration of butoxamine and ketanserin.	Ketanserin	111-121	5-hydroxytryptamine receptor 2A	Rattus norvegicus	47-62
29017144-6	2017	Then, AtF1 was co-administered with different drugs, which act on GABAergic (bicuculline, picrotoxin, pentylenetetrazol, baclofen and phaclofen), or serotononinergic (DOI, 8-OH-DPAT, WAY 100635 and ketanserine) or glutamatergic (NMDA, MPEP and MK-801) systems.	Ketanserin	198-209	thioredoxin F-type 1	Arabidopsis thaliana	6-10
28208011-5	2017	The GS-induced intracellular calcium increase was dose-dependent, and antagonists such as ketanserin (Htr2a antagonist) and RS-127445 (Htr2b antagonist) significantly blocked the GS-induced responses.	Ketanserin	90-100	5-hydroxytryptamine receptor 2A	Homo sapiens	102-107
28687907-4	2017	The concentration-response curve of 5-HT shifted towards the right by the addition of increasing concentrations of ketanserin (with a pA 2 value of 9.18), indicating the involvement of the 5-HT2A receptor.	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Homo sapiens	189-204
28920103-11	2017	This action was blocked by the 5-HT2A antagonist ketanserin.	Ketanserin	49-59	5-hydroxytryptamine receptor 2A	Homo sapiens	31-37
28332205-10	2017	5-HT also activated an inward current (I5-HT ) in type II cells (EC50 ~200 nm) that was reversibly inhibited by ketanserin (1-10 nm), the Ca2+ chelator BAPTA-AM (5 mum), and low concentrations of carbenoxolone (5 mum), a putative Panx-1 channel blocker.	Ketanserin	112-122	Pannexin 1	Rattus norvegicus	230-236
29104045-6	2018	The 5-HT2A receptor antagonist ketanserin (10-100nM) elicited rightward shifts of 5-HT concentration-response curves, antagonising AUC and frequency responses with high affinity in tissues from both age groups (pKD values 8.4-8.8).	Ketanserin	31-41	5-hydroxytryptamine receptor 2A	Sus scrofa	4-19
28782175-7	2018	Fasting-induced c-Fos expression was further enhanced by DOI in prefrontal cortex, and these enhancements were inhibited by ketanserin.	Ketanserin	124-134	FBJ osteosarcoma oncogene	Mus musculus	16-21
28782175-8	2018	The increased BDNF levels by fasting were markedly inhibited by DOI in frontal cortex and hippocampus, and these effects of DOI on BDNF levels were also blocked by ketanserin.	Ketanserin	164-174	brain derived neurotrophic factor	Mus musculus	14-18
28782175-8	2018	The increased BDNF levels by fasting were markedly inhibited by DOI in frontal cortex and hippocampus, and these effects of DOI on BDNF levels were also blocked by ketanserin.	Ketanserin	164-174	brain derived neurotrophic factor	Mus musculus	131-135
29091968-7	2017	was prevented by the pretreatment with WAY100635 (a selective 5HT1a antagonist), ketanserin (a 5HT2a/c antagonist) and ondansetron (a selective 5ht3 antagonist), PCPA (an inhibitor of serotonin synthesis) but not with SCH23390 (dopaminergic D1 antagonist) and sulpiride (D2 antagonist).	Ketanserin	81-91	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	95-100
28711602-5	2017	Bilateral diaphragm electromyography (EMG) was performed in vagal-intact and spontaneously breathing rats before and after intravenous administration of the 5-HT2A receptor antagonist Ketanserin (1mg/kg).	Ketanserin	184-194	5-hydroxytryptamine receptor 2A	Rattus norvegicus	157-163
28263831-6	2017	Systemic administration of ketanserin (0.5mg/kg) prior to novel open-field exposure resulted in reduced total numbers of c-Fos-IR cells in dorsomedial PFC areas and the BLA.	Ketanserin	27-37	FBJ osteosarcoma oncogene	Mus musculus	121-126
28263831-7	2017	Moreover, there was a positive correlation between the relative time spent in the centre of the open-field and BLA c-Fos-IR in the ketanserin-treated animals.	Ketanserin	131-141	FBJ osteosarcoma oncogene	Mus musculus	115-120
28555112-16	2017	The 5-HT-induced-constriction in PCLS could be antagonized by ketanserin, a 5-HT2A receptor inhibitor.	Ketanserin	62-72	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	76-82
28101155-9	2016	Furthermore, the transcription and translation levels of KCC2 in the incision + ketanserin group decreased significantly in comparison to the incision + DMSO group (P<0.05), while an increase was detected in the incision + TCB-2 group (P<0.05).	Ketanserin	80-90	solute carrier family 12 member 5	Rattus norvegicus	57-61
28283227-7	2017	In relation to ERK1/2 activation, we found that 5-HT2A serotonin receptor antagonists Ketanserin and M100907, both partially reduced Clozapine effect.	Ketanserin	86-96	mitogen-activated protein kinase 3	Homo sapiens	15-21
29675430-11	2017	Expression of most genes was increased with PFD + M-DDO; 43.8% of ulcers were resolved using PFD + M-DDO and 23.5% with ketanserin.	Ketanserin	120-130	D-aspartate oxidase	Homo sapiens	52-55
28465511-5	2017	In the forced swimming test, berberine decreased the immobility time in a dose-dependent manner, reversing the depressive-like effect observed in ovariectomized mice, and this effect was blocked by the 5-HT2 antagonist ketanserin.	Ketanserin	219-229	hypothermia due to alcohol sensitivity 2	Mus musculus	204-207
28465511-8	2017	Ketanserin also antagonized the effect of berberine on the c-Fos expression.	Ketanserin	0-10	FBJ osteosarcoma oncogene	Mus musculus	59-64
26621247-5	2016	Systemic inflammation and sickness were produced by lipopolysaccharide (LPS, 0.1mg/kg, ip), while the 5-HT2A receptor was stimulated or blocked through the administration of the receptor agonist DOI or antagonist ketanserin (1mg/kg), respectively.	Ketanserin	213-223	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	102-117
27568460-9	2016	Ketanserin could alleviate atherosclerosis and markedly decrease oxidative stress and inflammation in alpha7nAChR+/+ mice.	Ketanserin	0-10	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	102-113
27531585-7	2016	However, the 5-HT2A antagonist, ketanserin (30-300 mumol/L), caused a shift of the 5-HT curve yielding an affinity estimate of 7.9.	Ketanserin	32-42	5-hydroxytryptamine receptor 2A	Homo sapiens	13-19
27847437-7	2016	The left shift of the 5-HT CRCs caused by ketamine was reversed with ketanserin, a competitive 5-HT2A receptor inhibitor, indicating that ketamine facilitated the activation of 5-HT2A receptors.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Rattus norvegicus	95-101
27847437-7	2016	The left shift of the 5-HT CRCs caused by ketamine was reversed with ketanserin, a competitive 5-HT2A receptor inhibitor, indicating that ketamine facilitated the activation of 5-HT2A receptors.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Rattus norvegicus	177-183
26921771-7	2016	These alterations induced by CUMS were reversed by pretreatment with the 5-HT2A receptor antagonist Ketanserin (Ket, 5 mug/0.5 muL into the OFC).	Ketanserin	100-110	5-hydroxytryptamine receptor 2A	Homo sapiens	73-88
26921771-7	2016	These alterations induced by CUMS were reversed by pretreatment with the 5-HT2A receptor antagonist Ketanserin (Ket, 5 mug/0.5 muL into the OFC).	Ketanserin	100-103	5-hydroxytryptamine receptor 2A	Homo sapiens	73-88
27571356-11	2016	Incubation with 0.5% plasma extracted from CB-exposed ApoE-/- mice caused vasoconstriction in aorta rings isolated from naive mice; this effect was abolished by the treatment with the serotonin receptor antagonist Ketanserin.	Ketanserin	214-224	apolipoprotein E	Mus musculus	54-58
27040714-4	2016	Treatment with the 5-HT2A receptor antagonist ketanserin (20mug) in the hindpaw following intraplantar injection of carrageenan inhibited the increase in nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d) reactivity, a marker of nitric oxide synthase (NOS), in the spinal dorsal horn.	Ketanserin	46-56	5-hydroxytryptamine receptor 2A	Rattus norvegicus	19-25
27040714-7	2016	The ketanserin treatment also reduced the repeated inflammation-induced expression of protein kinase gamma (PKCgamma) in the membrane of spinal dorsal horn neurons and increased PKCgamma protein level in the cytosol.	Ketanserin	4-14	protein kinase C, gamma	Rattus norvegicus	108-116
27040714-7	2016	The ketanserin treatment also reduced the repeated inflammation-induced expression of protein kinase gamma (PKCgamma) in the membrane of spinal dorsal horn neurons and increased PKCgamma protein level in the cytosol.	Ketanserin	4-14	protein kinase C, gamma	Rattus norvegicus	178-186
26621247-8	2016	Ketanserin reversed the LPS-induced expression of inducible NO synthase in the brain.	Ketanserin	0-10	nitric oxide synthase 2, inducible	Mus musculus	50-71
25660244-6	2015	These effects in vivo and ex vivo were blocked by the 5-HT2A receptor antagonist ketanserin and absent in mice without mast cells.	Ketanserin	81-91	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	54-69
26490063-5	2015	The selective 5-HT2A receptor antagonist ketanserin was given in the inflamed site.	Ketanserin	41-51	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-20
26490063-11	2015	The local treatment of ketanserin completely inhibited CFA-induced increase in NPY expression in superficial laminae of the spinal cord.	Ketanserin	23-33	neuropeptide Y	Rattus norvegicus	79-82
25933953-5	2015	RESULTS: Repeated treatment with nicotine in home cages evoked significant increases in [(3)H]ketanserin binding to 5-HT2A receptors in the prefrontal cortex, striatal subregions and ventral tegmental area as well as reductions in [(3)H]mesulergine binding to 5-HT2C receptors in subregions of the prefrontal cortex.	Ketanserin	94-104	5-hydroxytryptamine receptor 2A	Rattus norvegicus	116-122
25933953-5	2015	RESULTS: Repeated treatment with nicotine in home cages evoked significant increases in [(3)H]ketanserin binding to 5-HT2A receptors in the prefrontal cortex, striatal subregions and ventral tegmental area as well as reductions in [(3)H]mesulergine binding to 5-HT2C receptors in subregions of the prefrontal cortex.	Ketanserin	94-104	5-hydroxytryptamine receptor 2C	Rattus norvegicus	260-266
25732836-10	2015	The binding sites of 5-HT2A receptors on the plasma membrane of the prefrontal cortex (PFC) were assessed by a receptor-binding assay using tritium-labeled ketanserin, and the density and affinity were calculated from a Scatchard plot.	Ketanserin	156-166	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	21-27
25822577-5	2015	The selective 5-HT2A antagonist ketanserin was administered after each DOI dose-response curve was plotted.	Ketanserin	32-42	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-20
25084759-6	2015	Agmatine increased Akt and ERK phosphorylation and induced the transcription factor Nrf2 and the proteins HO-1 and GCLc; induction of these proteins was prevented by yohimbine, ketanserin, LY294002, and PD98059.	Ketanserin	177-187	heme oxygenase 1	Homo sapiens	106-119
25046277-9	2015	[(3)H]-ketanserin specific binding to striatal and pallidal 5-HT2A receptors was increased in L-DOPA-treated MPTP monkeys as compared to controls, saline and L-DOPA+MPEP MPTP monkeys and no difference between the latter groups was observed; dyskinesia scores correlated positively with this binding.	Ketanserin	7-17	5-hydroxytryptamine receptor 2A	Homo sapiens	60-66
26080602-2	2015	At the same time 5-HTA receptor activation with DOI (0.5 and 1.0 mg/kg, i. p.) abolished the 5-HT1A receptor-mediated hypothermic reaction, whereas 5-HT2A receptor blockade with ketanserin (1.0 and 2.0 mg/kg, i. p.) increased this 5-HT1A receptor functional response.	Ketanserin	178-188	5-hydroxytryptamine receptor 2A	Homo sapiens	148-163
26080602-3	2015	Moreover, we revealed that 5-HT2A receptor antagonist ketanserin (1.0 and 2.0 mg/kg, i. p.; or 20 and 40 nmol, i. c. v.) produced the considerable dose-dependent hypothermia.	Ketanserin	54-64	5-hydroxytryptamine receptor 2A	Homo sapiens	27-42
26080602-4	2015	This ketanserin-induced (40 nmol, i. c. v.) hypothermic reaction was significantly attenuated by pretreatment with 5-HT1A receptor antagonist WAY-100635 (1.0 mg/kg, i. p.), indicating that 5-HT2A receptor-related hypothermic response is mediated, at least partially, via activation of 5-HT1A receptors.	Ketanserin	5-15	5-hydroxytryptamine receptor 1A	Homo sapiens	115-130
26080602-4	2015	This ketanserin-induced (40 nmol, i. c. v.) hypothermic reaction was significantly attenuated by pretreatment with 5-HT1A receptor antagonist WAY-100635 (1.0 mg/kg, i. p.), indicating that 5-HT2A receptor-related hypothermic response is mediated, at least partially, via activation of 5-HT1A receptors.	Ketanserin	5-15	5-hydroxytryptamine receptor 2A	Homo sapiens	189-204
26080602-4	2015	This ketanserin-induced (40 nmol, i. c. v.) hypothermic reaction was significantly attenuated by pretreatment with 5-HT1A receptor antagonist WAY-100635 (1.0 mg/kg, i. p.), indicating that 5-HT2A receptor-related hypothermic response is mediated, at least partially, via activation of 5-HT1A receptors.	Ketanserin	5-15	5-hydroxytryptamine receptor 1A	Homo sapiens	115-121
25045122-9	2014	The results indicated that ketanserin inhibited 5-HT-activated TGF-beta1-smad2/3 signaling in vitro and thereby depressed the MF conversion of PFs.	Ketanserin	27-37	transforming growth factor, beta 1	Rattus norvegicus	63-72
25150943-5	2014	The 5-HT2AR density evaluated by [(3)H]ketanserin binding was significantly lower in antidepressant-treated subjects (Bmax = 313 +- 17 fmol/mg protein; p < 0.05) compared to controls (Bmax = 360 +- 12 fmol/mg protein) but not in antidepressant-free subjects (Bmax = 394 +- 16 fmol/mg protein; p > 0.05).	Ketanserin	39-49	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-11
25185755-7	2014	5-HT also caused Smad3 phosphorylation and ketanserin diminished 5-HT-induced Smad3 activation.	Ketanserin	43-53	SMAD family member 3	Rattus norvegicus	78-83
24780897-7	2014	In five subjects, pretreatment with the 5-HT(2A) receptor antagonist ketanserin before a second PET scan significantly decreased [(11)C]Cimbi-36 binding in all cortical regions with no effects in cerebellum.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Homo sapiens	40-57
24844635-8	2014	This effect was reversed by 5-10 min of drug washout and ROB discharge was inhibited by both synaptic activity and coapplication of the 5-HT2A/2C antagonist ketanserin.	Ketanserin	157-167	5-hydroxytryptamine receptor 2A	Homo sapiens	136-142
24523680-8	2014	This was blocked by the 5-HT2A/C antagonist ketanserin suggesting that 5-HT2-like receptors mediate the behavioral effect of alpha-m5HT.	Ketanserin	44-54	5-hydroxytryptamine receptor 2A	Homo sapiens	24-30
24012617-6	2014	Autoradiographic studies showed that 5-APB displaced both [(125)I] RTI-121 and [(3)H] ketanserin from rat brain tissue suggesting affinity at the dopamine transporter and 5-HT2 receptor sites respectively.	Ketanserin	86-96	arginyl aminopeptidase	Rattus norvegicus	39-42
24309097-5	2014	The effects of the hallucinogenic 5-HT2AR agonists on D2R density and affinity were blocked by the 5-HT2A antagonist ketanserin.	Ketanserin	117-127	5-hydroxytryptamine receptor 2A	Homo sapiens	34-40
24012617-8	2014	5-APB also caused vasoconstriction of rat aorta, an effect antagonised by the 5-HT2A receptor antagonist ketanserin, and caused contraction of rat stomach fundus, which was reversed by the 5-HT2B receptor antagonist RS-127445.	Ketanserin	105-115	arginyl aminopeptidase	Rattus norvegicus	2-5
24241347-10	2013	In addition, ketanserin markedly increased the expression of VAChT and alpha7-nAChR in ischemic myocardium.	Ketanserin	13-23	solute carrier family 18 member A3	Rattus norvegicus	61-66
21849351-7	2013	Ketanserin (0.6 mg/kg/day) enhanced BRS, and increased capillary density, regional blood flow, and VEGF.	Ketanserin	0-10	vascular endothelial growth factor A	Rattus norvegicus	99-103
23954471-0	2013	The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway.	Ketanserin	25-35	nitric oxide synthase 2, inducible	Mus musculus	111-132
23954471-0	2013	The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway.	Ketanserin	25-35	midkine	Mus musculus	152-155
23954471-0	2013	The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway.	Ketanserin	25-35	mitogen-activated protein kinase 1	Mus musculus	156-159
23954471-2	2013	This work tested the hypothesis that ketanserin could attenuate endotoxic shock by inhibiting the expression of inducible NO synthase (iNOS).	Ketanserin	37-47	nitric oxide synthase 2, inducible	Mus musculus	112-133
23954471-2	2013	This work tested the hypothesis that ketanserin could attenuate endotoxic shock by inhibiting the expression of inducible NO synthase (iNOS).	Ketanserin	37-47	nitric oxide synthase 2, inducible	Mus musculus	135-139
23954471-3	2013	The results demonstrated that ketanserin could inhibit iNOS expression in the heart, lungs, liver, and kidneys and nitrate production in the serum upon endotoxic shock in mice.	Ketanserin	30-40	nitric oxide synthase 2, inducible	Mus musculus	55-59
23954471-4	2013	In RAW264.7 cells, ketanserin significantly inhibited the expression of iNOS and decreased the production of NO, TNFalpha, IL-6, and reactive oxygen species upon lipopolysaccharide (LPS) challenge.	Ketanserin	19-29	nitric oxide synthase 2, inducible	Mus musculus	72-76
23954471-4	2013	In RAW264.7 cells, ketanserin significantly inhibited the expression of iNOS and decreased the production of NO, TNFalpha, IL-6, and reactive oxygen species upon lipopolysaccharide (LPS) challenge.	Ketanserin	19-29	tumor necrosis factor	Mus musculus	113-121
23954471-4	2013	In RAW264.7 cells, ketanserin significantly inhibited the expression of iNOS and decreased the production of NO, TNFalpha, IL-6, and reactive oxygen species upon lipopolysaccharide (LPS) challenge.	Ketanserin	19-29	interleukin 6	Mus musculus	123-127
23954471-7	2013	Knockdown of 5-HT2A receptor by siRNA abolished the inhibitory effect of ketanserin on the expression of iNOS.	Ketanserin	73-83	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	13-28
23954471-7	2013	Knockdown of 5-HT2A receptor by siRNA abolished the inhibitory effect of ketanserin on the expression of iNOS.	Ketanserin	73-83	nitric oxide synthase 2, inducible	Mus musculus	105-109
23954471-8	2013	These results indicated that the inhibitory effect of ketanserin on the expression of iNOS is mediated by blocking the 5-HT2A receptor.	Ketanserin	54-64	nitric oxide synthase 2, inducible	Mus musculus	86-90
23954471-8	2013	These results indicated that the inhibitory effect of ketanserin on the expression of iNOS is mediated by blocking the 5-HT2A receptor.	Ketanserin	54-64	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	119-134
23954471-9	2013	Furthermore, ketanserin significantly inhibited the activation of ERK1/2 and NF-kappaB signal.	Ketanserin	13-23	mitogen-activated protein kinase 3	Mus musculus	66-72
23954471-9	2013	Furthermore, ketanserin significantly inhibited the activation of ERK1/2 and NF-kappaB signal.	Ketanserin	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	77-86
23954471-10	2013	Pretreatment with PD184352, a specific inhibitor of ERK1/2, blocked the inhibitory effect of ketanserin on the expression of iNOS and NO production, indicating a critical role for the MEK/ERK1/2 signaling pathway.	Ketanserin	93-103	mitogen-activated protein kinase 3	Mus musculus	52-58
23954471-10	2013	Pretreatment with PD184352, a specific inhibitor of ERK1/2, blocked the inhibitory effect of ketanserin on the expression of iNOS and NO production, indicating a critical role for the MEK/ERK1/2 signaling pathway.	Ketanserin	93-103	nitric oxide synthase 2, inducible	Mus musculus	125-129
23954471-10	2013	Pretreatment with PD184352, a specific inhibitor of ERK1/2, blocked the inhibitory effect of ketanserin on the expression of iNOS and NO production, indicating a critical role for the MEK/ERK1/2 signaling pathway.	Ketanserin	93-103	midkine	Mus musculus	184-187
23954471-10	2013	Pretreatment with PD184352, a specific inhibitor of ERK1/2, blocked the inhibitory effect of ketanserin on the expression of iNOS and NO production, indicating a critical role for the MEK/ERK1/2 signaling pathway.	Ketanserin	93-103	mitogen-activated protein kinase 3	Mus musculus	188-194
23954471-11	2013	Collectively, our findings indicate that inhibition of the expression of iNOS via the MEK/ERK pathway mediates the protective effects of ketanserin against LPS-induced shock in mice.	Ketanserin	137-147	nitric oxide synthase 2, inducible	Mus musculus	73-77
23954471-11	2013	Collectively, our findings indicate that inhibition of the expression of iNOS via the MEK/ERK pathway mediates the protective effects of ketanserin against LPS-induced shock in mice.	Ketanserin	137-147	midkine	Mus musculus	86-89
23954471-11	2013	Collectively, our findings indicate that inhibition of the expression of iNOS via the MEK/ERK pathway mediates the protective effects of ketanserin against LPS-induced shock in mice.	Ketanserin	137-147	mitogen-activated protein kinase 1	Mus musculus	90-93
23787365-6	2013	Local microinjection of the 5-HT1A antagonist WAY-100635 or the preferential 5-HT2A antagonist ketanserin was ineffective.	Ketanserin	95-105	5-hydroxytryptamine receptor 2A	Rattus norvegicus	77-83
23747494-5	2013	RESULTS: The anti-immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice with the antagonists, NAN-190 (5-HT(1A) receptor), ketanserin (5-HT(2A/2C) receptor), prazosin (alpha1-adrenoceptor), yohimbine (alpha2-adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2 receptor).	Ketanserin	156-166	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	58-61
23747494-5	2013	RESULTS: The anti-immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice with the antagonists, NAN-190 (5-HT(1A) receptor), ketanserin (5-HT(2A/2C) receptor), prazosin (alpha1-adrenoceptor), yohimbine (alpha2-adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2 receptor).	Ketanserin	156-166	dopamine receptor D1	Mus musculus	266-286
23747494-5	2013	RESULTS: The anti-immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice with the antagonists, NAN-190 (5-HT(1A) receptor), ketanserin (5-HT(2A/2C) receptor), prazosin (alpha1-adrenoceptor), yohimbine (alpha2-adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2 receptor).	Ketanserin	156-166	dopamine receptor D2	Mus musculus	303-323
23785166-7	2013	All of these effects were blocked by pretreatment with the 5-HT2A antagonist ketanserin, indicating that activation of 5-HT2A receptors by psilocybin profoundly modulates the neurophysiological and phenomenological indices of visual processing.	Ketanserin	77-87	5-hydroxytryptamine receptor 2A	Homo sapiens	59-65
23785166-7	2013	All of these effects were blocked by pretreatment with the 5-HT2A antagonist ketanserin, indicating that activation of 5-HT2A receptors by psilocybin profoundly modulates the neurophysiological and phenomenological indices of visual processing.	Ketanserin	77-87	5-hydroxytryptamine receptor 2A	Homo sapiens	119-125
22975078-4	2013	Moreover, inhibition of 5-HT-stimulated Akt activation by either ketanserin (a specific 5-HT2A receptor antagonist) or knocking-down the expression of 5-HT2A receptor promoted 5-HT-stimulated IRS-1 dissociation from 14-3-3beta in LDM, leading to drastic ubiquitination.	Ketanserin	65-75	AKT serine/threonine kinase 1	Homo sapiens	40-43
23390031-10	2013	The cortical binding of [(18) F]MH.MZ and [(18) F]altanserin was blocked by ketanserin supporting that both radioligands bind to 5-HT2A receptors in the pig brain.	Ketanserin	76-86	5-hydroxytryptamine receptor 2A	Sus scrofa	129-135
23159275-6	2013	The selective 5-HT2A antagonist ketanserin was administered after each DOI dose-response curve.	Ketanserin	32-42	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-20
23123346-6	2013	Knockout mice have enhanced brain monoaminergic activity which occurs secondary to NMDA receptor dysfunction, and the observed resistance to the isoflurane LORR ED(50)-sparing effect of nitrous oxide could be abolished by pretreatment with the dopamine D(2) receptor antagonist droperidol or with the serotonin 5-HT(2A) receptor antagonist ketanserin.	Ketanserin	340-350	dopamine receptor D2	Mus musculus	244-266
23362947-7	2013	5-HT2A receptor antagonists (ketanserin and sarpogrelate) inhibited viability and wound healing in LX-2 cells and induced apoptosis.	Ketanserin	29-39	5-hydroxytryptamine receptor 2A	Homo sapiens	0-15
23219842-5	2013	The pronociceptive effect of DOI (10 nmol/paw), 5-HT (100 nmol/paw) and fluoxetine (1 nmol/paw) was blocked by selective 5-HT2A (ketanserin), 5-HT2B (RS-127445), and 5-HT2C (RS-102221) receptor antagonists.	Ketanserin	129-139	5-hydroxytryptamine receptor 2A	Rattus norvegicus	121-127
23219842-5	2013	The pronociceptive effect of DOI (10 nmol/paw), 5-HT (100 nmol/paw) and fluoxetine (1 nmol/paw) was blocked by selective 5-HT2A (ketanserin), 5-HT2B (RS-127445), and 5-HT2C (RS-102221) receptor antagonists.	Ketanserin	129-139	5-hydroxytryptamine receptor 2B	Rattus norvegicus	142-148
22975078-4	2013	Moreover, inhibition of 5-HT-stimulated Akt activation by either ketanserin (a specific 5-HT2A receptor antagonist) or knocking-down the expression of 5-HT2A receptor promoted 5-HT-stimulated IRS-1 dissociation from 14-3-3beta in LDM, leading to drastic ubiquitination.	Ketanserin	65-75	5-hydroxytryptamine receptor 2A	Homo sapiens	88-103
22609381-7	2012	Ketanserin and scopolamine each prevented the ability of SERT knockout or inhibition to increase mucosal growth and proliferation.	Ketanserin	0-10	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	57-61
22975078-4	2013	Moreover, inhibition of 5-HT-stimulated Akt activation by either ketanserin (a specific 5-HT2A receptor antagonist) or knocking-down the expression of 5-HT2A receptor promoted 5-HT-stimulated IRS-1 dissociation from 14-3-3beta in LDM, leading to drastic ubiquitination.	Ketanserin	65-75	insulin receptor substrate 1	Homo sapiens	192-197
22800924-7	2012	Combined injections of ketanserin (10 nmol/0.1 mul), a 5-HT(2A/2C) receptor antagonist, and 0.01 nmol of mCPP (Experiment 3), selectively and completely blocked the OAA enhancement induced by mCPP.	Ketanserin	23-33	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	55-62
22094071-5	2012	In addition, blockade of 5-HT2A/C receptors via ketanserin decreased premature responding but had no effects on percent choice for delayed reward; blockade of 5-HT2C receptors via SB 242084 had opposite effects.	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Rattus norvegicus	25-31
22342663-0	2012	Inhibition of SNL-induced upregulation of CGRP and NPY in the spinal cord and dorsal root ganglia by the 5-HT(2A) receptor antagonist ketanserin in rats.	Ketanserin	134-144	calcitonin-related polypeptide alpha	Rattus norvegicus	42-46
22342663-0	2012	Inhibition of SNL-induced upregulation of CGRP and NPY in the spinal cord and dorsal root ganglia by the 5-HT(2A) receptor antagonist ketanserin in rats.	Ketanserin	134-144	neuropeptide Y	Rattus norvegicus	51-54
22342663-2	2012	To explore the mechanisms involved, we examined whether ketanserin reversed the plasticity changes associated with calcitonin gene-related peptides (CGRP) and neuropeptide Y (NPY) which may reflect distinct mechanisms: involvement and compensatory protection.	Ketanserin	56-66	calcitonin-related polypeptide alpha	Rattus norvegicus	115-147
22342663-2	2012	To explore the mechanisms involved, we examined whether ketanserin reversed the plasticity changes associated with calcitonin gene-related peptides (CGRP) and neuropeptide Y (NPY) which may reflect distinct mechanisms: involvement and compensatory protection.	Ketanserin	56-66	calcitonin-related polypeptide alpha	Rattus norvegicus	149-153
22342663-2	2012	To explore the mechanisms involved, we examined whether ketanserin reversed the plasticity changes associated with calcitonin gene-related peptides (CGRP) and neuropeptide Y (NPY) which may reflect distinct mechanisms: involvement and compensatory protection.	Ketanserin	56-66	neuropeptide Y	Rattus norvegicus	159-173
22342663-2	2012	To explore the mechanisms involved, we examined whether ketanserin reversed the plasticity changes associated with calcitonin gene-related peptides (CGRP) and neuropeptide Y (NPY) which may reflect distinct mechanisms: involvement and compensatory protection.	Ketanserin	56-66	neuropeptide Y	Rattus norvegicus	175-178
22342663-6	2012	Daily injection of ketanserin (0.3 mg/kg, s.c.) for two weeks suppressed the increase in CGRP-IR and NPY-IR in the spinal cord or DRG.	Ketanserin	19-29	calcitonin-related polypeptide alpha	Rattus norvegicus	89-93
22342663-6	2012	Daily injection of ketanserin (0.3 mg/kg, s.c.) for two weeks suppressed the increase in CGRP-IR and NPY-IR in the spinal cord or DRG.	Ketanserin	19-29	neuropeptide Y	Rattus norvegicus	101-104
22428927-5	2012	At the concentration of 10 muM, safflomide was able to increase adiponectin protein production in 3T3-L1 cells more than 4-fold (p < 0.05), which was greater than the 5-HT2A antagonist ketanserin.	Ketanserin	188-198	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	170-176
21627639-0	2012	Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects.	Ketanserin	41-51	brain-derived neurotrophic factor	Rattus norvegicus	74-107
22209919-7	2012	We report that 5HT pretreatment enhances TRPV1-evoked thermal hyperalgesia, which is attenuated with local pretreatment with ketanserin, granisetron, or sumatriptan.	Ketanserin	125-135	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
21627639-0	2012	Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects.	Ketanserin	41-51	catenin beta 1	Rattus norvegicus	109-121
21627639-4	2012	KEY RESULTS: mRNA for BDNF was increased in the CA3 field and dentate gyrus of the hippocampus by combined treatment with fluoxetine + ketanserin.	Ketanserin	135-145	brain-derived neurotrophic factor	Rattus norvegicus	22-26
21627639-4	2012	KEY RESULTS: mRNA for BDNF was increased in the CA3 field and dentate gyrus of the hippocampus by combined treatment with fluoxetine + ketanserin.	Ketanserin	135-145	carbonic anhydrase 3	Rattus norvegicus	48-51
21627639-5	2012	Expression of beta-catenin was increased in total hippocampal homogenate and in the membrane fraction, but unchanged in the nuclear fraction after combined treatment with fluoxetine + ketanserin.	Ketanserin	184-194	catenin beta 1	Rattus norvegicus	14-26
22048642-10	2012	Ketanserin suppressed CSM-induced IL-8 release by inhibiting p38, ERK1/2 MAPK, and Nrf2 signaling pathways and partially inhibited CSM-induced reduction of rGSH/GSSG ratio.	Ketanserin	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
22048642-10	2012	Ketanserin suppressed CSM-induced IL-8 release by inhibiting p38, ERK1/2 MAPK, and Nrf2 signaling pathways and partially inhibited CSM-induced reduction of rGSH/GSSG ratio.	Ketanserin	0-10	mitogen-activated protein kinase 1	Homo sapiens	61-64
22048642-10	2012	Ketanserin suppressed CSM-induced IL-8 release by inhibiting p38, ERK1/2 MAPK, and Nrf2 signaling pathways and partially inhibited CSM-induced reduction of rGSH/GSSG ratio.	Ketanserin	0-10	mitogen-activated protein kinase 3	Homo sapiens	66-72
22048642-10	2012	Ketanserin suppressed CSM-induced IL-8 release by inhibiting p38, ERK1/2 MAPK, and Nrf2 signaling pathways and partially inhibited CSM-induced reduction of rGSH/GSSG ratio.	Ketanserin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	83-87
22048642-11	2012	Our data demonstrated the novel antioxidative and anti-inflammatory role of ketanserin via the Nrf2 signaling pathway in CSM-exposed human bronchial epithelial cells.	Ketanserin	76-86	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
23080170-7	2012	5-HT and the 5-HT2A antagonist ketanserin dose-dependently activated chemoreceptor cells as assessed by their capacity to release catecholamines from freshly isolated CB.	Ketanserin	31-41	5-hydroxytryptamine receptor 2A	Rattus norvegicus	13-19
22128258-7	2011	The 5-HT-induced contraction was enhanced by the 5HT(2) receptor antagonist ketanserin and the 5-HT(3) receptor antagonist ondansetron but was inhibited by the 5-HT(1) receptor antagonist methysergide and 5-HT(4) receptor antagonist GR113808.	Ketanserin	76-86	5-hydroxytryptamine receptor 2A	Homo sapiens	49-64
21917879-8	2011	RESULTS: Ketanserin significantly increased survival time and decreased serum levels of tumor necrosis factor alpha and interleukin (IL) 1beta in mice with endotoxic shock.	Ketanserin	9-19	tumor necrosis factor	Mus musculus	88-115
21917879-8	2011	RESULTS: Ketanserin significantly increased survival time and decreased serum levels of tumor necrosis factor alpha and interleukin (IL) 1beta in mice with endotoxic shock.	Ketanserin	9-19	interleukin 1 beta	Mus musculus	120-142
21917879-9	2011	At a dose of 10 mg/kg, ketanserin also significantly increased serum IL-10 concentration.	Ketanserin	23-33	interleukin 10	Mus musculus	69-74
21917879-10	2011	The antishock effect of ketanserin was also apparent in IL-10-knockout mice.	Ketanserin	24-34	interleukin 10	Mus musculus	56-61
22048642-0	2012	The role of MAPK and Nrf2 pathways in ketanserin-elicited attenuation of cigarette smoke-induced IL-8 production in human bronchial epithelial cells.	Ketanserin	38-48	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
22048642-0	2012	The role of MAPK and Nrf2 pathways in ketanserin-elicited attenuation of cigarette smoke-induced IL-8 production in human bronchial epithelial cells.	Ketanserin	38-48	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
22048642-4	2012	In this study, we investigated the antioxidative and anti-inflammatory properties of ketanserin and its underlying mechanism of action on cigarette smoke-induced interleukin (IL)-8 release in vitro.	Ketanserin	85-95	C-X-C motif chemokine ligand 8	Homo sapiens	162-180
22532793-1	2012	From computational simulations of a serotonin 2A receptor (5-HT(2A)R) model complexed with pharmacologically and structurally diverse ligands we identify different conformational states and dynamics adopted by the receptor bound to the full agonist 5-HT, the partial agonist LSD, and the inverse agonist Ketanserin.	Ketanserin	304-314	5-hydroxytryptamine receptor 2A	Homo sapiens	36-57
21959103-8	2011	CONCLUSIONS: Postnatal treatment with the 5-HT(2) receptor antagonist, ketanserin, blocked specific consequences of maternal separation, including anxiety behavior and dysregulated gene expression in the prefrontal cortex.	Ketanserin	71-81	5-hydroxytryptamine receptor 2A	Homo sapiens	42-58
21660445-8	2011	The inhibitory effect caused by DOI, RO 60-0175, and mCPP was also blocked by previous intra-dPAG injection of the preferential 5-HT2A receptor antagonist ketanserin.	Ketanserin	155-165	5-hydroxytryptamine receptor 2A	Rattus norvegicus	128-134
21962069-5	2011	Ketanserin (100 nM), a 5-HT2A antagonist, shifted the 5-HT potency to a far greater extent than 1 muM GR-55562, a 5-HT1B/D inhibitor.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Ovis aries	23-29
21473029-15	2004	Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent antagonist of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (9, 10).	Ketanserin	50-60	5-hydroxytryptamine receptor 2A	Sus scrofa	104-110
21737202-8	2011	Sumatriptan, ketanserin, and granisetron treatment attenuated calcium accumulation and 5HT enhancement of capsaicin-evoked CGRP release.	Ketanserin	13-23	calcitonin-related polypeptide alpha	Rattus norvegicus	123-127
21562484-4	2011	Ketanserin is a 5-HT(2A) receptor blocker and pindolol a 5-HT(1A) receptor blocker.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	16-23
21174090-9	2011	The cortical binding of [(11)C]Cimbi-36 was decreased by pretreatment with ketanserin, supporting 5-HT(2A) receptor selectivity in vivo.	Ketanserin	75-85	5-hydroxytryptamine receptor 2A	Sus scrofa	98-115
21223996-5	2011	5-HT2A and 5-HT2B receptor agonist-induced pMF were both blocked by selective antagonists (ketanserin and SB206553, respectively), but not by antagonists to the other receptor subtype.	Ketanserin	91-101	5-hydroxytryptamine receptor 2A	Rattus norvegicus	0-6
21223996-5	2011	5-HT2A and 5-HT2B receptor agonist-induced pMF were both blocked by selective antagonists (ketanserin and SB206553, respectively), but not by antagonists to the other receptor subtype.	Ketanserin	91-101	5-hydroxytryptamine receptor 2B	Rattus norvegicus	11-17
21276431-2	2011	These include the 5-HT2 receptor, which is further sub classified into 5-HT2A, B and C. Studies have described both a pro- and antinociceptive action following 5-HT2A-receptor activation; therefore, to shed light on the directional nature of spinal 5-HT2A receptor activity, we investigated the effects of spinal administration of the 5-HT2A receptor antagonist, ketanserin, on the evoked responses of dorsal horn neurones to electrical, mechanical and thermal stimulation.	Ketanserin	363-373	5-hydroxytryptamine receptor 2A	Rattus norvegicus	160-166
21276431-2	2011	These include the 5-HT2 receptor, which is further sub classified into 5-HT2A, B and C. Studies have described both a pro- and antinociceptive action following 5-HT2A-receptor activation; therefore, to shed light on the directional nature of spinal 5-HT2A receptor activity, we investigated the effects of spinal administration of the 5-HT2A receptor antagonist, ketanserin, on the evoked responses of dorsal horn neurones to electrical, mechanical and thermal stimulation.	Ketanserin	363-373	5-hydroxytryptamine receptor 2A	Rattus norvegicus	160-166
21276431-2	2011	These include the 5-HT2 receptor, which is further sub classified into 5-HT2A, B and C. Studies have described both a pro- and antinociceptive action following 5-HT2A-receptor activation; therefore, to shed light on the directional nature of spinal 5-HT2A receptor activity, we investigated the effects of spinal administration of the 5-HT2A receptor antagonist, ketanserin, on the evoked responses of dorsal horn neurones to electrical, mechanical and thermal stimulation.	Ketanserin	363-373	5-hydroxytryptamine receptor 2A	Rattus norvegicus	160-166
21185821-3	2011	Intraplantar injection of ketanserin (20 mug) inhibited carrageenan-induced increase in CGRP immunoreactivity-positive neurons in DRG.	Ketanserin	26-36	calcitonin-related polypeptide alpha	Rattus norvegicus	88-92
21473027-15	2004	Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent antagonist of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (9, 10).	Ketanserin	50-60	5-hydroxytryptamine receptor 2A	Homo sapiens	104-110
21144854-7	2011	[(3)H]ketanserin specific binding to 5-HT(2A) receptors was increased in the frontal cortex and the striatum of monkeys treated with 17beta-estradiol in both the lesioned and intact sides of the brain.	Ketanserin	6-16	5-hydroxytryptamine receptor 2A	Homo sapiens	39-44
21172407-8	2011	Moreover, the ambient temperature-dependent response to DOI was completely blocked by pretreatment with the 5-HT(2A) receptor antagonist ketanserin.	Ketanserin	137-147	5-hydroxytryptamine receptor 2A	Homo sapiens	108-125
20956470-10	2010	Ketanserin treatment reduced the cortical binding potentials to cerebellar levels, indicating that in vivo (11)C-CIMBI-5 binds selectively to the 5-HT(2A) receptor in the pig brain.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Sus scrofa	146-163
20847126-8	2010	Furthermore, a 5-HT(2A) antagonist (ketanserin) significantly reduced 3-G (120 min) load-induced Fos expression in the medial vestibular nucleus, and chronically administered ketanserin ameliorated hypergravity-induced hypophagia.	Ketanserin	36-46	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	97-100
20478359-4	2010	The results showed that intra-dPAG injection of WAY-100635 or ketanserin, 5-HT(1A) and 5-HT(2A/2C) receptor antagonists, respectively, counteracted the anti-escape effect caused by bilateral intra-LHb injection of kainic acid (60pmol/0.2microl).	Ketanserin	62-72	5-hydroxytryptamine receptor 2A	Rattus norvegicus	87-94
20478359-4	2010	The results showed that intra-dPAG injection of WAY-100635 or ketanserin, 5-HT(1A) and 5-HT(2A/2C) receptor antagonists, respectively, counteracted the anti-escape effect caused by bilateral intra-LHb injection of kainic acid (60pmol/0.2microl).	Ketanserin	62-72	luteinizing hormone subunit beta	Rattus norvegicus	197-200
20338635-5	2010	Our results showed a concentration-dependent increase of cell viability by DOI, which was reversed by ketanserin, a selective 5-HT(2A) receptor antagonist.	Ketanserin	102-112	5-hydroxytryptamine receptor 2A	Homo sapiens	126-143
20378714-8	2010	Ketanserin also caused rightward shifts of the contractile curves to 8-OH-DPAT, RU24969, and the 5-HT(2B) receptor agonist (alpha-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine) (BW723C86).	Ketanserin	0-10	5-hydroxytryptamine receptor 2B	Rattus norvegicus	97-104
20467592-3	2010	There is evidence indicating that the nonselective serotonin 5-HT(2A/2C) receptor antagonists, ritanserin, ketanserin, seganserin and ICI-169369, the selective 5-HT(2A) receptor antagonist eplivanserin and the 5-HT(2A) receptor inverse agonist pimavanserin, increase SWS in subjects with normal sleep.	Ketanserin	107-117	5-hydroxytryptamine receptor 2A	Homo sapiens	160-177
19913012-0	2010	Topical and systemic administrations of ketanserin attenuate hypersensitivity and expression of CGRP in rats with spinal nerve ligation.	Ketanserin	40-50	calcitonin-related polypeptide alpha	Rattus norvegicus	96-100
19913012-8	2010	Moreover, ketanserin (0.3mg/kg) reversed the increase in CGRP-IR expression in L4 and L6 DRG neurons.	Ketanserin	10-20	calcitonin-related polypeptide alpha	Rattus norvegicus	57-61
19913012-10	2010	This study suggests that 5-HT and 5-HT(2A) receptors contribute to the maintenance of neuropathic pain by up-regulating the expression of CGRP-IR, and that topical and systemic administrations of ketanserin are promising therapies for relieving neuropathic pain without tolerance.	Ketanserin	196-206	calcitonin-related polypeptide alpha	Rattus norvegicus	138-142
19933527-6	2010	Knockout mice were previously shown to have enhanced monoaminergic tone as a result of genetic manipulation, and this increase in MAC could be abolished in our experiments by pretreatment with the serotonin 5-hydroxytryptamine type 2A receptor antagonist ketanserin or with the dopamine D2 receptor antagonist droperidol at doses that did not affect MAC values in wild-type animals.	Ketanserin	255-265	dopamine receptor D2	Mus musculus	278-298
19763327-7	2009	Further, starting from the model structure of human 5-HT(2A) receptor, docking studies were attempted to envisage how it might interact with eight of its ligands (such as serotonin, dopamine, DOI, LSD, haloperidol, ketanserin, risperidone and clozapine).	Ketanserin	215-225	5-hydroxytryptamine receptor 2A	Homo sapiens	52-69
19801536-3	2009	The 5-HT-induced contractions were fully inhibited by ketanserin (5-HT(2A) antagonist).	Ketanserin	54-64	5-hydroxytryptamine receptor 2A	Homo sapiens	66-73
19187600-0	2008	High extracellular potassium ion concentration attenuates the blockade action of ketanserin on Kv1.3 channels expressed in xenopus oocytes.	Ketanserin	81-91	potassium channel, voltage gated shaker related subfamily A, member 3 S homeolog	Xenopus laevis	95-100
19288193-9	2009	Ketanserin, an antagonist of 5-HT(2A), reversed the effect of 5HT on 10% ethanol induced ALDH activity in hepatocytes.	Ketanserin	0-10	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	89-93
19016481-4	2009	Stimulation of G alpha q/11 by 5-HT (30 microM) and DOI (30 microM) was abolished by the selective 5-HT(2A) vs. 5-HT(2C)/5-HT(2B) antagonists, ketanserin (pK(B) values of 9.11 and 8.88, respectively) and MDL100,907 (9.82 and 9.68).	Ketanserin	143-153	G protein subunit alpha q	Rattus norvegicus	15-24
18762202-5	2009	The 5-HT2AR response dominated the MAPK signaling pathway when co-expressed with 5-HT1AR, and diminution of the response by the 5-HT2AR antagonist Ketanserin could not be rescued by the 5-HT1AR agonist.	Ketanserin	147-157	mitogen-activated protein kinase 3	Homo sapiens	35-39
18817806-3	2009	A 5-HT1 receptor antagonist (WAY-100635) and a 5-HT2 receptor antagonist (ketanserin), injected i.c.v., induced hyperalgesia and inhibited fluvoxamine"s anti-nociceptive effects.	Ketanserin	74-84	5-hydroxytryptamine receptor 2A	Homo sapiens	47-61
19548619-7	2009	Inhibition of serotonin response by ketanserin, a 5HT2A receptor blocker, did not depend on the presence of 15 mM KCl.	Ketanserin	36-46	5-hydroxytryptamine receptor 2A	Rattus norvegicus	50-55
18950618-7	2008	Ketanserin, a 5-HT2a and 5-HT2c receptor antagonist, significantly attenuates nicotine effects on attention and memory.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-40
18574455-0	2008	The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-a-go-go-related gene (hERG) potassium channels.	Ketanserin	21-31	ETS transcription factor ERG	Homo sapiens	104-108
19075042-5	2009	The 5-HT(2A) receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to alpha-Me-5-HT, with a pK(B) value consistent with its known affinity for the 5-HT(2A) receptor (pK(B) = 8.47 +/- 0.16, n = 5), but it had no effect on the response to oxytocin.	Ketanserin	34-44	5-hydroxytryptamine receptor 2A	Homo sapiens	4-21
19075042-5	2009	The 5-HT(2A) receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to alpha-Me-5-HT, with a pK(B) value consistent with its known affinity for the 5-HT(2A) receptor (pK(B) = 8.47 +/- 0.16, n = 5), but it had no effect on the response to oxytocin.	Ketanserin	34-44	protein tyrosine kinase 2 beta	Homo sapiens	187-191
19075042-5	2009	The 5-HT(2A) receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to alpha-Me-5-HT, with a pK(B) value consistent with its known affinity for the 5-HT(2A) receptor (pK(B) = 8.47 +/- 0.16, n = 5), but it had no effect on the response to oxytocin.	Ketanserin	34-44	5-hydroxytryptamine receptor 2A	Homo sapiens	242-259
19075042-5	2009	The 5-HT(2A) receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to alpha-Me-5-HT, with a pK(B) value consistent with its known affinity for the 5-HT(2A) receptor (pK(B) = 8.47 +/- 0.16, n = 5), but it had no effect on the response to oxytocin.	Ketanserin	34-44	protein tyrosine kinase 2 beta	Homo sapiens	261-265
18574455-2	2008	The purpose of the present study was to determine whether ketanserin would block human cardiac ether-a-go-go-related gene (hERG) potassium channels.	Ketanserin	58-68	ETS transcription factor ERG	Homo sapiens	123-127
18574455-4	2008	KEY RESULTS: Ketanserin blocked hERG current (I(hERG)) in a concentration-dependent manner (IC50=0.11 microM).	Ketanserin	13-23	ETS transcription factor ERG	Homo sapiens	32-36
18574455-4	2008	KEY RESULTS: Ketanserin blocked hERG current (I(hERG)) in a concentration-dependent manner (IC50=0.11 microM).	Ketanserin	13-23	ETS transcription factor ERG	Homo sapiens	48-52
18574455-6	2008	Voltage-dependence for inactivation of hERG channels was negatively shifted by 0.3 microM ketanserin.	Ketanserin	90-100	ETS transcription factor ERG	Homo sapiens	39-43
18574455-8	2008	In addition, the hERG mutants in pore helix and S6 also significantly reduced the channel block (2-59 fold) by ketanserin.	Ketanserin	111-121	ETS transcription factor ERG	Homo sapiens	17-21
18574455-9	2008	CONCLUSIONS AND IMPLICATIONS: These results suggest that ketanserin binds to and blocks the open hERG channels in the pore helix and the S6 domain; channel inactivation is also involved in the blockade of hERG channels.	Ketanserin	57-67	ETS transcription factor ERG	Homo sapiens	97-101
18574455-9	2008	CONCLUSIONS AND IMPLICATIONS: These results suggest that ketanserin binds to and blocks the open hERG channels in the pore helix and the S6 domain; channel inactivation is also involved in the blockade of hERG channels.	Ketanserin	57-67	ETS transcription factor ERG	Homo sapiens	205-209
19088945-5	2008	The flunitrazepam-induced head twitch response was antagonized by ketanserin, a 5- HT(2A) receptor antagonist.	Ketanserin	66-76	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	80-98
18690396-1	2008	In the present study, we investigated the inhibitory action of ketanserin on wild-type (WT) and Y652 mutant human ether-a-go-go-related gene (HERG) potassium channels expressed in Xenopus oocytes and the effects of changing the channel molecular determinants characteristics on the blockade with and without ketanserin intervention using standard two-microelectrode voltage-clamp techniques.	Ketanserin	63-73	potassium voltage-gated channel subfamily H member 2	Homo sapiens	142-146
18690396-5	2008	The results showed that ketanserin blocked WT HERG currents in voltage- and concentration-dependent manner and showed minimal tonic blockade of HERG current evaluated by the envelope of tails test.	Ketanserin	24-34	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50
18690396-10	2008	Ketanserin could also modulate the inactivation of HERG channel, which shifted the voltage-dependence of WT HERG channel inactivation curve from (-51.71+/-2.15) mV to (-80.76+/-14.98) mV (P<0.05, n=4).	Ketanserin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	108-112
18690396-14	2008	In conclusion, ketanserin blocks WT HERG currents in voltage- and concentration-dependent manner and preferentially blocks open-state HERG channels.	Ketanserin	15-25	potassium voltage-gated channel subfamily H member 2	Homo sapiens	36-40
18690396-14	2008	In conclusion, ketanserin blocks WT HERG currents in voltage- and concentration-dependent manner and preferentially blocks open-state HERG channels.	Ketanserin	15-25	potassium voltage-gated channel subfamily H member 2	Homo sapiens	134-138
18321937-6	2008	Blockage of 5-HT2A receptors by ketanserin and 5-HT2B receptors by SB215505 reduced bleomycin-induced lung fibrosis, as demonstrated by reduced lung collagen content and reduced procollagen 1 and procollagen 3 mRNA expression.	Ketanserin	32-42	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	12-18
18336813-2	2008	Among the tested antagonists and alpha1-adrenoceptors subtypes, ketanserin showed significantly lower affinity for the alpha1B-adrenoceptor subtype in intact tissue sampled from the rat tail artery, thoracic aorta, and cerebral cortex (functional pKB and binding pKi were approximately 6), than in cerebral cortex membrane preparations or whole cell and membrane preparations of alpha1B-adrenoceptor transfected human embryonic kidney 293T (HEK 293T) cells (pKi was approximately 8).	Ketanserin	64-74	adrenoceptor alpha 1B	Rattus norvegicus	119-139
18690396-10	2008	Ketanserin could also modulate the inactivation of HERG channel, which shifted the voltage-dependence of WT HERG channel inactivation curve from (-51.71+/-2.15) mV to (-80.76+/-14.98) mV (P<0.05, n=4).	Ketanserin	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	51-55
18367171-7	2008	The 5-HT-activated K+ current was mimicked by a 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide, and was reversibly blocked by a 5-HT1A receptor antagonist, 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide, but not by a 5-HT2 receptor antagonist, ketanserin.	Ketanserin	299-309	5-hydroxytryptamine receptor 1A	Rattus norvegicus	48-54
18367171-7	2008	The 5-HT-activated K+ current was mimicked by a 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-dipropylaminotetralin hydrobromide, and was reversibly blocked by a 5-HT1A receptor antagonist, 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide, but not by a 5-HT2 receptor antagonist, ketanserin.	Ketanserin	299-309	5-hydroxytryptamine receptor 1A	Rattus norvegicus	159-165
18574455-10	2008	Blockade of hERG channels most likely contributes to the prolongation of QT intervals in ECG observed clinically at therapeutic concentrations of ketanserin.	Ketanserin	146-156	ETS transcription factor ERG	Homo sapiens	12-16
20641567-15	2004	Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent inhibitor of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (8, 9).	Ketanserin	50-60	5-hydroxytryptamine receptor 2A	Homo sapiens	103-109
18336813-2	2008	Among the tested antagonists and alpha1-adrenoceptors subtypes, ketanserin showed significantly lower affinity for the alpha1B-adrenoceptor subtype in intact tissue sampled from the rat tail artery, thoracic aorta, and cerebral cortex (functional pKB and binding pKi were approximately 6), than in cerebral cortex membrane preparations or whole cell and membrane preparations of alpha1B-adrenoceptor transfected human embryonic kidney 293T (HEK 293T) cells (pKi was approximately 8).	Ketanserin	64-74	adrenoceptor alpha 1B	Rattus norvegicus	379-399
18336813-3	2008	In these tissues and cells, however, ketanserin showed a similar affinity (pKi = approximately 8) for alpha1A- and alpha1D-adrenoceptors even though the assays were conducted under different conditions.	Ketanserin	37-47	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	102-109
17766642-2	2007	Based on our previous studies using photoaffinity-labeling techniques in characterizing the VMAT2-specific ligands ketanserin and tetrabenazine, this study describes the synthesis and characterization of a fluorenone-based compound, iodoaminoflisopolol (IAmF), as a photoprobe to identify the substrate binding site(s) of VMAT2.	Ketanserin	115-125	solute carrier family 18 member A2	Homo sapiens	92-97
18417104-6	2008	ketanserin (a 5-HT2A receptor antagonist) on tramadol analgesia was observed.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	14-20
18287883-11	2008	It also had competitive binding effects in human platelet with [H]yohimbine (alpha2), [H]ketanserin (5-HT2A).	Ketanserin	89-99	5-hydroxytryptamine receptor 2A	Homo sapiens	101-107
17869437-7	2007	This study demonstrates multiple, but not single applications of the 5-HT(2) receptor agonist alpha-Me-5-HT caused a long-lasting inhibition of both spontaneous and fictive inspiratory-related GABAergic neurotransmission to CVNs, which can be prevented by the 5-HT(2B) receptor antagonist SB204741, but persisted with the 5-HT(2A/2C) receptor antagonist ketanserin.	Ketanserin	354-364	5-hydroxytryptamine receptor 2A	Homo sapiens	69-85
17869437-8	2007	The 5-HT(2) receptor agonist alpha-Me-5-HT also reversibly and transiently excited central fictive inspiratory activity, which was abolished by ketanserin, but was unaffected by the 5-HT(2B) receptor antagonist SB204741.	Ketanserin	144-154	5-hydroxytryptamine receptor 2A	Homo sapiens	4-20
17663006-6	2007	The stimulation induced by 5-HT (30 microM) was partially inhibited by both WAY 100135 (300 nM) and ketanserin (300 nM), antagonists of 5-HT(1A) and 5-HT(2) receptors, respectively.	Ketanserin	100-110	5-hydroxytryptamine receptor 1A	Homo sapiens	136-143
17654097-0	2007	Endothelin-1-induced cerebral ischemia: effects of ketanserin and MK-801 on limb placing in rats.	Ketanserin	51-61	endothelin 1	Rattus norvegicus	0-12
17965538-4	2007	Selective 5-HT2A antagonists (risperidone, spiperone, ketanserin, AMI-193, and MDL 11,939) dose-dependently attenuated the hyperenzymemia; and their potency order, excepting that of ketanserin which has considerable affinity at the 5-HT2C receptor as well, paralleled their reported pKi values at the 5-HT2A receptor.	Ketanserin	54-64	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	10-16
17965538-4	2007	Selective 5-HT2A antagonists (risperidone, spiperone, ketanserin, AMI-193, and MDL 11,939) dose-dependently attenuated the hyperenzymemia; and their potency order, excepting that of ketanserin which has considerable affinity at the 5-HT2C receptor as well, paralleled their reported pKi values at the 5-HT2A receptor.	Ketanserin	182-192	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	10-16
17640952-6	2007	Samples of frontal cortex were obtained for each animal immediately following behavioral testing, and 5-HT2A receptor density was measured using [3H]ketanserin.	Ketanserin	149-159	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	102-117
17556652-6	2007	Contractions in aorta from both males and females were abolished by a serotonergic 5HT2A receptor antagonist (ketanserin), however there was no sex difference in 5HT2A receptor expression.	Ketanserin	110-120	5-hydroxytryptamine receptor 2A	Homo sapiens	83-97
17582781-0	2007	Blockade action of ketanserin and increasing effect of potassium ion on Kv1.3 channels expressed in Xenopus oocytes.	Ketanserin	19-29	potassium channel, voltage gated shaker related subfamily A, member 3 S homeolog	Xenopus laevis	72-77
17582781-1	2007	The goal of this study was to investigate the pharmacological effects of ketanserin (KT) and elevated extracellular potassium ([K+]o) on Kv1.3 potassium channels.	Ketanserin	73-83	potassium channel, voltage gated shaker related subfamily A, member 3 S homeolog	Xenopus laevis	137-142
17582781-1	2007	The goal of this study was to investigate the pharmacological effects of ketanserin (KT) and elevated extracellular potassium ([K+]o) on Kv1.3 potassium channels.	Ketanserin	85-87	potassium channel, voltage gated shaker related subfamily A, member 3 S homeolog	Xenopus laevis	137-142
17523441-10	2007	At the same time, ketanserin administration led to a significant decrease in the level of c-Fos protein in the hypothalamus in OVX rats as compared to the intact control.	Ketanserin	18-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	90-95
17572501-9	2007	Furthermore, MDMA depleted intracellular glutathione (GSH) levels in a concentration dependent manner, an effect that was attenuated by Ketanserin, a competitive 5-HT(2A)-receptor antagonist.	Ketanserin	136-146	5-hydroxytryptamine receptor 2A	Homo sapiens	162-179
17446559-8	2007	The addition of ketanserin, a competitive antagonist of 5-HT2 receptor, nullified the antiapoptotic effects of serotonin.	Ketanserin	16-26	5-hydroxytryptamine receptor 2A	Homo sapiens	56-70
17481814-4	2007	We examined the association between different 5-HT2A (T102C) genotypes and [(3)H] ketanserin binding in the temporal and frontal cortex of 20 AD and 14 control human brains.	Ketanserin	82-92	5-hydroxytryptamine receptor 2A	Homo sapiens	46-52
18239778-2	2007	Administration of ultralow-dose antibodies to S-100 protein in combination with serotoninergic agents (ketanserin and 5-hydroxytryptophan) reduced the anxiolytic and antidepressant effects of antibodies.	Ketanserin	103-113	S100 calcium binding protein A1	Homo sapiens	46-51
17407556-7	2007	The increased concentration-effect curves could be shifted rightwards in a parallel manner by ketanserin, a selective 5-HT2A receptor antagonist, indicating that the responses are mediated by 5-HT2A receptors.	Ketanserin	94-104	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	118-133
17238805-4	2006	[3H]-5-HT and [3H]-ketanserin autoradiography on sections of human eyes revealed a high density of 5-HT2 receptor binding sites in the iris, ciliary epithelium, and longitudinal CM.	Ketanserin	19-29	5-hydroxytryptamine receptor 2A	Homo sapiens	99-113
16861698-5	2006	In aorta contracted with 5-HT (10(-5) mol/l), tyrosine phosphorylation (Tyr410) of CAS was significantly increased (approximately 225%), and both contraction and CAS phosphorylation were reduced by the 5-HT(2A/2C) receptor antagonist ketanserin (3 x 10(-8) mol/l).	Ketanserin	234-244	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	83-86
17060493-8	2007	In contrast, the 5HT2 receptor antagonist ketanserin (0.1 mg/kg i.m.)	Ketanserin	42-52	5-hydroxytryptamine receptor 2A	Homo sapiens	17-30
17940359-6	2007	Doxazosin (dox, an alpha1-receptor antagonist) and ketanserin (ketan, a 5-HT2A receptor antagonist) significantly inhibited or abolished the sustained contraction.	Ketanserin	51-61	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	72-87
17940359-6	2007	Doxazosin (dox, an alpha1-receptor antagonist) and ketanserin (ketan, a 5-HT2A receptor antagonist) significantly inhibited or abolished the sustained contraction.	Ketanserin	51-56	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	72-87
16846619-6	2006	The antiallodynic effects of systemic fluvoxamine were also reduced by both systemic and intrathecal administration of ketanserin, a 5-HT2A/2C receptor antagonist.	Ketanserin	119-129	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	133-139
17103145-4	2006	The contractions to 5-HT were competitively antagonized by the 5-HT(2A) receptor antagonist ketanserin, whilst those to noradrenaline were antagonized by alpha(1)-(prazosin), alpha(2)-(rauwolscine and yohimbine) and alpha(2C/2B)-(OPC-28326) adrenoceptor antagonists.	Ketanserin	92-102	5-hydroxytryptamine receptor 2A	Homo sapiens	63-70
16887872-8	2006	Spaced application of 5-HT activated protein kinase C (PKC) as evidenced by increased phosphorylations of PKC at Thr(514) and myristoylated alanine-rich C kinase substrate (MARCKS) and these effects were abolished by ketanserin as well as bisindolylmaleimide (Bis-1), an inhibitor of PKC.	Ketanserin	217-227	myristoylated alanine rich protein kinase C substrate	Mus musculus	126-171
16760346-7	2006	Application of 5-HT2A, 5-HT2C, and alpha1-NE receptor antagonists (ketanserin, RS 102221, and WB 4101, respectively) significantly reduced the Na PICs, and a combined application of these three monoamine antagonists completely eliminated the Na PIC, in both acute and chronic spinal rats.	Ketanserin	67-77	5-hydroxytryptamine receptor 2A	Rattus norvegicus	15-21
16760346-7	2006	Application of 5-HT2A, 5-HT2C, and alpha1-NE receptor antagonists (ketanserin, RS 102221, and WB 4101, respectively) significantly reduced the Na PICs, and a combined application of these three monoamine antagonists completely eliminated the Na PIC, in both acute and chronic spinal rats.	Ketanserin	67-77	5-hydroxytryptamine receptor 2C	Rattus norvegicus	23-29
16647209-1	2006	We investigated effects of topical application of ketanserin, a 5-HT2A receptor antagonist, on hyperalgesia and edema in the arthritic rat, a chronic pain model with inflammation.	Ketanserin	50-60	5-hydroxytryptamine receptor 2A	Rattus norvegicus	64-70
16887872-8	2006	Spaced application of 5-HT activated protein kinase C (PKC) as evidenced by increased phosphorylations of PKC at Thr(514) and myristoylated alanine-rich C kinase substrate (MARCKS) and these effects were abolished by ketanserin as well as bisindolylmaleimide (Bis-1), an inhibitor of PKC.	Ketanserin	217-227	myristoylated alanine rich protein kinase C substrate	Mus musculus	173-179
16871540-6	2006	Pretreatment with the select 5-HT2 receptor antagonist Ketanserin blocked DOI-induced ERK1/2 phosphorylation.	Ketanserin	55-65	5-hydroxytryptamine receptor 2A	Homo sapiens	29-43
16871540-6	2006	Pretreatment with the select 5-HT2 receptor antagonist Ketanserin blocked DOI-induced ERK1/2 phosphorylation.	Ketanserin	55-65	mitogen-activated protein kinase 3	Homo sapiens	86-92
16527989-5	2006	The effects of 5-HT on KV currents and contraction were markedly prevented by the 5-HT2A receptor antagonist ketanserin.	Ketanserin	109-119	5-hydroxytryptamine receptor 2A	Rattus norvegicus	82-88
16571613-7	2006	This increase in P(pa) was abolished by the serotonin receptor-2A antagonist ketanserin, but not the serotonin receptor-1B antagonist GR127935.	Ketanserin	77-87	preproenkephalin	Mus musculus	17-22
16571613-7	2006	This increase in P(pa) was abolished by the serotonin receptor-2A antagonist ketanserin, but not the serotonin receptor-1B antagonist GR127935.	Ketanserin	77-87	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	44-65
16481292-5	2006	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on the expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	transforming growth factor beta 1	Homo sapiens	181-213
16195541-9	2006	Akt phosphorylation and cell proliferation were also blocked by the antioxidants, N-acetyl-l-cysteine, Ginko biloba 501, and tiron, the reduced nicotinamide adenine dinucleotide phosphate oxidase inhibitor, diphenyleneiodonium, and the 5-HT2 receptor antagonists ketanserin and mianserin, but not by the 5-HT serotonin transporter or 5-HT 1B/1D receptor antagonists.	Ketanserin	263-273	AKT serine/threonine kinase 1	Homo sapiens	0-3
16730785-3	2006	The 5-HT-induced hyperalgesia was abolished by ketanserin (5-HT2A antagonist, 10 microg, intraplantarly or i.pl.	Ketanserin	47-57	5-hydroxytryptamine receptor 2A	Rattus norvegicus	59-65
16481292-5	2006	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on the expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	transforming growth factor beta 1	Homo sapiens	215-224
16481292-5	2006	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on the expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	SMAD family member 4	Homo sapiens	230-235
16360124-4	2006	The mCPP-induced increase in the serum concentration of corticosterone was not blocked by the 5-HT2C antagonist SB242084, but was blocked by the 5-HT2A antagonist ketanserin.	Ketanserin	163-173	5-hydroxytryptamine receptor 2A	Rattus norvegicus	145-151
16219295-3	2005	The enhancing effect of 5-HT on cell migration was markedly inhibited in the presence of ketanserin, a 5-HT2 receptor antagonist, but not by GR 55562, a 5-HT1 receptor antagonist.	Ketanserin	89-99	5-hydroxytryptamine receptor 2A	Homo sapiens	103-117
16269092-2	2005	In an attempt to tease out the relationship between these elements, this study tested the effects of the hallucinogenic mixed 5-HT1A/2A receptor agonist psilocybin alone and after pretreatment with the 5-HT2A antagonist ketanserin.	Ketanserin	220-230	5-hydroxytryptamine receptor 2A	Homo sapiens	202-208
15972834-9	2005	The effects of 5-HT were blocked by the 5-HT1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide (NAN-190) but not by ketanserin, a 5-HT(2/1C) antagonist.	Ketanserin	149-159	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
15827572-7	2005	and of a combination of the selective serotonin reuptake inhibitor (SSRI) citalopram (10 micromol/kg, s.c.) with the 5-HT2C antagonist ketanserin (100 nmol/kg, s.c).	Ketanserin	135-145	5-hydroxytryptamine receptor 2C	Rattus norvegicus	117-123
15551121-4	2005	METHODS: Postmortem frontal and temporal cortical 5-HT 2A receptors were measured by [3H]ketanserin binding in aged controls as well as in a cohort of AD patients who had been longitudinally assessed for cognitive decline and behavioral symptoms.	Ketanserin	89-99	5-hydroxytryptamine receptor 2A	Homo sapiens	50-57
16204433-7	2005	RESULTS: Compared with the placebo condition, subjects showed a significantly decreased insulin sensitivity after ketanserin (placebo: 9.4 +/- 3.6 mg/kg/min; ketanserin: 7.7 +/- 2.1 mg/kg/min; p = .047).	Ketanserin	114-124	insulin	Homo sapiens	88-95
16204433-7	2005	RESULTS: Compared with the placebo condition, subjects showed a significantly decreased insulin sensitivity after ketanserin (placebo: 9.4 +/- 3.6 mg/kg/min; ketanserin: 7.7 +/- 2.1 mg/kg/min; p = .047).	Ketanserin	158-168	insulin	Homo sapiens	88-95
15882780-2	2005	The fever induced by IL-1beta was significantly attenuated by pretreatment with intracerebroventricular injection of 5-HT2A receptor antagonists including cyproheptadine, ketanserin, or mianserin.	Ketanserin	171-181	interleukin 1 beta	Rattus norvegicus	21-29
15882780-4	2005	The DOI-induced (present results) or IL-1beta-induced (previous results) fever was further attenuated by pretreatment with an intracerebroventricular dose of mu-opioid receptor antagonists (e.g., buprenorphine or cyclic d-phe-cys-Try-d-Arg-Thr-pen-Thr-NH2) or 5-HT receptor antagonists (e.g., ketanserin or cyproheptadine).	Ketanserin	293-303	interleukin 1 beta	Rattus norvegicus	37-45
15565434-7	2005	The effects of DOI were reversed by the 5HT2A/2C antagonist ketanserin.	Ketanserin	60-70	5-hydroxytryptamine receptor 2A	Rattus norvegicus	40-45
15821444-6	2005	5-HT induced a contraction that was inhibited by the 5-HT2A receptor antagonist ketanserin.	Ketanserin	80-90	5-hydroxytryptamine receptor 2A	Homo sapiens	53-68
15796067-8	2005	The 5-HT-induced GDNF release was partially, but significantly, blocked by ketanserin, a 5-HT2A receptor antagonist.	Ketanserin	75-85	glial cell derived neurotrophic factor	Rattus norvegicus	17-21
15601754-7	2005	Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT.	Ketanserin	46-56	5-hydroxytryptamine receptor 2A	Rattus norvegicus	19-25
15601754-7	2005	Treatment with the 5-HT2A receptor antagonist ketanserin (10 nM) inhibited JAK2 activation by 5-HT.	Ketanserin	46-56	Janus kinase 2	Rattus norvegicus	75-79
15601754-8	2005	Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg.kg-1.day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo.	Ketanserin	55-65	Janus kinase 2	Rattus norvegicus	106-110
15601754-8	2005	Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg.kg-1.day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo.	Ketanserin	55-65	signal transducer and activator of transcription 1	Rattus norvegicus	115-120
15601754-8	2005	Treatment of streptozotocin-induced diabetic rats with ketanserin (5 mg.kg-1.day-1) reduced activation of JAK2 and STAT1 but not STAT3 in endothelium-denuded thoracic aorta in vivo.	Ketanserin	55-65	signal transducer and activator of transcription 3	Rattus norvegicus	129-134
15962186-11	2005	The present findings suggest that the 5-HT2A/2C receptor agonist has an inhibitory effect on maternal aggressive behavior when microinjected into the DPAG and no effect when microinjected into the MS. Ketanserin (1.0 microg/0.2 microl) decreased locomotion when microinjected into the DPAG and MS, but did not affect aggressive behavior.	Ketanserin	201-211	5-hydroxytryptamine receptor 2A	Rattus norvegicus	38-44
16047547-7	2005	The catalepsy is also potentiated by WAY 100135 (5-HT1a receptor antagonist), ketanserin (5HT2a and alfal adrenergic receptor antagonist), and ritanserin (5-HT2a and 5HT2c receptor antagonist).	Ketanserin	78-88	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	90-95
15755310-4	2005	The 5-HT-induced contraction occurred via 5-HT2A receptors, since the selective 5-HT2A antagonist ketanserin blocked the 5-HT-induced contraction in the fresh segments with a pA2 value 9.5 (slope was 0.98 with 95% confidence intervals from 0.8 to 1.1).	Ketanserin	98-108	5-hydroxytryptamine receptor 2A	Rattus norvegicus	42-48
15755310-4	2005	The 5-HT-induced contraction occurred via 5-HT2A receptors, since the selective 5-HT2A antagonist ketanserin blocked the 5-HT-induced contraction in the fresh segments with a pA2 value 9.5 (slope was 0.98 with 95% confidence intervals from 0.8 to 1.1).	Ketanserin	98-108	5-hydroxytryptamine receptor 2A	Rattus norvegicus	80-86
15796067-8	2005	The 5-HT-induced GDNF release was partially, but significantly, blocked by ketanserin, a 5-HT2A receptor antagonist.	Ketanserin	75-85	5-hydroxytryptamine receptor 2A	Rattus norvegicus	89-95
15168214-8	2004	The D2 agonist bromocriptine and 5-HT2A antagonist, ketanserin attenuated the haloperidol-induced neuronal toxicity.	Ketanserin	52-62	5-hydroxytryptamine receptor 2A	Homo sapiens	35-39
15107968-6	2004	RESULTS: Infusion of DOI into the CA1 region of the dorsal hippocampus elicited head bobs that were blocked by prior intrahippocampal injection of the 5-HT(2A) receptor antagonist ketanserin.	Ketanserin	180-190	carbonic anhydrase 1	Oryctolagus cuniculus	34-37
15587814-4	2004	The 5-HT2A receptor antagonist ketanserin (1.0 and 2.0 mg/kg) prevented the increase in testosterone induced by the presence of females.	Ketanserin	31-41	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	4-19
15327806-7	2004	After incubating the slices in ketanserin (an antagonist which shows selectivity for 5HT(1D) over 5HT(1B) receptors) sumatriptan had little effect on eEPSC amplitude.	Ketanserin	31-41	5-hydroxytryptamine receptor 1D	Rattus norvegicus	85-91
15342106-9	2004	Intra-DPAG injection of the 5-HT1A agonist 8-OH-DPAT and of DOI, a preferential 5-HT2A agonist, also inhibited escape, an effect antagonized by WAY-100635 and ketanserin, respectively.	Ketanserin	159-169	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
14627998-13	2004	Conversely, the 5-HT(2A/C) antagonist, ketanserin, attenuated cue reinstatement, but failed to alter cocaine reinstatement.	Ketanserin	39-49	5-hydroxytryptamine receptor 2A	Rattus norvegicus	16-23
14726440-6	2004	Contractions induced by U46619, 5-HT, and ET-1 were blocked by the thromboxane receptor antagonist SQ 29,548, the 5-HT(2A) receptor antagonist ketanserin, and the ET(A) receptor antagonist BQ 123, respectively.	Ketanserin	143-153	endothelin 1	Bos taurus	42-46
15007537-4	2004	5-HT-evoked contractions were antagonized partially by both 5-HT(1B)-selective SB224289 (200 nM) and 5-HT(2A)-selective ketanserin (1 microM) but not by 5-HT(1D)-selective BRL15572 (500 nM) or prazosin (1 microM).	Ketanserin	120-130	5-hydroxytryptamine receptor 2A	Homo sapiens	103-108
14996544-7	2004	mCPP-induced hyperactivity was attenuated in 5-HT2C KO mice by the 5-HT1B receptor antagonist SB 224289 (2.5 mg/kg), and the 5-HT2A receptor antagonists ketanserin (0.3 mg/kg) and M100907 (0.01 mg/kg) but not by the 5-HT1A receptor antagonist WAY 100635 (1 mg/kg).	Ketanserin	153-163	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	125-140
14697877-8	2004	5-HT2A antagonist, ketanserin and MDL100907 were able to abolish the aggression, suggesting that the aggressive behavior may be mediated by 5-HT2A receptor.	Ketanserin	19-29	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	140-155
15095157-2	2004	We compared the action of gramine with that of ketanserin, a 5-HT (2A) antagonist; both compounds induced concentration-dependent relaxation in precontracted arterial rings.	Ketanserin	47-57	5-hydroxytryptamine receptor 2A	Homo sapiens	61-69
15006475-6	2004	ICV pretreatment with the 5-HT(2A) receptor antagonist ketanserin inhibited ICV DOI-elicited head bobs establishing that 5-HT(2A) receptors activation elicits head bobs.	Ketanserin	55-65	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	26-43
12873638-4	2003	These antinociceptive effects were reversed by microinjections of the opioid antagonist naltrexone or the specific 5-HT2A receptor antagonist ketanserin into the stimulation sites.	Ketanserin	142-152	5-hydroxytryptamine receptor 2A	Homo sapiens	115-130
15340248-9	2004	The serotonin 5-HT2 receptor antagonist ketanserin increased the serum prolactin levels and potentiated the effect of DAMGO.	Ketanserin	40-50	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-28
15340248-9	2004	The serotonin 5-HT2 receptor antagonist ketanserin increased the serum prolactin levels and potentiated the effect of DAMGO.	Ketanserin	40-50	prolactin	Rattus norvegicus	71-80
15075453-6	2003	Both release of secretin and pancreatic exocrine secretion (PES) elicited by duodenal acidification were also inhibited dose-dependently by Met-enkepahlin, 5-HT(2) antagonist, ketanserin and 5-HT(3) antagonist, ondansetron.	Ketanserin	176-186	secretin	Rattus norvegicus	16-24
12798981-1	2003	The 5-HT2A receptor binding parameters using [3H]ketanserine and its intracellular signal inositol 1,4,5 trisphosphate (IP3) concentrations were determined in platelets from schizophrenic patients so as to assess differences with respect to a control group and to a standardized antipsychotic drug treatment.	Ketanserin	49-60	5-hydroxytryptamine receptor 2A	Homo sapiens	4-19
15085887-7	2004	RESULTS: Thrombin-induced myometrial contractions were significantly and concentration-dependently inhibited by ketanserin and methysergide.	Ketanserin	112-122	coagulation factor II	Rattus norvegicus	9-17
14665977-8	2003	The antagonistic effect of ketanserin indicates that the effect of DOI was probably mediated by 5-HT2A rather than 5-HT2C receptors, since ketanserin is relatively selective for 5-HT2A receptors.	Ketanserin	27-37	5-hydroxytryptamine receptor 2A	Rattus norvegicus	96-102
12444501-7	2002	Alpha-methyl-5-HT, a selective 5-HT(2) receptor agonist, induced contractions that were antagonized in a competitive manner by ketanserin.	Ketanserin	127-137	5-hydroxytryptamine receptor 2A	Homo sapiens	31-47
12887773-4	2003	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	transforming growth factor beta 1	Homo sapiens	177-209
12887773-4	2003	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	transforming growth factor beta 1	Homo sapiens	211-220
12887773-4	2003	Western blot hybridization was used to elucidate the effect of 5-hydroxytamine and its 2A receptor antagonist ketanserin and 3 receptor antagonist ondanosetron on expression of transforming growth factor-beta1 (TGF-beta1) and Smad4 in HSC.	Ketanserin	110-120	SMAD family member 4	Homo sapiens	226-231
12578853-6	2003	The inhibitory effect of 5-HT on TNF-alpha production was antagonized by ketanserin, a selective 5-HT(2A) antagonist, and mimicked by DOI, a selective 5-HT(2A/2C) agonist.	Ketanserin	73-83	tumor necrosis factor	Homo sapiens	33-42
12654345-14	2003	In rabbits, the 5-HT2A receptor antagonists ketanserin (0.3 mg/kg i.v.)	Ketanserin	44-54	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	16-31
12457458-7	2002	The restraint stress-induced AVP response was inhibited by pretreatment with the 5-HT(2A+2C) antagonists ketanserin (KET) and LY-53857 (LY) and the 5-HT(3+4) antagonist ICS-205930 (ICS), whereas the 5-HT(1A) antagonist WAY-100635 (WAY) had no effect.	Ketanserin	105-115	5-hydroxytryptamine receptor 2A	Rattus norvegicus	81-88
12457458-7	2002	The restraint stress-induced AVP response was inhibited by pretreatment with the 5-HT(2A+2C) antagonists ketanserin (KET) and LY-53857 (LY) and the 5-HT(3+4) antagonist ICS-205930 (ICS), whereas the 5-HT(1A) antagonist WAY-100635 (WAY) had no effect.	Ketanserin	117-120	5-hydroxytryptamine receptor 2A	Rattus norvegicus	81-88
12122486-11	2002	The stimulant effect of MDMA was attenuated by GR127935 and ketanserin, indicating facilitatory roles of 5-HT(1B) and 5-HT(2A) receptors in mediating this effect.	Ketanserin	60-70	5-hydroxytryptamine receptor 1B	Rattus norvegicus	105-112
12097814-3	2002	Administration of 5-HT2A receptor antagonists ketanserin (1.0 and 2.0 mg/kg i.p.)	Ketanserin	46-56	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	18-33
12044802-6	2002	Incubation with the 5-HT(2) receptor antagonist ketanserin (10 microM) eliminated the low affinity component of the concentration-response curve of donitriptan and the resultant E(max) and pEC(50) were 9+/-2% and 7.33+/-0.21, respectively.	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Homo sapiens	20-36
12052193-0	2002	Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	58-65
12164263-7	2002	The results indicate that IHp treatment caused a significant decrease in the binding of [3H] spiroperone (DA-D2 receptor) to the striatum and an increase in the binding of [3H] ketanserin (5-HT2A receptor) and [3H] flunitrazepam (BDZ receptor) to the frontal cortex in rats.	Ketanserin	177-187	5-hydroxytryptamine receptor 2A	Rattus norvegicus	189-195
11900808-6	2002	The selective 5-HT2A receptor antagonist ketanserin (1-3 micromol/kg), 1 h before DOI (0.3 micromol/kg) challenge, significantly attenuated head bobs, but not body shakes.	Ketanserin	41-51	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	14-29
12269391-3	2002	injection of nantenine (13.3, 20 and 30 mg/kg) as well as the 5-HT2A receptor antagonist ketanserin (0.0625, 0.25 and 1 mg/kg) inhibited the 5-hydroxy-L-tryptophan (l-5-HTP; 75 mg/kg, i.p.)	Ketanserin	89-99	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	62-77
11675041-0	2001	Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	82-89
11897772-7	2002	Unlike in aorta, 5-HT-induced contraction in DOCA-salt small arteries was shifted competitively by the 5-HT2A receptor antagonist ketanserin (-log K(B) [mol/L] for both sham and DOCA-salt, 9.25+/-0.1), and contraction to the 5-HT2B agonist BW723C86 was not observed.	Ketanserin	130-140	5-hydroxytryptamine receptor 2B	Rattus norvegicus	225-231
12095161-4	2002	The effect of 5-HT (100 microM) was inhibited by a 5-HT2A receptor antagonist (ketanserin; 1 microM).	Ketanserin	79-89	5-hydroxytryptamine receptor 2A	Homo sapiens	51-66
11786272-6	2002	No effect was also observed by pretreatment with ketanserin (2.5 mg/kg) a compound with high affinity for the 5-HT(2A)-receptor and the vesicular monoamine transporter.	Ketanserin	49-59	5-hydroxytryptamine receptor 2A	Homo sapiens	110-127
11767193-10	2001	This response was inhibited by the 5-HT2A receptor antagonist ketanserin.	Ketanserin	62-72	5-hydroxytryptamine receptor 2A	Homo sapiens	35-50
11767193-13	2001	The response to 5-HT was blocked by the 5-HT2A-receptor antagonist ketanserin at 10(-6) M (n = 4).	Ketanserin	67-77	5-hydroxytryptamine receptor 2A	Homo sapiens	40-55
11937776-4	2002	Among the three drugs, ketanserin showed the highest affinity for alpha(1a)-, alpha(1b)- and alpha(1d)-ARs (pKi 8.0, 8.3 and 7.6, respectively).	Ketanserin	23-33	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	66-74
11805206-7	2002	5-HT(2A) receptor desensitization induced by 5-HT and prolonged ketanserin treatment, but not by short-term ketanserin treatment, was prevented by the expression of the dominant negative mutant of G protein-coupled receptor kinase (GRK)2, GRK2-K220R, and by an anti-GRK2/3 antibody.	Ketanserin	64-74	G protein-coupled receptor kinase 2	Homo sapiens	197-237
11767117-3	2001	Suppressive effects of mCPP on hyperphagia induced by 2-DG were inhibited by the 5-HT2A/2B/2C receptor antagonist, ritanserin, although the 5-HT2, receptor antagonist ketanserin was without effect.	Ketanserin	167-177	5-hydroxytryptamine receptor 2A	Rattus norvegicus	140-155
11511381-2	2001	5-HT reduction elicited by p-chloroamphetamine was inhibited by the 5-HT(2A/2B/2C) receptor antagonist, LY 53857 and the 5-HT(2A) receptor antagonist, ketanserin.	Ketanserin	151-161	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	121-138
11561066-7	2001	Additionally, several drugs without significant antipsychotic actions (M100907, ketanserin, mianserin, ritanserin, and amitriptyline) were potent inverse agonists at the 5-HT2C-INI isoform expressed in HEK-293 cells.	Ketanserin	80-90	5-hydroxytryptamine receptor 2C	Homo sapiens	170-176
11483243-6	2001	Prior administration of the 5-HT2A/2C receptor antagonist, ritanserin (1 mg/kg) or the 5-HT2A receptor antagonist, ketanserin (1 mg/kg) completely blocked the DOI-induced increases in striatal PPT mRNA in both lesioned and intact animals.	Ketanserin	115-125	tachykinin, precursor 1	Rattus norvegicus	193-196
11508497-6	2001	there were significant decreases in [3H]ketanserin binding to 5-HT2A receptors in the frontal cortex in hypothyroid rats as compared with controls; this decrease was reversed by thyroxine treatment.	Ketanserin	36-50	5-hydroxytryptamine receptor 2A	Rattus norvegicus	62-68
11518230-4	2001	Contractile responses to ergovaline and ergotamine were surmountably antagonized by the 5-HT2A receptor antagonist ketanserin (3 nM).	Ketanserin	115-125	5-hydroxytryptamine receptor 2A	Rattus norvegicus	88-94
11161597-7	2001	Both the 5-HT(2) antagonist methysergide and the 5-HT(2A) selective antagonist ketanserin were able to block partially or totally the depressive action of 5-HT on GABA responses.	Ketanserin	79-89	5-hydroxytryptamine receptor 2A	Rattus norvegicus	49-56
11259531-5	2001	The 5-HT(1E/1F) receptor agonist BRL 54443 also induced contraction (-log EC(50) = 6.52); however, the 5-HT2A receptor antagonist ketanserin antagonized this contraction.	Ketanserin	130-140	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	103-118
11259531-6	2001	Our hypothesis was further supported by the finding that antagonists with affinity for the 5-HT2A receptor, ketanserin, 1-(1-naphthyl)piperazine, spiperone, and LY53857, reduced 5-HT-induced contraction.	Ketanserin	108-118	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	91-106
11303767-3	2001	Responses to SKF-38393 were prevented by SCH-23390 (10 microM, D1 antagonist) whereas DOI-stimulated increases were prevented by ketanserin (10 microM, 5-HT2A antagonist).	Ketanserin	129-139	5-hydroxytryptamine receptor 2A	Homo sapiens	152-158
11323083-3	2001	Evidence indicates that SB-224289 (a 5-HT1B receptor inverse agonist) post-training injection facilitated learning consolidation in an associative autoshaping learning task, this effect was partially reversed by GR 127935 (a 5-HT1B/1D receptor antagonist), but unaffected by MDL 100907 (a 5-HT2A receptor antagonist) or ketanserin (a 5-HT1D/2A/7 receptor antagonist) at low doses.	Ketanserin	320-330	5-hydroxytryptamine receptor 1B	Homo sapiens	37-43
11323083-3	2001	Evidence indicates that SB-224289 (a 5-HT1B receptor inverse agonist) post-training injection facilitated learning consolidation in an associative autoshaping learning task, this effect was partially reversed by GR 127935 (a 5-HT1B/1D receptor antagonist), but unaffected by MDL 100907 (a 5-HT2A receptor antagonist) or ketanserin (a 5-HT1D/2A/7 receptor antagonist) at low doses.	Ketanserin	320-330	5-hydroxytryptamine receptor 1B	Homo sapiens	225-231
11323083-8	2001	Notably, SB-224289 at 1.0mg/kg potentiated a subeffective dose of the 5-HT1B/1D receptor agonist/antagonist mixed GR 127935, which facilitated learning consolidation and this effect was abolished by ketanserin at a higher dose.	Ketanserin	199-209	5-hydroxytryptamine receptor 1B	Homo sapiens	70-76
11347816-13	2001	However, metergoline, a 5HT1/5HT2 receptor antagonist, and ketanserin, a 5HT2A receptor antagonist, but not the 5HT1A antagonist WAY100635, increased the resting release of dopamine and blocked the effects of nicotine.	Ketanserin	59-69	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	73-87
11044887-4	2000	Moreover, the specific hypothalamic uptake was blocked by pretreatment with SERT selective competing drugs, such as paroxetine and (+)McN5652, while other noncompeting drugs, such as ketanserin, raclopride, and methylphenidate, showed no effect.	Ketanserin	183-193	solute carrier family 6 member 4	Rattus norvegicus	76-80
11044889-8	2000	The labeling of human 5-HT(2A) receptors with [(3)H]M100907 was inhibited by the addition of the 5-HT(2A) receptor blockers ketanserin or SCH 23390 (10 microM), leaving a very low background of nonspecific binding.	Ketanserin	124-134	5-hydroxytryptamine receptor 2A	Homo sapiens	22-39
11053216-7	2000	Using membranes from cells co-expressing the porcine 5-HT(1D) receptor and rat G(alphail)Cys(351) Ile protein, it was shown that 5-HT and zolmitriptan increased, while ketanserin decreased basal [(35)S]-GTPgammaS binding.	Ketanserin	168-178	5-hydroxytryptamine receptor 1D	Cavia porcellus	53-70
11076827-8	2000	The effect of 5-HT on IL-6 production was significantly inhibited by the 5-HT(2) receptor antagonist ketanserin and the selective 5-HT(2A) receptor antagonist sarpogrelate.	Ketanserin	101-111	interleukin 6	Homo sapiens	22-26
11076827-8	2000	The effect of 5-HT on IL-6 production was significantly inhibited by the 5-HT(2) receptor antagonist ketanserin and the selective 5-HT(2A) receptor antagonist sarpogrelate.	Ketanserin	101-111	5-hydroxytryptamine receptor 2A	Homo sapiens	73-89
11229360-5	2000	EGb caused a significant 16.9% decrease in [3H]ketanserin binding to 5-HT2A receptors in the frontal cortex of MAO A KO mice but did not change the receptor affinity for [3H]ketanserin.	Ketanserin	43-57	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	69-75
11229360-5	2000	EGb caused a significant 16.9% decrease in [3H]ketanserin binding to 5-HT2A receptors in the frontal cortex of MAO A KO mice but did not change the receptor affinity for [3H]ketanserin.	Ketanserin	43-57	monoamine oxidase A	Mus musculus	111-116
11141696-14	2000	Ketanserin was given to 2 patients with Nelson"s syndrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases.	Ketanserin	0-10	proopiomelanocortin	Homo sapiens	79-83
11141696-15	2000	An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing"s disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome.	Ketanserin	39-49	proopiomelanocortin	Homo sapiens	53-57
10936201-1	2000	Molecular cloning and expression of canine (ca) serotonin 5-HT(1B) and ca 5-HT(1D) receptor subtypes showed that besides the lower binding affinity of ketanserin for the ca 5-HT(1D) receptor, the ligand binding profiles were similar to their human homologues.	Ketanserin	151-161	5-hydroxytryptamine receptor 1B	Canis lupus familiaris	58-65
10973613-10	2000	The present study demonstrated that ketanserin, a 5-HT(2A) receptor antagonist reversed the effect of dizocilpine on morphine dependence.	Ketanserin	36-46	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	50-67
10993216-3	2000	After the administration of 3 mg/kg ketanserin, the expression of Fos-ir cells in the periglomerular cell layer in response to male Wistar urine was inhibited, while that in the mitral/tufted cell and granule cell layers was not changed.	Ketanserin	36-46	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	66-69
10704941-3	2000	Ketanserin binding affinity was 21-fold increased from pK(i): 5.79 (wt h 5-HT(1B) receptor) to pK(i): 7.11 at the 5-HT(1B/2A) chimeric receptor, this latter value being close to that of the wt h 5-HT(1D) receptor (pK(i): 7.62).	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	73-80
10804232-9	2000	Finally, we found that the effects of handling on NGFI-A and AP-2 expression were significantly reduced by concurrent treatment with either PTU or ketanserin, effects that paralleled those on cAMP formation.	Ketanserin	147-157	early growth response 1	Rattus norvegicus	50-56
10804232-9	2000	Finally, we found that the effects of handling on NGFI-A and AP-2 expression were significantly reduced by concurrent treatment with either PTU or ketanserin, effects that paralleled those on cAMP formation.	Ketanserin	147-157	transcription factor AP-2 alpha	Rattus norvegicus	61-65
10704941-3	2000	Ketanserin binding affinity was 21-fold increased from pK(i): 5.79 (wt h 5-HT(1B) receptor) to pK(i): 7.11 at the 5-HT(1B/2A) chimeric receptor, this latter value being close to that of the wt h 5-HT(1D) receptor (pK(i): 7.62).	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	114-121
10704941-4	2000	This enhanced ketanserin binding affinity was lost when the last 44 C-terminal amino acids of the 5-HT(2A) receptor were deleted in the chimera 5-HT(1B/2ADelta44) (pK(i): 5.80).	Ketanserin	14-24	5-hydroxytryptamine receptor 1B	Homo sapiens	144-151
10870512-7	2000	Ketanserin, a specific 5-HT2A antagonist, counteracts the IOP increase brought about by fluoxetine, thus emphasizing the role of serotonin in the regulation of IOP and stressing the importance of including ophthalmological examination in the protocol of depressed patients undergoing SSRI therapy.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Homo sapiens	23-29
10627607-5	2000	The 5-HT(2A)-selective antagonist ketanserin did not completely block the developmental effects of 5-HT.	Ketanserin	34-44	5-hydroxytryptamine receptor 2A	Homo sapiens	4-11
10867971-7	2000	Ketanserin, a selective 5-HT2A antagonist (5 mg/kg) also inhibited the 5-HT syndrome.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Rattus norvegicus	24-30
10698012-8	2000	Pretreatment with the 5-HT2 receptor antagonist ketanserin (2 mg/kg, i.p.)	Ketanserin	48-58	5-hydroxytryptamine receptor 2A	Homo sapiens	22-36
10698013-4	2000	The selective effect of a low dose of DOI (0.1 mg/kg) on premature responding was completely blocked by ketanserin (0.2 mg/kg), a 5-HT2A antagonist, and ritanserin (0.3 mg/kg), a 5-HT(2A/2C) antagonist, but only partially blocked by a high dose of SER082 (1.0 mg/kg), a 5-HT2C antagonist.	Ketanserin	104-114	5-hydroxytryptamine receptor 2A	Rattus norvegicus	130-136
10698013-4	2000	The selective effect of a low dose of DOI (0.1 mg/kg) on premature responding was completely blocked by ketanserin (0.2 mg/kg), a 5-HT2A antagonist, and ritanserin (0.3 mg/kg), a 5-HT(2A/2C) antagonist, but only partially blocked by a high dose of SER082 (1.0 mg/kg), a 5-HT2C antagonist.	Ketanserin	104-114	5-hydroxytryptamine receptor 2C	Rattus norvegicus	270-276
11145008-9	2000	MIL also decreased the binding (Bmax) or [3H]-ketanserin to 5-HT2A receptors in the cerebral cortex.	Ketanserin	41-56	5-hydroxytryptamine receptor 2A	Rattus norvegicus	60-66
10456237-5	1999	5-HT1A and 5-HT2A receptors were quantitated by radioligand binding of [3H]ketanserin and [3H]8-OH DPAT, respectively, in hypothalamus and amygdala from male and female rats at days 8-16 pp.	Ketanserin	71-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-12
10772043-10	2000	The response to 5-HT could be blocked by 10(-6) M of the 5-HT2A-receptor antagonist ketanserin, and that of U46619 by 10(-6) M of the TXA2-receptor antagonist SQ30741.	Ketanserin	84-94	5-hydroxytryptamine receptor 2A	Homo sapiens	57-72
10647092-5	1999	The pharmacological profile of the [3H]mesulergine binding was consistent with that of 5-HT2C receptors, since the most effective displacers were ritanserin, mesulergine and mianserine, followed by clozapine, ketanserine and m-CPP, while other compounds had a negligible or no effect.	Ketanserin	209-220	5-hydroxytryptamine receptor 2C	Homo sapiens	87-93
10564740-5	1999	5-HT(1B) receptor binding sites ([125I]cyanopindolol) were significantly increased in the hypothalamic arcuate nucleus (ARC) of DiO rats (58%; P<0.05), as were 5-HT(2A) receptor binding sites ([3H]ketanserin) in both the ARC (44%; P<0.05) and lateral hypothalamic area (LHA) (121%; P<0.05).	Ketanserin	200-210	5-hydroxytryptamine receptor 1B	Rattus norvegicus	0-7
10471096-4	1999	Thirty minute pretreatment with ritanserin, ketanserin, metergoline or DOI (at the doses above) afforded 49-65% protection against the loss of 5-HT2A binding sites induced by EEDQ (6 mg/kg).	Ketanserin	44-54	5-hydroxytryptamine receptor 2A	Rattus norvegicus	143-149
10510170-3	1999	The inhibitory action of DOB, LSD and 5-HT on the NMDA transmission was blocked by the 5-HT2A receptor antagonists R-(+)-alpha-(2, 3-dimethoxyphenil)-1-[4-fluorophenylethyl]-4-piperidineme thanol (M100907) and ketanserin.	Ketanserin	210-220	5-hydroxytryptamine receptor 2A	Rattus norvegicus	87-93
10544393-8	1999	In conclusion, our experiments suggest that the 5-HT2A receptors in monoamine-impaired rats are involved in the mediation of antidepressant-induced behavioral phenomena, but chronic antidepressant treatment downregulates [3H]-ketanserin binding independently from the state of monoaminergic neurotransmission.	Ketanserin	226-236	5-hydroxytryptamine receptor 2A	Rattus norvegicus	48-54
10544955-4	1999	Competition studies of [3H]MDL100907 binding in cerebral cortex with ketanserin showed the appearance of an additional low affinity site for 5-HT2A receptors in diabetic state, which was reversed to control pattern by insulin treatment.	Ketanserin	69-79	5-hydroxytryptamine receptor 2A	Rattus norvegicus	141-147
10708299-2	1999	The complex combines the 4-(4-fluoro)-benzoyl piperidine portion derived from the 5-HT2A receptor antagonist ketanserin with a neutral oxotechnetium(V) chelate in form of a mixed ligand "3 + 1" unit containing the SNS/S donor set.	Ketanserin	109-119	5-hydroxytryptamine receptor 2A	Homo sapiens	82-97
10708299-9	1999	This enrichment can be blocked by 5-HT2A receptor antagonists such as mianserin and ketanserin and is therefore specific.	Ketanserin	84-94	5-hydroxytryptamine receptor 2A	Homo sapiens	34-49
10516655-6	1999	Ketanserin (5-HT2A-selective antagonist, 0.1 microM) inhibited 5-HT-induced contractions only at non-physiological/pathological concentrations of 5-HT (>0.1 microM) whilst GR55562 (5-HT1B/1D-selective antagonist, 1 microM) inhibited 5-HT-induced contractions at all concentrations of 5-HT (estimated pKB=7.7+/-0.2).	Ketanserin	0-10	5-hydroxytryptamine receptor 1B	Homo sapiens	184-190
10564383-0	1999	Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL100,907,[125I](+/-)DOI and [3H]ketanserin.	Ketanserin	127-137	5-hydroxytryptamine receptor 2A	Homo sapiens	33-39
10564383-7	1999	These results confirm the presence of 5-HT2A receptors in human striosomes and in those areas where [3H]ketanserin presented a high nonspecific binding, and they highlight the advantage of using [3H]MDL100,907 to visualize these receptors.	Ketanserin	104-114	5-hydroxytryptamine receptor 2A	Homo sapiens	38-44
10415365-0	1999	Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A.	Ketanserin	0-10	monoamine oxidase A	Mus musculus	64-83
10457188-4	1999	Both the facilitating and inhibitory action were blocked by the highly selective 5-HT2A receptor antagonist R-(+)-alpha-(2, 3-dimethoxyphenil)-1-[4-fluorophenylethyl]-4-piperidineme thanol (M100907) and the 5-HT2 receptor antagonist ketanserin, thus indicating that both facilitation and inhibition were mediated by the activation of the 5-HT2A receptor subtype.	Ketanserin	233-243	5-hydroxytryptamine receptor 2A	Rattus norvegicus	81-87
10415365-3	1999	Our results show that ketanserin and tetrabenazine (TBZ) strikingly abolished the aggressive behavior of MAO A-deficient mice.	Ketanserin	22-32	monoamine oxidase A	Mus musculus	105-110
10415365-4	1999	The anti-aggressive effect of ketanserin may be primarily mediated by 5-HT(2A) receptors.	Ketanserin	30-40	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	70-77
10415365-6	1999	Ketanserin and TBZ are both antagonists of the vesicular monoamine transporter (VMAT2).	Ketanserin	0-10	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	80-85
10415365-7	1999	The anti-aggressive effect of TBZ and part of the effect of ketanserin may be mediated by the VMAT2.	Ketanserin	60-70	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	94-99
10463324-5	1999	A further six healthy men were recruited to an equivalent study to examine the effect of ketanserin (a 5-HT receptor antagonist with some preference for 5-HT1D over 5-HT1B receptors) on the growth hormone response to zolmitriptan.	Ketanserin	89-99	growth hormone 1	Homo sapiens	190-204
10455272-9	1999	The selective 5-HT2A antagonist ketanserin against sumatriptan and 5-nonyloxytryptamine behaved as a weak antagonist while against 5-HT demonstrated a competitive antagonism (pKB 8.56).	Ketanserin	32-42	5-hydroxytryptamine receptor 2A	Homo sapiens	14-20
10463324-7	1999	The increase in growth hormone produced by zolmitriptan was significantly attenuated by ketanserin.	Ketanserin	88-98	growth hormone 1	Homo sapiens	16-30
10512006-2	1999	The effect was dependent on type and dose of 5-HT2 antagonist used: 5-HT2A antagonist ketanserin increased startle amplitude at the dose of 0.5 mg/kg and decreased it at the dose of 2 mg/kg.	Ketanserin	86-96	5-hydroxytryptamine receptor 2A	Rattus norvegicus	68-74
10401550-5	1999	Blockade of 5-HT1B 1D and 5-HT2A receptors with GR127935 (1 microM) and ketanserin (0.1 microM), respectively, antagonized the vasoconstrictor component of the response and unmasked a concentration-dependent relaxation to 5-HT, 5-CT and 5-methoxytryptamine; sumatriptan and alpha-methyl-5-HT remained inactive as relaxant agonists.	Ketanserin	72-82	5-hydroxytryptamine receptor 1B	Canis lupus familiaris	12-18
10422894-10	1999	There were no significant differences between the ketanserin-induced decrease in NPY-LI levels and the effects of the following two-drug combinations: ketanserin and SCH 23390, ketanserin and L-745,870, and ketanserin and prazosin.	Ketanserin	50-60	neuropeptide Y	Rattus norvegicus	81-84
10424728-5	1999	In conclusion, our experiments demonstrate that repeated apomorphine treatment upregulates the maximal number of the 5-HT2A receptors in rat frontal and cerebral cortex as measured by [3H]ketanserin binding and this phenomenon is independent from the development of aggressive behaviour.	Ketanserin	188-198	5-hydroxytryptamine receptor 2A	Rattus norvegicus	117-123
10224126-6	1999	The stimulatory effects of 5-HT and m-HT were suppressed in the presence of submicromolar concentrations of ketanserin (a selective 5-HT2A antagonist) providing further evidence that the increase in glucose uptake was specifically mediated via the 5-HT2A receptor.	Ketanserin	108-118	5-hydroxytryptamine receptor 2A	Rattus norvegicus	132-138
10408247-1	1999	The density of 5-HT2A binding sites in the brain of Sardinian alcohol-preferring (sP) and nonpreferring (sNP) rats was evaluated, using [3H]ketanserin for quantitative autoradiography.	Ketanserin	140-150	5-hydroxytryptamine receptor 2A	Rattus norvegicus	15-21
10224126-6	1999	The stimulatory effects of 5-HT and m-HT were suppressed in the presence of submicromolar concentrations of ketanserin (a selective 5-HT2A antagonist) providing further evidence that the increase in glucose uptake was specifically mediated via the 5-HT2A receptor.	Ketanserin	108-118	5-hydroxytryptamine receptor 2A	Homo sapiens	248-263
10223282-7	1999	The ACTH response to 5-HT or 5-HTP/Flx was inhibited by injection with the 5-HT1A+2A+2c+5A+7 antagonist methysergide, the 5-HT2A antagonist ketanserine and the 5-HT2C+2A antagonist LY 53857.	Ketanserin	140-151	5-hydroxytryptamine receptor 2A	Rattus norvegicus	122-128
10101238-5	1999	The observed [35S]GTPgammaS binding responses in the substantia nigra are likely to be mediated by stimulation of the 5-HT1B receptor subtype, since they were antagonized by the 5-HT1B inverse agonist SB 224289 (10 microM), and not by the 5-HT2A/1D antagonist ketanserin (10 microM).	Ketanserin	260-270	5-hydroxytryptamine receptor 1B	Rattus norvegicus	118-124
10101238-5	1999	The observed [35S]GTPgammaS binding responses in the substantia nigra are likely to be mediated by stimulation of the 5-HT1B receptor subtype, since they were antagonized by the 5-HT1B inverse agonist SB 224289 (10 microM), and not by the 5-HT2A/1D antagonist ketanserin (10 microM).	Ketanserin	260-270	5-hydroxytryptamine receptor 1B	Rattus norvegicus	178-184
10376810-5	1999	Ketanserin and mianserin (1 and 3 nM), 5-HT2A antagonists, were equipotent and had high affinity in antagonising the 5-HT-induced IP accumulation and [Ca2+]i change with pK(B) values of 8.6-9.1 and 8.6-9.4, respectively.	Ketanserin	0-10	5-hydroxytryptamine receptor 2A	Canis lupus familiaris	39-45
10087024-9	1999	Furthermore, the combination of ketanserin and GR 127935 produced a significantly greater blockade of the amplified response than either antagonist alone, supporting the conclusion that both 5-HT2A and 5-HT1B receptors mediate the K+-amplified response to serotonin in the rabbit ear artery.	Ketanserin	32-42	5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus	202-208
10024307-4	1999	This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist.	Ketanserin	187-197	solute carrier family 6 member 4	Rattus norvegicus	33-49
10090630-9	1999	Acute endurance exercise reduced the density of platelet 5-HT2A receptor [3H]ketanserin binding sites at I and II (P < 0.05).	Ketanserin	77-87	5-hydroxytryptamine receptor 2A	Homo sapiens	57-72
10211591-3	1999	The effect of either 5-HT or DOI is blocked by selective 5-HT2A receptor antagonists such as spiperone and ketanserin and more markedly by mixed 5-HT2 receptor antagonists, such as ritanserin, methysergide and mesulergine, with higher affinity at the 2C subtype.	Ketanserin	107-117	5-hydroxytryptamine receptor 2A	Rattus norvegicus	57-63
10080233-11	1999	Because methysergide is a nonspecific antagonist of 5-HT receptors, and ketanserin acts with a high degree of specificity at 5-HT2/5-HT1C receptors, the present results suggest that activation of 5-HT2/5-HT1C receptors may be implicated in the antinociception induced by stimulation of the inferior colliculus.	Ketanserin	72-82	5-hydroxytryptamine receptor 2C	Homo sapiens	131-137
10080233-11	1999	Because methysergide is a nonspecific antagonist of 5-HT receptors, and ketanserin acts with a high degree of specificity at 5-HT2/5-HT1C receptors, the present results suggest that activation of 5-HT2/5-HT1C receptors may be implicated in the antinociception induced by stimulation of the inferior colliculus.	Ketanserin	72-82	5-hydroxytryptamine receptor 2C	Homo sapiens	202-208
10024307-4	1999	This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist.	Ketanserin	187-197	solute carrier family 6 member 4	Rattus norvegicus	51-56
10024307-4	1999	This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist.	Ketanserin	187-197	solute carrier family 6 member 4	Rattus norvegicus	89-94
10065902-4	1998	5-HT1A and 5-HT2A receptors were characterised by saturation studies using [3H] 8-OH-DPAT and [3H] Ketanserin respectively.	Ketanserin	99-109	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-12
9855638-3	1998	This was investigated with a chimeric 5-HT1B/1D receptor analysis and using ketanserin as a selective antagonist of h5-HT1D (h5-HT1D) Ki = 24-27 nM) as opposed to h5-HT1B (Ki = 2193-2902 nM) receptors.	Ketanserin	76-86	5-hydroxytryptamine receptor 1D	Homo sapiens	117-123
9918563-5	1999	This effect was 1) additive with that of a pure H3-receptor antagonist, ciproxifan, 2) mimicked by a 5-HT2A receptor antagonist, ketanserin, 3) reversed by a 5-HT2A receptor agonist, DOI, 4) not shared by antipsychotics with low affinity for the 5-HT2A receptor, i.e., haloperidol, sulpiride, raclopride, or remoxipride that, on the contrary, tended to reduce tele-methylhistamine levels.	Ketanserin	129-139	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	101-116
9918230-7	1999	This oestradiol-induced surge of LHRH was blocked by ketanserin, ritanserin and the highly selective 5-HT2A receptor antagonist, RP62203, but not by fluoxetine.	Ketanserin	53-63	gonadotropin releasing hormone 1	Rattus norvegicus	33-37
10065902-9	1998	Autoradiography of 5-HT2A receptors using [3H] Ketanserin showed no difference in the binding in SFV-infected brains.	Ketanserin	47-57	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	19-25
9778658-2	1998	The effectiveness of these drug treatments to downregulate 5-HT2A receptors was confirmed by measuring the binding of [3H]-ketanserin in cortical homogenates, because all of these drug treatments have been shown to result in the downregulation of 5-HT2A receptor sites.	Ketanserin	123-133	5-hydroxytryptamine receptor 2A	Rattus norvegicus	59-65
9808259-3	1998	The 5-HT2A receptor antagonists, ketanserin (2.5, 5 and 10 mg/kg) and ritanserin (0.5, 1 and 2 mg/kg), dose-dependently blocked MK-801 (0.5 mg/kg)-induced hyperlocomotion.	Ketanserin	33-43	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	4-19
9739147-9	1998	Ritanserin was more potent than ketanserin at inhibiting the DOI induced increase in c-Fos labelled cells in the SCN.	Ketanserin	32-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-90
9744919-7	1998	The 5-HT1A antagonist pindobind-5-HT1A (PBD; 1-3 microM) and the 5-HT2/5-HT1 receptor antagonist spiperone (1-10 microM) suppressed 5-HTH and the hyperpolarizing phase of biphasic responses; the 5-HT2 receptor antagonist ketanserin (3 microM) was without significant effect.	Ketanserin	221-231	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
9744919-11	1998	The 5-HT2 receptor agonist alpha-methyl-5-HT (50 microM) depolarized RVLM neurons, and the 5-HT2 antagonist ketanserin (1-10 microM) attenuated the 5-HTD and the depolarizing phase of biphasic responses, whereas the 5-HT1A receptor antagonist PBD (2 microM) was without effect.	Ketanserin	108-118	5-hydroxytryptamine receptor 1A	Rattus norvegicus	216-222
9723944-15	1998	We conclude that the ketanserin-resistant fraction of the 5-HT effects and the effects of sumatriptan are mediated by 5-HT1B receptors.	Ketanserin	21-31	5-hydroxytryptamine receptor 1B	Homo sapiens	118-124
9692769-13	1998	Treatment with ketanserin or cimetidine resulted in a partial but significant decrease of the ovalbumin-induced AHR compared to ovalbumin-challenged controls (P<0.05) and reduced eosinophil infiltration after ovalbumin challenge by 60% and 58%, respectively.	Ketanserin	15-25	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	94-103
9692769-13	1998	Treatment with ketanserin or cimetidine resulted in a partial but significant decrease of the ovalbumin-induced AHR compared to ovalbumin-challenged controls (P<0.05) and reduced eosinophil infiltration after ovalbumin challenge by 60% and 58%, respectively.	Ketanserin	15-25	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	128-137
9692769-13	1998	Treatment with ketanserin or cimetidine resulted in a partial but significant decrease of the ovalbumin-induced AHR compared to ovalbumin-challenged controls (P<0.05) and reduced eosinophil infiltration after ovalbumin challenge by 60% and 58%, respectively.	Ketanserin	15-25	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	128-137
9618398-5	1998	Trazodone was potently counteracted (IC50 = 2.7 nM) by the selective 5-HT2B/5-HT2C receptor antagonist N-(1-methyl-5-indolyl)-N-(3-pyridil) urea HCl and, less potently (IC50 = 95 nM), by ketanserin, a 5-HT2A/5-HT2C receptor blocker.	Ketanserin	187-197	5-hydroxytryptamine receptor 2B	Rattus norvegicus	69-75
9692616-10	1998	Ketanserin produced a decrease in ristocetin-induced platelet aggregation, fibrinogen, and prolongation of the bleeding time.	Ketanserin	0-10	fibrinogen beta chain	Homo sapiens	75-85
9768567-7	1998	Pharmacological studies showed that responding on the DOI and ketanserin lever reflected agonist and antagonist activity at 5-HT2A receptors, and hence, was a suitable model for evaluating the in vivo functional properties of DMT.	Ketanserin	62-72	5-hydroxytryptamine receptor 2A	Homo sapiens	126-130
9796938-0	1998	Characteristics of agonist displacement of [3H]ketanserin binding to platelet 5-HT2A receptors: implications for psychiatric research.	Ketanserin	43-57	5-hydroxytryptamine receptor 2A	Homo sapiens	78-84
9796938-3	1998	We examined [3H]ketanserin"s saturable binding to platelet 5-HT2A receptors and characteristics of agonist displacement curves of [3H]ketanserin binding in healthy control subjects.	Ketanserin	16-26	5-hydroxytryptamine receptor 2A	Homo sapiens	59-65
9622445-2	1998	The present study examined the discriminative stimulus effects of the 5-HT2A/2C agonist (-)-dimethoxy-4-indophenyl-2-aminopropane (DOI) and the 5-HT2A antagonist ketanserin in rats trained to discriminate either 1.5 g/kg of ethanol from water (intragastrically, n = 7) or 2.0 g/kg of ethanol from water (intragastrically, n = 8).	Ketanserin	162-172	5-hydroxytryptamine receptor 2A	Rattus norvegicus	144-150
9580630-6	1998	The ability of 5-HT to increase GABAergic synaptic activity in the presence of 5-HT3 receptor blockade was mimicked by the selective 5-HT2 agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and blocked by the selective 5-HT2 antagonist ketanserin.	Ketanserin	245-255	5-hydroxytryptamine receptor 3A	Rattus norvegicus	79-93
9605562-3	1998	The present study was devoted to establish the contribution of 5-HT1B/1D receptors in the constriction of AVAs elicited by 5-HT (in presence of 0.5 mg kg(-1) ketanserin), ergotamine and dihydroergotamine in anaesthetized pigs.	Ketanserin	158-168	5-hydroxytryptamine receptor 1B	Sus scrofa	63-69